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1.  Introduction  
1.1.  NK  cells  
1.1.1.  Definition  of  an  NK  cell  –  An  historical  overview  
  
The  first  definition  of  what  a  Natural  Killer  (NK)  cell  is  dates  back  to  1975,  when  Kiessling  
and  Herberman  groups  indipendently  discovered  that  “lymphocytes  of  undefined  nature”  
were  capable  of  “spontaneous  cytotoxic  activity”  against  different  tumor  cell   lines1,  2.  The  
term  “natural”  was  added  to  distinguish  this  mechanism  from  the  one  observed  until  then  
with   T   and   B   lymphocytes,   which   in   turn   was   specific   and   MHC-­‐‑restricted3.   In   the  
following  years  several  investigators  tried  to  better  characterize  not  only  the  function,  but  
also   the   phenotype   and   the   developmental   origin   of   NK   cells:   their   definition   then  
switched   to   “large  granular   lymphocytes”  belonging   to   a   “separate   lymphocyte   lineage,  
with   both   cytotoxicity   and   effector   functions”4.   This   statement   has   been,   and   still   is,  
generally   accepted   within   the   scientific   community,   even   if   a   more   recent   attempt   to  
update  it  has  been  carried  on  by  Vivier  group,  on  the  basis  of  the  multitude  of  information  
nowadays  available  on   this  cell   type:   their   formalization  of  what  a  NK  cells   is  would  be  
“an   NKp46+   CD3-­‐‑,   IL-­‐‑15-­‐‑dependent,   IL-­‐‑12-­‐‑responsive   lymphocyte,   present   in   all  
mammalian  species.  Upon  maturation,  the  NK  cell  is  an  early  source  of  IFN-­‐‑γ  and  a  potent  
cytotoxic   lymphocyte   in   response   to  various   cellular   targets,  which   lack   constitutive   self  
molecules  and  that  express  stress-­‐‑induced  self  molecules  or  microbial  molecules”5.  
Regardless  of  the  complexity  of  such  a  definition,  it  clearly  shows  how  much  is  currently  
known  on  NK  cells.  
Firstly,   what   does   an   NK   cell   do?   It   has   been   classically   described   as   a   powerful  
component   of   the   innate   branch   of   the   immune   system,   involved   in   the   immune  
surveillance  and  in  the  response  against  tumor  cells  and  virus-­‐‑infected  cells6.    
Since   their   discovery,   NK   cells   were   described   as   effector   lymphocytes   that   recognized  
cells  that  did  not  express  the  Major  Histocompatibility  Complex  I  (MHC-­‐‑I)  molecule,  in  an  
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opposite   fashion   from  what  happened   for  T   lymphocytes,  whose   target   recognition  was  
instead  “MHC-­‐‑restricted”7.  This  huge  difference  was  later  elucidated  by  the  work  of  Karre  
and  colleagues,  that  for  the  first  time  hypothesized  the  “missing  self”  theory  8.  According  
to   this   revolutionary   view,  NK   cells  were   indeed   able   to   discriminate   transformed   (and  
dangerous)   cells   by   self   cells   through   specific   receptors   for   MHC-­‐‑I   molecules:   the  
recognition  of  those  molecules  by  means  of  specific  receptors  caused  the  inhibition  of  NK  
cell  cytotoxic  activity  (against  self),  while  the  absence  of  the  surface  expression  of  MHC-­‐‑I  
on  any  cell  would  trigger  the  NK  cell  response,  activating  the  “natural”  cytolysis.  
Later   on,   it   was   described   how   NK   cells   were   also   able   to   target   MHC-­‐‑I   expressing  
tumors9,  10,  11,  and  this  raised  questions  on  alternative  mechanisms  of  cell  recognition  used  
by  the  NK  population12.  In  fact,  today  it  is  known  that  there  are  several  activatory  signals  
that   stimulate  NK   cell   activation   and   degranulation   capacity.  Altogether,   these   findings  
brought   to   the  concept   that  “a  balance  of   inhibitory  and  activatory  signals   regulates  NK  
cell  responses”13,  widely  accepted  today.  
  
  
Figure   1   -­‐‑   Regulation   of   NK   cell   effector   responses.   The   balance   between  
inhibitory   and   activating   receptors   determines   the   fate   of   target   cell.   Under  
normal   circumstances,   MHC-­‐‑I   receptors   dominate   over   activating   receptors.  
When  MHC-­‐‑I   is  downregulated  (missing  self,   left),   the   inhibition  signal   is   lost  
and   the  NK   cell   releases   cytotoxic   granules.   If   the   target   cell   is   “stressed”   its  
activating   ligands   are   overexpressed   and   inhibiting   signals   are   overcome  
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1.1.2.  NK  cell  receptors  
  
As  shown  in  Figure  1,  the  result  of  the  encounter  of  an  NK  cell  with  a  potential  target  cell  
depends   on   the   integration   of   a   multitude   of   signals,   deriving   from   the   wide   array   of  
inhibitory  and  activatory  receptors  engaged  in  that  moment.  
As  this  work  regards  the  mouse  immune  system,  the  following  part  will  be  mainly  focused  
on  murine  NK  cells,  with  a  particular  attention  on  the  difference  with  the  human  immune  
system  when  needed.  
The   most   peculiar   set   of   receptors   present   on   NK   cell   surface   is   probably   the   one  
belonging  to  “the  NK  complex”,  a  C-­‐‑type  lectin  superfamily  of  at  least  nine  highly  related  
genes   present   on   mouse   chromosome   6,   that   are   able   to   bind   polymorphic   H-­‐‑2   class-­‐‑I  
molecules,  and  can  either  be  activatory  or  inhibitory15.  
  
Activating   receptors.   Among   the   activatory   receptors,   Ly49H   is   important   for   the  
recognition  of  mouse  cytomegalovirus  (MCMV)16,  17,  18,  an  herpesvirus  which  is  particularly  
susceptible   to  NK  cell   immune  surveillance.  The  epitope  recognized  by  Ly49H   is  a  viral  
protein  expressed  by  MCMV-­‐‑infected  cells,  m157.    
Activating  NK  cell  receptors  are  also  able  to  recognize  “stress  signals”,  the  most  important  
of   which   are   Rae-­‐‑1   (RNA   export   homolog   1),   H60   (histocompatibility-­‐‑60)   and   MULT1  
(murine  ULBP-­‐‑like   trancript   1),   the   ligands   of  NKG2D19:   these  molecules   are   frequently  
overexpressed  by  transformed  cells20,  21,  virus-­‐‑infected  cells22  or  even  by  cells  that  suffered  
from   genotoxic-­‐‑stress,   or   DNA-­‐‑damage23.   NKG2D   belongs   to   the   NKG2   (Natural   Killer  
Group   2)   family,   which   contains   four   genes   in   total   (NKG2A,   NKG2C,   NKG2E   and  
NKG2D/F)24,  that  together  with  CD94  are  part  of  the  C-­‐‑type  lectin  superfamily.  
NK   cells   can   also   sense   microbial   particles   through   Toll-­‐‑like   receptors   (TLRs),   such   as  
double-­‐‑strand  DNA  (viral  origin  -­‐‑  TLR3)  and  CpG  (bacterial  origin  –  TLR9)25,  even  though  
there   are   doubts   regarding  NK   cell   intrinsic   capacity   to   respond   to   TLR   ligands,   as   the  
interaction  with   accessory   cells   like   dendritic   cells   (DCs)   significantly   increases  NK   cell  
Introduction	  
8	  
activation.   In   fact,   this  might  hide  an   indirect   role   for  NK  cells   in  vivo  upon   stimulation  
with  microbial  molecules26,  27.  
Other   activating   receptors   are   those   called   natural   cytotoxicity   receptors   (NCRs),   the  
NKp46  (NCR1),  NKp44  (NCR2)  and  NKp30  (NCR3)28,  which  are  not  only  strong  activators  
of  NK  cell  function,  but,  in  the  case  of  NKp46,  a  potential  marker  for  the  NK  cell  lineage  5,  
29(with  the  exception  of  IL-­‐‑22+  Ror-­‐‑γT+  innate  lymphoid  cells  residing  in  the  gut30,  31  and  of  
discrete  subsets  of  T  cells31).  As  NKp46  is  well-­‐‑conserved  across  species  (differently  from  
other  classic  NK  lineage  markers,  such  as  CD56  in  humans  and  NK1.1  in  C57BL/6  mice),  it  
might   represent   the   real  NK   cell  marker.   For  what   concerns  NCR   ligands,   they   are   not  
very   well   defined:   an   interaction   between   influenza   virus   hemagglutinins   and   Sendai  
virus  hemagglutinin/neuraminidase  with  NKp46  has  been  reported  some  years  ago32,  but  
its  biological   relevance   remains   to  be  elucidated.  Furthermore,  NKp46  seems   to  mediate  
cytotoxicity   also   against   Mycobacterium   Tubercolosis   infected   cells33,   while   in   human  
NKp30   has   been   shown   to   ligate   the   HCMV   tegument   protein   pp65,   leading   to   the  
inhibition   of  HCMV   infected   cells34.   The   difficulty   in   finding   a   good   candidate   as  NCR  
ligand  are  increased  by  the  absence  of  a  murine  ortholog  for  NKp44,  and  by  the  fact  that  
NKp30  is  a  pseudogene  in  mus  musculus,  but  in  general  NCRs  are  believed  to  be  mainly  
involved  against  tumor  cells31.  
Although   exclusive,   at   least   until   now,   for   humans,   the   killer   cell   immunoglobulin-­‐‑like  
receptors   (KIRs)   and   leukocyte   immunoglobulin-­‐‑like   receptors   (LILRs)   role   shoud   be  
reminded:  they  are  type  I  glycoproteins  and  members  of  the  Ig  superfamily35,  36,  are  able  to  
bind,   like   Ly49s,   human   leukocyte   antigen-­‐‑A   (HLA-­‐‑A),   HLA-­‐‑B   and   HLA-­‐‑C,   and   their  
genetic  locus  is  highly  variable,  polygenic  and  polymorphic  within  human  population;  in  
addition,  depending  on  their  structure  and  on  the  adaptor  molecules  they  are  associated  
with,  KIRs  can  both  inhibit  and  activate  NK  cell  function  upon  the  receptor  engagement19.  
Taken   together,   the   receptor   families   described   above   are   those   responsible   for   the   so  
called   “natural   cytotoxicity”,   or   the   capacity   to   recognize   non-­‐‑self   or   stressed   cells   by  
means  of  germinally  encoded  proteins.  
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An   alternative   pathway   leading   to   NK   cell   activation   is   the   antibody-­‐‑dependent   cell  
cytotoxicity   (ADCC),  which   is   exerted   through  CD16   (FcγRIIIA):  CD16   is   a   low   affinity  
receptor   for   IgG   that   recognizes   antibody-­‐‑coated   cells,   signalling   through   its   associated  
molecules  FcεRI  γ  chain  and  T  cell  receptor  (TCR)  ζ  chain,  triggering  granule  release  and  
cytokine  production37.  CD16  stimulation  is  so  powerful  that  can  lead  to  NK  cell  activation  
by   itself,  similarly   to  what  happens  with   the  multipotent  TCR  and  BCR  receptors   (along  
with   costimulatory  molecules),  while   none   of   the   other   activatory  NK   cell   receptors   are  
able  to  elicit  a  response  by  themselves  (and  are  thus  defined  “coactivatory”)38.  
  
Inhibitory  receptors.  Many  of  the  members  of  the  inhibitory  receptor  group  belong  to  the  
families  cited  above,   like  KIRs  and  LILRs  in  humans,  and  Ly49s  in  mice.  They  recognize  
both  MHC-­‐‑I-­‐‑related  and  –unrelated  molecules,  and  the  inhibitory  signal  deriving  from  the  
engagement   of   these   receptors   counterbalances   the   stimuli   that   come   from   activatory  
receptors.  Examples  of  inhibitory  receptors  are  Ly49A-­‐‑I  (with  the  exception  of  Ly49D  and  
Ly49H),  which  are  specific  for  MHC-­‐‑I  molecules,  and  KLRG1,  a  member  of  C-­‐‑type  lectin-­‐‑




Figure  2  –  NK  cell  receptors.  A  scheme  of  human  and  murine  NK  cell  surface  
molecules,   divided   in   activating   (with   their   coupled   adaptors),   inhibitory,  
cytokinic,   chemotactic   and   adhesion   receptors.   The   majority   of   them   are  
conserved  in  the  two  species39.  
  
Tipically  the  signaling  trasduced  by  either  an  inhibitory  or  an  activatory  receptor  depends  
on  the  presence  of  specific  aminoacidic  motifs,  known  as  immunoreceptor  tyrosine-­‐‑based  
inhibitory   motif   (ITIM)   on   the   receptor   cytoplasmic   tail   or   of   immunoreceptor   tyrosin-­‐‑
based  activatory  motif  (ITAM)  present  on  associated  adaptor  proteins,  respectively.  If  an  
inhibitory  receptor  binds  its  ligand,  the  tyrosine  on  the  ITIM  domain  is  phosphorylated  by  
a   kinase   (likely   a   Src-­‐‑family   kinase)   and   then   recruits   phosphatases   through   the  
recognition  of  SH-­‐‑2  domains,  decreasing  the  Ca2+  cytoplasmic  concentration,  and  thus  cell  
activation.  
Conversely,   if   an   activatory   receptor   is   stimulated   the   tyrosines   present   on   the   ITAM  
motifs   of   FcεRIϒ,   CD3ζ,   DAP10   or   DAP12   is   phosphorylated   and   recognized   by   Syk  
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kinases   and   ZAP70   kinases,   activating   a   wide   range   of   intracellular   events,   leading   to  
chemokine  and  cytokine  gene  trascription  and  cell  degranulation19.  
The   process   of   NK   cell   activation   can   trigger   several   responses,   depending   on   the  
receptors  engaged,  on  the  environment,  on  interactions  with  other   immune  cells,  and  on  
the  phenotype  of  the  NK  cell.  The  most  characterized  of  those  responses  are  the  release  of  
cytotoxic   granules   containing   perforin   (protein   able   to   generate   pores   on   the   target   cell  
membrane,   disrupting   the   transmembrane   ionic   gradient   and   inducing   cell   lysis),  
granzymes,  and  the  secretion  of   interferon-­‐‑γ  (IFNγ),  a  cytokine   that   interferes  with  viral  
replication   and   addresses   the   inflammation   towards   a   type-­‐‑1   response4,   40.   Besides,   NK  
cells  can  produce  proinflammatory  cytokines  such  as  interleukin-­‐‑1  (IL-­‐‑1),  IL-­‐‑12,  IL-­‐‑15,  IL-­‐‑
18  and  tumor  necrosis  factor-­‐‑α  (TNF-­‐‑α)  or  immunosuppressive  molecules,  like  IL-­‐‑5,  IL-­‐‑10  
and   IL-­‐‑13.   Furthermore   growth   factors   like   granulocyte  macrophage   colony-­‐‑stimulating  
factor  (GM-­‐‑CSF),  granulocyte  colony-­‐‑stimulating  factor  (G-­‐‑CSF)  and  IL-­‐‑3  can  be  secreted.  
Finally,  NK   cells   are   an   efficient   source   of   chemokines,   including  CCL2   (MCP-­‐‑1),  CCL3  
(MIP-­‐‑1α),  CCL4  (MIP-­‐‑1β),  CCL5  (RANTES),  XCL1  (lymphotactin)  and  CXCL8  (IL-­‐‑8)39,  41.  
  
1.1.3.  Between  innate  and  adaptive  immunity  
  
Interactions  with  other  immune  cells.  In  the  last  decade,  it  has  been  widely  acknowledged  
that  NK  cells  are  not  mere  aspecific  effector  lymphocytes  anymore,  but  are  able  to  mediate  
numerous  functions  classically  attributed  to  the  adaptive  immunity:  for  example  NK  cells  
can  act   like   regulatory  cells,   interacting  with  and,  more   importantly,   impacting  on  other  
cellular  components  of  the  immune  system  (Figure  3),  be  it  of  the  innate  (DCs,  neutrophils,  
macrophages)42   or   of   the   adaptive   branch40,   43,   44.   In   fact,   NK   cells   have   been   shown   to  
qualitatively  and  quantitavely  regulate  T  and  B  cell  responses  activating  or  killing  antigen-­‐‑
presenting  cells   (APCs)  and  regulatory  T  cells   (Tregs)45,  46,  modulating   the  cytotoxicity  of  





Figure  3  -­‐‑  NK  cell  regulation  of  immune  responses.  After  stimulation  (priming)  
with   different   cytokines   (i.e.   IL-­‐‑15).   NK   cells   can   exert   boosting   effects   (red  
arrows)   on   DC   maturation   or   macrophage   activation,   but   can   also   mediate  
cytolysis   against   activated   CD4+   T   cells,   immature   DCs   or   activated  
macrophages  (blue  arrows)49.  
  
Memory  NK  cells.  Among  other  typical  features  of  the  adaptive  immunity,  the  discovery  
of  putative  memory  NK  cell  has  been  of  much  importance:  it  has  been  described  in  classic  
models  of  antigen-­‐‑specific  memory  such  as  hapten-­‐‑induced  contact  hypersensitivity  (CHS)  
and  viral  infections,  that  NK  cells  are  able  to  display  a  “learned”  response  (that  requires  an  
episode   of   sensitization)   and   to   “remember”   sensitizing   antigens   after   a   long   period   of  
time  (in  this  case  4  months)50.  This  findings  clearly  demonstrate  the  existence  of  an  NK  cell  
subset  distinct  from  conventional  ones,  which  half-­‐‑life  has  been  shown  to  be  of  about  17  
days51.  In  this  study  the  authors  also  describe  the  tissue  localization  of  memory  NK  cells,  
which  in  fact  reside  within  the  liver  in  the  CHS  model,  while  are  spread  in  all   lymphoid  
organs,   and   particularly   in   the   spleen,   in   the  MCMV-­‐‑infection  model.   The  markers   for  
these   (different)   types   of   memory   NK   cells   are   CXCR6   (the   receptor   for   CXCL16)   and  
Ly49H,  respectively.  It  is  also  shown  that  long-­‐‑lived,  antigen-­‐‑specific  NK  cells  are  present  
in   other   inflammation   models,   such   as   vesicular   stomatitis   virus   (VSV),   influenza   and,  
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curiously,  HIV-­‐‑152.  Although  some  characteristics  of   this  new  NK  cell   subset  are  already  
described,  much   remains,   at   least   partially,   unexplained,   like   the  mechanism   of   antigen  
recognition,  the  stimuli  needed  for  their  survival,  or  the  dynamics  of  their  activation  upon  
antigen  encounter.  Furthermore,   little   is  known  about  their  equivalent   in  human,  even  if  
some  studies  seem  to  point  in  that  direction53.  
  
Polarization.   An   aspect   reminiscent   of   T   and   B   cell   biology   is   certainly   the   capacity   of  
these   cells   to  have  a  polarized   response   in   consequence  of   environmental   cues   (i.e.  Th1,  
Th2,   Th17,   Th22   for   CD4+   T   helper   cells).   Recently   some   groups   have   shown   how   this  
polarization  can  be  obtained  also  with  NK  cells,  both  in  humans  and  in  mouse  models54,  55,  
defining  NK1  and  NK2  subsets  according   to   their  ability   to  produce  and  secrete   in  vitro  
IFN-­‐‑γ  or  IL-­‐‑5  and  IL-­‐‑13  (but  not  IL-­‐‑4),  respectively.  However,  the  mechanisms  leading  to  
the  production  of  type  1  or  type  2  cytokines  are  not  well  defined,  as  for  example  IFN-­‐‑γ  can  
be  produced,  together  with  IL-­‐‑13,  by  IL-­‐‑12+IL-­‐‑18-­‐‑stimulated  murine  NK  cells56.  Moreover,  
the   transcription   factors   determining   NK   cell   polarization   are   still   on   the   way   to   be  
demonstrated,   even   if   some   evidence  would   suggest   that  GATA3,  ROG   and   STAT6   are  
NK2-­‐‑polarizing   factors,   while   T-­‐‑bet,   and   STAT4   are   NK1   differentiation   inducers55.   An  
interesting  view  on  NK  cell   (but   it   also  applies   to  T   cells)  polarization  process  has  been  
given   by   Perussia   et   al.57:   the   authors   challenge   the   classical   model   of   lymphocyte  
development,   called  “branching  1-­‐‑2”,   according   to  which  naive   (and  N0,  or  non-­‐‑primed  
NK  cells)  CD4  T  cells  still  retain  the  potential  to  be  polarized  to  any  inflammatory  type  (1,  
2,   17,   22),   and   only   by   subsequent   exposition   to   environmental   factors   are   irreversibly  
directed  towards  their  terminal  phenotype.  Conversely,  it  is  proposed  that  most  immature  
cells  have  a  type  2  phenotype,  which  can,  or  can  not,  switch  to  an  intermediate  stage  (here  
called  type  0),  and  afterwards  to  type  1  NK  cells.  There  are  several  evidences  supporting  
this   model   ,   such   as   the   ability   of   NK1   cells   to   produce   IL-­‐‑10   upon   stimulation   with  
different  stimuli54,  58,  59,  that  so  far  has  not  been  observed  in  NK2  cells.  Furthermore,  while  it  
is  possible   to  convert  an  NK2  to  an  NK1  phenotype,   the  opposite  has  not  been  possible,  
suggesting  that  the  NK1  might  be  the  terminal  state  of  NK  cell  differentiation,  at  least  for  
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what   concerns   physiological   conditions.   Although   these   are   intriguing   and   stimulating  
possibilities,  definitive  proofs  in  in  vivo  studies  are  needed,  since  both  in  homeostatic  and  
pathological   conditions,   NK   cell   phenotype   and   functionality   seem   to   be   significantly  
plastic.  
  
Education  and  tolerance.   In  order   to  avoid  self-­‐‑reactivity,   thymocytes  are  selected   in   the  
thymus,   where   clones   that   do   not   recognize,   or   recognize   too   efficiently,   self   ligands  
bound  to  MHC-­‐‑I  molecules  are  negatively  selected  and  consequently  undergo  apoptosis.  
This   process   endows  mature   T   cells  with   the   capacity   to   discriminate   self   and   non   self  
molecules,  escaping  autoimmunity.  Furthermore,  naive  T  cells  are  not  fully  functional,  and  
must  be  "ʺprimed"ʺ  through  the  recognition  of  a  specific  ligand,  as  well  as  by  the  signalling  
triggered  by  cytokines  and  co-­‐‑stimulatory  molecules  (such  as  CD28):  only  after  this  T  cells  
reach  their  terminal  maturation  stage.  
In   parallel   with   the   ability   to   polarize   their   response,   probably   the   most   important  
similarity   of  NK   cell   biology   and   adaptive   immunity   is   the   existence   of   an   "ʺeducation"ʺ  
process  during  NK  cell  maturation  and  development.  The  necessity  for  such  a  mechanism  
has   emerged   for   several   reasons.   Firstly,  when   it   has   been   highlighted   that   1)  NK   cells  
express  activatory  receptors  for  self-­‐‑MHC  molecules   19,  60,  61  and  2)   there  are  NK  cells   that  
lack  of   at   least  one   inhibitory   receptor   for   self-­‐‑MHC  molecules   62,  63:   indeed,   the   classical  
definition  of  the  NK  cell  activation  state  as  "ʺresult  of  the  integration  of  the  signals  deriving  
from  activatory  and  inhibitory  signals"ʺ  did  not  explain  why,  then,  NK  cells  did  not  show  
manifestations  of  autoimmunity.  
Secondly,   because   of   the   data   showing   that   the   NK   cell   population   displayed   various  
degrees  of  functionality,  depending  on  their  developmental  stage.  
The   term   education   defines   the   "ʺhost   effects   on   NK   cell   function   which   could   include  
MHC-­‐‑dependent   and  MHC-­‐‑independent   effects"ʺ   14,   and   includes   both   the   acquisition  of  
complete   functionality   (licensing)   and   the   capacity   to   recognize   and   thus   spare   cells  
expressing  self  molecules,  also  known  as  tolerance.  
The  processes  leading  to  licensing  and  tolerance  are  still  being  debated,  as  there  still  is  no  
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conclusive  evidence   that   clearly  demonstrates  how   those  properties  are  obtained  by  NK  
cells.  However,   two  main  models  have  been  proposed  by  Yokoyama  and  Raulet   group:  
the   first   hypothesis   postulates   that   the   binding   to   self   MHC-­‐‑1   ligands   with   inhibitory  
receptors  promotes  NK  cell  licensing  63,  and  is  referred  to  as  "ʺarming"ʺ  model.  
This   is   the   simplest   model   of   the   two,   it   is   supported   by   data   showing   that   MHC-­‐‑I  
deficient  mice   -­‐‑  derived  NK  cells  have  a   significant   functional   impairment   64,  65,   and   that  
the  ITIM  motif  contained  in  the  cytoplasmic  tail  of  the  inhibitory  receptors  is  required  to  
reach   a   licensed   state63.   Though   this   hypothesis   has   been   strenghtened   also   by   human  
studies   66,   67   doubts   remain   on   the   possibility   that   a   inhibitory   signal   derived   from   the  
engagement  of  a   self  MHC-­‐‑I   receptor,   coupled  with  phosphatases  activity  might  as  well  
lead  to  a  positive  signal,  represented  by  the  acquisition  of  functional  maturation  14.  
An  alternative  hypothesis  for  the  licensing  mechanism  is  known  as  "ʺdisarming"ʺ  model  68,  69,  
and   proposes   that   all  NK   cells   are   initially   responsive,   but   the   absence   of   an   inhibitory  
signal  deriving  from  a  self  MHC-­‐‑I  receptor  might  unbalance  the  chronic  stimulation  with  a  
putative  self-­‐‑specific  activatory   ligand,   leading   the  cell   to  an  anergic   state,   similar   to   the  
one  observed  in  T  cells.  The  presence  of  an  unknown  activatory  ligand  is  supported  by  the  
fact  that  MHC-­‐‑I  deficient  cells  are  efficiently  killed  by  WT  NK  cells  65,  and  by  studies  with  
transgenic  mice  (i.e.  overexpressing  NKG2D  ligands),  and  on  humans  41.  Nevertheless,  the  
disarming   model   poses   some   questions,   in   the   first   place   regarding   the   unknown  
activatory  self  ligand,  and  then  concerning  the  experimental  models  used  to  demonstrate  
this  hypothesis,  which  might  present  important  limitations  14.    
A   third   model,   known   as   "ʺrheostat"ʺ   model   has   been   proposed   by   Karre   group,   and  
postulates  that  the  process  of  NK  cell  education  and  licensing  is  not  an  "ʺon  and  off"ʺ  switch,  
but   conversely   is   a   gradual   acquisition   of   functional   competence,   proportionally   to   the  
number   of   self  MHC-­‐‑I   receptors   expressed   by   a   certain   cell,   and   by   the   affinity   of   each  
receptor   for   self  MHC-­‐‑I   ligands70.  This   is   supported  by  evidences  showing   that  NK  cells  
expressing  two  or  more  inhibitory  receptors  for  MHC-­‐‑I  respond  more  strongly  and  more  
frequently   than   those   expressing  only   one   receptor   70,  71.   Education   is   thus   likely   to   be   a  
quantitative   process,   regulated   by   the   binding   of   inhibitory   receptors   to   self   MHC-­‐‑I  
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molecules,   either  opposing   chronic   activating   receptor   stimulation,   or  by   trasmitting  yet  
undefined  activating  signals  themselves72.  
  
1.1.4.  NK  cell  development  
  
Commitment  and  maturation  –   from  HSCs   to   immature  NK  cells.  While   there  has   been  
extensive  and   fruitful   research   regarding   the  molecular  mechanisms  underlying  NK  cell  
activity   and   function,   those   concerning   NK   cell   development   are   probably   largely  
uncovered73,   though   alterations   of   the  process   of  NK   cell  maturation   can   lead   to   critical  
pathologies,   such  as   immune  deficiencies,   autoimmunity  and  NK  cell  malignancies,   that  
are  extremely  difficult  to  diagnose  and  to  eradicate74,  75,  76.  
Nevertheless,   it  has  been  known  since  more  than  25  years  that  the  bone  marrow  (BM)  is  
the   main   site   of   NK   cell   development,   this   notion   coming   from   studies   in   which   BM  
ablation   with   several   approaches,   such   as   treatment   with   bone-­‐‑seeking   isotopes   and  
following   estrogen-­‐‑induced   osteopetrosis77,   78   caused   a   severe   impairment   of   NK   cell  
population  number   and   functionality   in  mice.   In   addition,   other  hematopoietic   lineages,  
such   as  myeloid   and,   to   some   extent,   lymphoid   cells,   follow   their  maturation   pathway  
within  the  BM,  starting  from  the  common  progenitor  called  hematopoietic  stem  cell  (HSC).  
The  reasons  for  this  phenomenon  might  reside  in  the  peculiar  microenvironment  that  BM  
displays,  made  of  soluble  stimuli,  feeding-­‐‑stromal  cells,  and  low  oxygen  pressure79:  in  fact,  
it  has  been  progressively  clearer  that  NK  cell  development  is  a  process  dependent  on  cell-­‐‑
intrinsic  and  cell-­‐‑extrinsic   factors   (to  say,   transcription  factors  and  interaction  with  other  
cells),  and  within  the   latter  group  both  cell-­‐‑contact  with  stromal  cells  and  the  binding  of  
soluble  cytokines  have  an  important  role  for  the  complete  NK  cell  maturation.  
As  it  happens  for  other  cell  types,  the  NK  cell  development  is  generally  thought  to  occur  
starting  from  a  multipotent  progenitor,  the  HSC,  and  then  to  pass  through  several  stages  
of   progressive   differentiation,   during   which   their   “lineage   restriction”   accordingly  
increases.  
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The   first   steps   in   the   classical   view   of   NK   cell   development   are   represented   by   the  
transition  from  the  HSC  to  the  early  lymphoid  progenitor  (ELP)  and  then  to  the  common  
lymphoid   progenitor   (CLP),   which   are   identified   as   lineage-­‐‑negative   (Lin-­‐‑),   c-­‐‑kit+   Flt3+  
and  Lin-­‐‑  c-­‐‑kit+  IL-­‐‑7Rα+,  respectively80,  81:  this  passage  is  referred  to  as  “commitment”,  and  
involves  the  impossibility  to  differentiate  to  other  hematopoietic  lineages,  in  this  case  the  
myeloid   family.   Indeed,   ELPs   and   CLPs   can   still   become   B   and   T   lymphocytes,   or  NK  
cells.  
An   additional   phase   before   the   definitive   specification   to   the  NK   cell   lineage  might   be  
attributed   to   a  bipotent  T/NK  cell  precursor   (TNKP),   that  has  been   identified   in  murine  
fetal   liver   (Lin-­‐‑   c-­‐‑kit+   NK1.1+)   and   in   murine   and   human   fetal   thymus   (CD34+   CD7+  
CD1a-­‐‑)82,  83,  84,   but   it   is  not   clear  whether   a  part  of   the  NK  developing  population   (rather  
than   all   NK   cells)   might   acquire   this   phenotype,   or   even   whether   the   differentiation  
potential  towards  NK  and  T  cells  is  equivalent  at  this  stage79.  
What  most  of   the   scientific   community  agrees  on   is   the  phenotypic   signature  of   the  NK  
cell   precursor   (NKP)   present   in   the   fetal   thymus   and   in   the   BM   of   adult   mice,   which  
expresses   the   common   β   chain   of   the   IL-­‐‑2   and   IL-­‐‑15   receptors   (CD122),   and   lacks   the  
surface   expression   of   T   lymphocyte   co-­‐‑receptors   CD4   and   CD885,  86,   so   that  NKP   global  
phenotype   is  Lin-­‐‑  NK1.1-­‐‑  DX5-­‐‑  CD122+.  The   acquisition  of   this  molecule   endows  NKPs  
with  the  capacity  to  respond  to  IL-­‐‑15,  which  has  been  demonstrated  to  be  necessary  for  the  
complete   NK   cell   maturation,   from   the   NKP   stage   onwards87,   while   it   has   been  
demonstrated  that  the  generation  of  NKPs  from  HSC  does  not  depend  on  the  effect  of  IL-­‐‑
1588.   Most   likely   the   effect   mediated   by   IL-­‐‑15   occurs   in   the   BM,   which   is   a   rich   IL-­‐‑15-­‐‑
producing  cells  environment.  The  presentation  of  IL-­‐‑15  is  believed  to  be  mediated  by  other  
hematopoietic   (i.e.   DCs)89   and   non-­‐‑hematopoietic   (stromal)79   cells,   that   present   the  
complex   IL-­‐‑15/IL-­‐‑15Rα   in   trans   to   the   IL-­‐‑15Rβ/γ  present   on   the  NK   cell   surface;   the   IL-­‐‑
15β/γ-­‐‑receptor  is  able  to  recognize  its  ligand  even  in  absence  of  the  α-­‐‑subunit,  but  with  a  
much  lower  affinity,  and  thus  biological  efficacy.  
Interestingly,   NKPs   have   been   found   also   outside   the   BM,   as   they   can   be   detected   in  
murine  thymus,  spleen,  and  lymph  nodes  (LN)85,  90,  but  it   is  still  unknown  whether  these  
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cells  are  generated  in  situ  or  else  they  originate  in  the  BM  (or  in  the  fetal   liver)  and  then  
traffick  to  the  peripheral  organs  passing  by  the  circulation.  
Other  NK  cell  specific  surface  markers  have  been  proposed  to  be  expressed  by  the  NKPs  
population,  in  particular  NKG2D  (but  also  2B4)73,  88:  actually,  since  only  12%  of  NKPs  give  
rise   to   NK   cells   in   vitro85,   and   because   about   10%   of   NKPs   are   NKG2D+,   it   has   been  
hypothesized  that  real  NKPs  shoud  be  defined  as  Lin-­‐‑  CD122+  NKG2D+.    
An   example   of   extra-­‐‑BM   NKPs   has   been   described   also   in   humans,   where   a   CD34dim  
CD45RA+  integrin  α4β7high  precursor  that  was  present  in  peripheral  blood  and  was  highly  
enriched  in  LNs,  was  shown  to  retain  the  capacity  to  generate  in  vitro  CD56bright  NK  cells,  
after  stimulation  with  IL-­‐‑2  and  IL-­‐‑1591.  
As   of   now,   there   is   no   certainty   on   which   are   the   transcription   factors   needed   for   the  
commitment   to   become  NKPs73,   but   a   complex   interplay   seems   to   exist   among   some   of  
them.  Studying  gene-­‐‑deficient  mice,   it  has  been  demonstrated   that  Ets-­‐‑1,  PU.1  and  MEF  
are,   though  partially,   important   for   the   formation  of  a  complete  and  mature  pool  of  NK  
cells,   especially   in   the   early   phase   of   the   development92,   93,   94.   The   demonstration   of   a  
determined   role   for   each   one   of   these   factors   is   complicated   by   a   certain   degree   of  
redundancy  that  might  occur  in  case  of  deletion  of  just  one  of  them.  
An  exception  to   this  redundancy   is  represented  by  the  basic   leucine  zipper   transcription  
factor   E4BP4,   whose   absence   leads   to   the   complete   lack   of   NK   cells,   in   every   organ,  
similarly   to  what   is  observed   in   IL15-­‐‑KO  mice95.  Gascoyne  and  colleagues  demonstrated  
that  E4BP4  acts  downstream  of  IL15,  but  its  deficiency  does  not  affect  the  development  of  
other  IL-­‐‑15-­‐‑dependent  lineages,  like  CD8+  T  cells  and  NKT  cells,  pointing  out  its  NK-­‐‑cell  
specificity.  
Moreover,   two  members   of   the   inhibitors   of  DNA  binding   (Id   proteins   2   and   3)   family  
have  been  associated  with  the  regulation  of  HSCs  (or  ELP  or  CLP)  transition  to  NKP  stage,  
but  a  mechanism  for  this  was  not  found96.  
The   following   step   in   the   classical   model   of   NK   cell   development   is   the   generation   of  
immature  NK  cells  (iNK),  which  consists  of  irreversibly  committed  cells  that  have  not  yet  
gained  most   of   the   functional   properties   and   do   not   express   the   surface  molecules   that  
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characterize  mature  peripheral  NK  cells79.  In  the  scheme  of  temporal  acquisition  of  surfece  
markers,  NKR-­‐‑P1C  (recognized  by  anti-­‐‑NK1.1  mAb  PK136)  is  the  first  to  appear  on  iNKs,  
followed  by  the  CD94/NKG2A/C/E  complex  and  some  Ly49  receptors73.  Consequently,  the  
typical   phenotype   of   an   iNK   is   CD122+   NKG2D+   NK1.1+   DX5-­‐‑   (and   also   CD43low  
CD11blow),  and  these  cells  can  be  found  mainly  in  the  BM  but  are  also  enriched  in  the  liver  
in   adult   mice.   The   peculiarity   of   hepatic   iNK   cells   is   that   they   express   TNF-­‐‑related  
apoptosis-­‐‑inducing   ligand   (TRAIL),   through   which   they   can   trigger   cell   death   in  
susceptible   targets97.   Although   phenotypically   liver   NK   cells   might   resemble   immature  
cells,  recently  there  is  accumulating  evidence  that  NK1.1+  DX5-­‐‑  (CD49a+)  hepatic  NK  cells  
represent  a  completely  different  subset  from  the  conventional  splenic  DX5-­‐‑  NK  cells98:  for  
example,  it  has  been  shown  that  DX5-­‐‑  hepatic  NK  cells  are  tissue-­‐‑resident,  while  DX5+  are  
circulating;   furthermore,   DX5-­‐‑   cells   show   lower   proliferative   rates   than   their   DX5+  
counterpart,  and  are  most  likely  those  responsible  for  memory  NK  cell  response.  Overall,  
hepatic  iNKs  should  probably  not  be  the  same  as  iNK  found  in  other  organs,  like  BM.  
  
Generation   and   mantainance   of   mature   NK   cells.   The   acquisition   of   the   expression   of  
markers   like   the   integrin   DX5/CD49b,   CD27,   CD11b,   CD43,   other   Ly49   receptors,   and  
KLRG1  marks   the   further   transition   to   a   more   differentiated   NK   cell.   As   for   the   other  
phases  of  the  developmental  process,  also  this  one  is  transcriptionally  regulated,  and  the  
most  important  transcription  factors  involved  here  are  GATA-­‐‑3,  T-­‐‑bet,  Eomes  and  IRF-­‐‑2,  
even  if  their  exact  contribution  is  still  not  well  defined73.    
Along   with   transcriptional   factors,   stromal-­‐‑derived   and   soluble   molecules   can   exert   a  
regulatory  role  on  NK  cell  development.  Lymphotoxin-­‐‑α  is  a  cytokine  of  the  TNFα  family  
that  can   form  homotrimers   (LTα3)  binding  TNFR-­‐‑I  and  TNFR-­‐‑II,  or  associate  with   its  β-­‐‑
isoform,  form  heterotrimers  (LTα1β2),  binding  LTβR  on  stromal  cells:   it  has  been  shown  
that  to  have  a  complete  NK  developmental  process,  the  interaction  between  stromal  cells  
expressing   LTβR   and   LTα1β2   produced   by   NK   cells   is   required99,   and   its   function   is  
probably   upstream   of   IL-­‐‑15   requirement,   since   it   was   shown   that   it   can   trigger   IL-­‐‑15  
transcription  in  the  BM100.  
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Other  relevant  factors  playing  a  role  in  very  early  phase  of  NK  cell  development  are  c-­‐‑kitL  
and  Flt3,  like  they  do  in  other  lineages,  while  IL7  might  be  particularly  important  for  the  
maturation  of  thymic  NK  cells.  
In   a   simplistic   vision   of   NK   cell   development   and   trafficking   into   lymphoid   and   non  
lymphoid  organs,  once  these  cells  complete  their  developmental  process   in  the  BM,  they  
would  reach  peripheral  organs  and  exert  their  patrolling  function,  and  eventually  become  
senescent  and  undergo  apoptosis.  What  happens   in  vivo   is  quite  different,   since  specific  
signals   are   required   in   order   to   maintain   peripheral   NK   cell   pool,   and   again   the   most  
important   of   these  molecules   is   IL-­‐‑1551,  101,  102,   which   has   been   shown   to   induce  NK   cell  
survival,  proliferation  and  further  differentiation.  
An   opposite   function   is   attributed   to   transforming   growth   factor-­‐‑β   (TGF-­‐‑β),   which  
modulates   negatively   NK   cell   maintanance   in   the   periphery,   at   least   in   homeostatic  
conditions,  counterbalancing  the  effect  induced  by  IL-­‐‑15103.  
  
Every   maturation   step   described   above   refers   only   (perhaps   with   the   exception   of   the  
hepatic  NK  cells)  to  the  classical  paradygm  of  NK  cell  differentiation  in  the  BM.  Recently  
an   alternative   pathway   of   NK   cell   development   has   been   shown   to   take   place   in   the  
thymus104,   generating   a   phenotypically   and   functionally   different   subset   of   NK   cell,  
characterized  by  the  expression  of  the  α-­‐‑chain  of  IL7  receptor  (CD127)  and  high  amounts  
of  the  transcription  factor  GATA-­‐‑3.  In  this  study,  thymic  NK  cells  (tNK)  were  identified  as  
CD11blow   CD16-­‐‑   CD69high   Ly49low,   and   displayed   a   lower   lytic   activity   versus   the   NK-­‐‑
sensitive   lymphoma  cell   line  YAC-­‐‑1,   thus   looking   similar   to   conventional   immature  NK  
cells.  Nevertheless,   it  was   also   shown   how   their   cytokine   production   potential  was   not  
only  more  powerful,  but  even  wider  as  compared  to  classical  splenic  NK  cells,  suggesting  
that  thymic  NK  cells  could  represent  a  distinct  NK  cell  subset.  The  authors  demonstrated  
the  necessity   for  GATA-­‐‑3  and   IL7  presence   to  achieve  a  normal   tNK  reservoire   in  adult  
mice,  while  BM  and  peripheral  NK  cells  were  unaffected  by  the  absence  of  such  molecules.  
As  for  their  tissue  localization,  tNK  cells  have  been  proposed  to  reside  mainly  within  the  
lymph  nodes,  as  CD127+  represented  about  30%  of  total  NK  cells,  while  in  BM,  spleen  and  
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liver  this  frequency  was  not  superior  to  5%.  Interestingly,  CD127  and  GATA-­‐‑3  expression  
was   preferentially   observed   on   CD56bright   CD16-­‐‑   human   NK   cell   subset,   implying   a  
possible  link  between  CD127+  NK  cells  in  human  and  mouse.  
  
  
Figure   4   –  Different   pathways   of   NK   cell   development.   The   whole   process   of   NK   cell  
maturation,   from  HSC   to  mature  NK   (mNK),   takes   place   in   the   BM,   though   alternative  
developmental  routes  have  been  described  in  the  liver  and  in  thymus.  Typical  markers  of  
each   organ-­‐‑specific   NK   cell   are   described,   and   transcription   factors   that   regulate   the  
transition   from   a   differentiation   stage   to   the   next   are   shown   in   italics   (top   panel).   The  
earliest  NK  cell  commitment  marker  is  considered  to  be  CD244  (Pre-­‐‑NK),  while  mNKs  are  
characterized  by  CD49b.  Within  mNK,  CD27,  CD11b  and  KLRG1  define  additional  mNK  
cell  subsets  (adapted  from  73,  79)  
  
Mature  NK   cell   subsets   –  A   further   dissection.   NK   cell   population   heterogeneity   is   not  
limited   only   to   the   cited   developmental   stages,   but   has   a   further   degree   of   complexity  
since   even   within   what   is   currently   defined   a   mature   subset   several   subpopulations  
differing   in   functionality,   proliferative   potential   (and   consequently   maturation   degree)  
and  tissue  localization  can  be  identified.  
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The   first   study   in   which   the   existence   of   an   heterogeneous   response   in   the   NK   cell  
population   to   sensitive   targets   dates   back   to   1983,   and   was   conducted   on   human   NK  
cells105.    
Some  years  later,  the  same  group  reported  that  the  surface  expression  density  of  the  CD56  
marker  (CD56bright  and  CD56dim)  could  be  used  to  discriminate  between  the  two  subsets106,  
and  since   then   there  has  been  an  extensive   research  aimed  at   the  characterization  of   the  
different  properties  of  these  subpopulations.  
Murine  NK  cells  do  not  express   the  CD56  gene,   thus  a  comparison  between  human  and  
NK  cell  subsets  is  often  difficult.  
However,   as   already   discussed,   there   are   many   correlative   studies   that   show   how   the  
expression   of   molecules   such   as   Ly49   receptors   and   others   are   acquired   during  
maturation,  but  a  sequential  “A  to  B”  paradygm  was  not  estabilished  until  few  years  ago,  
when  the  presence  of  discrete  stages  of  NK  cell  maturation  in  mice,  corresponding  to  the  
progressive   acquisition   of   full   functional   competences,  was   formalized.   In   the   following  
years   it  has  been  shown  how  the  CD11bhigh  NK  cell  population  could  be   further  divided  
according   to   the   surface   expression   of   the   CD27,   a   member   of   the   TNF   receptor  
superfamily,   in   CD11bhighCD27+   and   CD11bhighCD27-­‐‑   subsets107,   and   that   these   subsets  
were   developmentally   related108.   Interestingly,   CD27   was   also   found   to   be   selectively  
expressed  by  the  CD56bright  human  NK  cell  subset,  which  is  thought  to  be  more  immature  
than  its  CD56dim  (CD27-­‐‑)  counterpart,  thus  resembling  the  situation  observed  in  mice109.  
  
Indeed,  the  proliferative  potential,   through  the  assessment  of  BrdU  incorporation  during  
homeostatic   immune  reconstitution  conditions,  was  proven  to  be  high  in  CD11blowCD27-­‐‑  
(double   negative,   DN)   subset,   and   to   decrease   gradually   in   CD11blowCD27+,  
CD11bhighCD27+(double   positive,   DP)   and   CD11bhighCD27-­‐‑   subsets,   indicating   a  
hierarchycal  order  in  the  generation  of  terminally  mature  NK  cells108.  
An  additional  study  evidenced  how  the  expression  of  the  inhibitory  receptor  KLRG1  was  
almost   exclusively   restricted   to   the   most   mature   CD11bhighCD27-­‐‑   subset,   and   was  
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associated   with   low   cytotoxic   capacity   against   NKG2D   ligands   expressing   targets,   and  
decreased  capacity  to  migrate  to  several  chemokines,  such  as  CXCL10  and  CXCL11110.  
  
These   reports   also   highlighted   the   differential   tissue   distribution   of   NK   cell  
subpopulations:   the  more   immature  subsets,  namely  DN  and  CD11blowCD27+  cells,  were  
mainly  represented  in  BM  and  lymph  nodes,  where  their  frequency  reached  50%  of  total  
NK   cells.   Conversely,   CD11bhigh   cells   (both   CD27+   and   CD27-­‐‑)   were   more   recurrent   in  
liver,  spleen,  lungs  and  blood,  up  to  the  85%  of  thewhole  NK  cell  population107.  This  shift  
in   the   subset   balance   in   different   organs   can   be   interpreted   in   several   ways:   firstly,   it  
reflects   the   importance   of   the   BM   and   LN   as  NK   cell-­‐‑generating   sites,   in   contrast  with  
other   peripheral   organs,   to   which   more   mature   cells   migrate   and   exert   their   immune  
function,   so   that   immature   cells   accumulate   in   BM   and   LN,   while   mature   ones   reside  
preferentially  in  the  periphery.    
  
  
Figure   5   –  Anatomical   localization   of  mNK   cell   subsets.   Outline   of  NK   cell   subset  
distribution   in   6-­‐‑10   weeks   old   C57BL/6J   mice,   according   to   CD11b   and   KLRG1  
expression.   The   most   mature   subset   (CD11bhigh/KLRG1+   cells,   in   yellow)   reside  
preferentially   in   spleen,   blood   and   non   lymphoid   organs   such   as   lung   and   liver.   In  
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contrast,   CD11blow/KLRG1-­‐‑   and   CD11bhigh/KLRG1-­‐‑   represent   great   part   of   NK   cell  
population  in  BM  and  lymph  nodes,  where  NK  cell  development  occurs.  
  
Secondly,  it  indicates  that  the  functional  differences  (i.e.  the  capacity  to  produce  cytokines  
versus  the  ability  to  kill  target  cells,  or  even  to  interact  with  other  hematopoietic  cells)  are  
exploited  according  to  the  organ  characteristics:  for  example,  CD11bhighCD27-­‐‑KLRG1+  NK  
cells,  account  for  more  than  75%  of  the  NK  cell  population  in  the  lung,  express  high  levels  
of  inhibitory  Ly49  receptors  and  thus  are  inefficiently  activated,  but  at  the  same  time  are  
continuously   exposed   to   exogenous   molecules   commonly   present   in   the   pulmonary  
airways,  and  are  probably  ideal  to  avoid  a  chronic  inflammatory  state  in  response  to  those  
stimuli.  Moreover,  DP  cells  have  been  shown  to  be  the  most  efficient  in  the  IFN-­‐‑γ  secretion  
in  response  to  IL-­‐‑12  and/or  IL-­‐‑18,  and  might  play  a  predominant  role  in  the  DC  activation  
and  promotion  of  CD4+  T  cell  Th1  priming  in  the  lymph  nodes,  where  their  frequency  is  
about  45%  of  total  NK  cells.  
Lastly,   an   important   aspect   in   the   regulation   of   the   different  NK   cell   localization   in   the  
body   is   represented   by   their   heterogeneous   expression   of   chemokine   receptors.   It   is  
known   that   organs   like  BM,   liver,   blood,   lymph  nodes   and   lungs   express   tissue-­‐‑specific  
chemotactic   factors,   that   selectively   attract   cells   able   to   recognize   those   factors   via   the  
corresponding  chemokine  receptors,  both  in  inflammatory  and  in  steady  state  conditions.  
For   example,   the   trafficking   to   the   lymph   nodes   is   modulated,   among   others,   by   the  
chemokines  CXCL9,  CXCL10  and  CXCL11,  and  their  receptor  CXCR3  is  mainly  expressed  
by   the  CD11blowCD27+  and  DP   subset,  which   together   represent   the  majority  of  LN  NK  
cells.   Likewise,   the   liver   sinusoids   have   been   described   to   express   CXCL16,   a   peculiar  
chemokine   that   exists   in   membrane-­‐‑bound   and   soluble   form,   and   consequently   DX5-­‐‑  
CD11blow  CD43low  hepatic  NK  cell  subset  is  CXCR6high111.  
Introduction	  
	   25	  
  
Figure  6  –  Expression  profile  of  chemotactic  receptors  of  NK  cell  subsets.  Each  stage  
of  NK   cell   development   is   characterized  by   specific   chemokine   receptors.  Those   in  
brackets  are  expressed  in  human  but  not  in  murine  NK  cells  112.  
  
BM   represents   an   interesting   example   of   how   the   modulation   of   several   chemokine  
receptors   complements  NK   cell   development   and   also   explains   their   positioning  within  
the   organ   compartments.   In   fact,   the   pattern   of   chemokine   receptor   expression   changes  
along  with  NK  cell  development,  likely  reflecting  the  need  for  different  cues  to  which  cells  
are  exposed  within  the  BM,  but  also  in  peripheral  organs.  
NK  cell  maturation   correlates  with   the  downmodulation  of  CXCR4,   a  key  player   in  BM  
NK   cell   retention113   and   development114:   its   ligand   CXCL12   is   presented   to  NK   cells   by  
CAR   (CXCL12   abundant   reticular)   cells,   which   are   localized   in   BM   parenchyma115,   and  
induce  CXCR4+  NK  cell  retention,  possibly  while  providing  pro-­‐‑survival  and  maturative  
stimuli   (e.g.   IL-­‐‑15)114.  CXCR4   is   robustly  expressed  by   iNKs  and  by   the  earliest  stages  of  
mNKs,  while  is  progressively  lost  on  CD27-­‐‑  mNKs113.    
S1P   is   a   secreted   lysophospholipid   bound   extensively   to   albumin   and   other   plasma  
proteins,  which  has  been  recently  demonstrated  to  regulate  cell  trafficking  to  BM  in  steady  
state   conditions116.   The   balance   of   anabolic   (sphingosine   kinases)   and   catabolic  
(Sphingosine   lyase   and   phosphatases)   processes   determine   an   in   vivo   gradient   of   S1P,  
with  high   concentrations   in   extracellular   fuids   and   low   levels   in   tissues117,  118.  Out  of   the  
five   S1P   receptors   (S1P1-­‐‑5),   just   S1P1   and   S1P5   are   expressed   on   NK   cells,   though   the  
function   of   the   former   is   unknown   yet.   Contrarily   to   CXCR4   expression   pattern,   S1P5  
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positively   correlates  with  NK  cell  development,  being  acquired   later  during  maturation.  
s1p5-­‐‑deficient  mice  display  a  significant   reduction  of  peripheral  NK  cells   (spleen,  blood,  
lung),  countered  by  the  increase  in  BM  and  LN  NK  cell  number,  and  thus  S1P5  is  believed  
to   represent   a   BM   (and   LN)   egress   signal   for   mature   CD27-­‐‑   NK   cells,   following   the  
chemotactic  gradient  of  S1P116.  
  
  
Figure  7  –  NK  cell  subset  trafficking  properties.  The  exit  signal  from  BM  and  
LNs  to  the  blood  can  be  provided  by  S1P5,  particularly  at  CD11bhigh/CD27-­‐‑  NK  
cell  maturation   stage.  Once   in   the  peripheral   circulation,  CXCR3   (mainly   on  
CD11blow/CD27+  NK  cells),  CCR2,  CCR5  and  CX3CR1  (just  for  CD27-­‐‑  NK  cells)  
drive  cell  trafficking  into  inflamed  tissues49.  
  
Collectively,   this   deep   specialization   in   differentiation   stage,   biological   functions,   and  
tissue  localization  of  the  different  mature  NK  cell  subsets  seems  to  be  important  for  innate  
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and  adaptive   immune  system  activity,  and   this  diversity  could  be  exploited   in   therapies  
against  infectious  diseases,  tumors  and  autoimmunity.  
  
1.2.   Drivers   of   leukocyte  migration:   chemokines   and  
their  receptors  
  
1.2.1.   General   concepts   –   Chemokine   structure,   nomenclature   and  
classification  
Perhaps   the   most   important   factor   that   directs   cell   migration   and   tissue   localization   is  
represented   by   chemotactic   cytokines,   or   in   short   chemokines.   This   family   of   small  
proteins   (their   molecular   weight   ranges   from   8   to   10   kDa),   includes   more   than   50  
members,  which   are   evolutionarily   conserved   and   structurally   related.   Through   several  
criteria,  chemokines  can  be  divided  in  subgroups,  or  subfamilies.  
About  25-­‐‑50%  of  the  aminoacidic  sequence  is  shared  by  all  chemokines,  and  in  particular  
the  N-­‐‑terminus  displays   two  highly   conserved   cysteines,   important   for   the   formation  of  
structurally   relevant   disulfide   bonds,   and   according   to   the   position   of   these   specific  
aminoacids,   4   different   classes   can   be   identified:  CXC,  CC,  CX3C   and  XC   (where   the  X  
stands   for  any  aminoacid).  Currently   chemokines  are  named  conformingly   to   their   class  
(i.e.  CXCL1  stands  for  CXC  chemokine   ligand  1),  simplifying  the  previous  nomenclature  
system  which  was   based   on   the  molecule   function   (i.e.  CCL2  was  previously   known   as  
monocyte   chemoattrattant   protein-­‐‑1,   MCP-­‐‑1).   In   addition,   this   method   applies   to  
respective  chemokine  receptors,   that  are  classified   in  accordance  with   the  class   to  which  
their  ligand(s)  belong  to  and  a  progressive  number  (i.e.  CXCR3  stands  for  CXC  chemokine  




Figure   8   –   The   complexity   of   chemokine   system.   Black   lines   describe   each   chemokine  
receptor   specificity   for   ligands   and   leukocytes,   highlighting   the   redundancy   and  
promiscuity   of   this   system.   In   fact,   different   chemokines   can   be   specific   for   the   same  
receptor,   and   a   single   chemokine   can   bind  more   than   one   receptor.   There   are   exceptions  
such   CX3CR1,   CXCR6   and   presumably   CXCR5,   which   are   considered   “monogamous”  
ligand-­‐‑receptor   pairs.  An   updated   overview   of   the   currently   known   atypical   receptors   is  
pictured  on  the  left  side,  while  classical  signaling  receptors  are  on  the  right  side119.  
  
Within  CXC  chemokines,  ELR-­‐‑  and  ELR+  subclasses  can  be   identified,  depending  on  the  
presence   or   the   absence   of   a   glutammic   acid-­‐‑leucine-­‐‑arginine   sequence   upstream   of   the  
first   conserved   cysteine.   CXCL1,   CXCL2,   CXCL3,   CXCL5,   CXCL6,   CXCL7   and   CXCL8  
(which   was   the   first   chemokine   to   be   discovered120)   are   ELR+,   while   CXCL4,   CXCL9,  
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CXCL10,   CXCL11   and   CXCL12   are   ELR-­‐‑.   All   of   them   are   tyipically   responsible   for  
neutrophil,   T   cells,   fibroblasts   and   hematopoietic   precursors   recruitment,   but   are  
particularly   related   to   angiogenesis121:   in   fact,   ELR-­‐‑   CXC   chemokines   are   classically  
considered  antiangiogenic,  while  ELR+  promote  angiogenesis122.  
Another  parameter  used  to  characterize  chemokines  is  related  to  their  function:  there  can  
be   inflammatory,   homeostatic   or   dual-­‐‑function   (mixed)   chemokines,   even   if   this   classic  
differentiation   is   continuously   challenged   by   new   studies   where   the   borders   of   such  
categories  are  quite  blurred.  For  example,  CX3CL1  is  considered  homeostatic  in  the  central  
nervous   system   (CNS),   but   inflammatory   in   the   periphery123,   124.   Nevertheless,   it   is  
undeniable   that  most  chemokines  are  predominantly,   if  not  completely,   important  either  
in  the  steady  state  or  during  inflammation.    
Inflammatory  chemokines  are  expressed  by   leukocytes  and  non  hematopoietic  cells  only  
upon   activation125,  126,   and   their   expression   is   triggered   by   diverse   stimuli,   such   as   TNF,  
IFNγ,   microbial   products   or   trauma.   Importantly,   this   class   of   chemokine   is   produced  
mainly  in  inflamed  tissues,  during  phlogosis,  and  thus  is  spatially  and  temporally  related  
to   the   inflammation.   On   the   contrary,   homeostatic   chemokines   are   constitutively  
expressed,  and  regulate  the  leukocyte  basal  movement  through  the  organs  (CCL19,  CCL21  
and   CXCL13)   as   well   as   the   complex   mechanisms   underlying   hematopoietic   cell  
development,   for  example   in   the   thymus  and   in   the  bone  marrow  (CCL25  and  CXCL12,  
respectively).  Moreover,  some  chemokines  are  abundant   in  specific   tissues,  such  as  skin,  
lungs  and  intestinal  mucosa,  and  are  likely  responsible  for  the  normal  patrolling  function  
exerted  by  many  organ-­‐‑specialyzed  leukocytes  during  the  steady  state.  
  
1.2.2.  Chemokine  receptors  
  
Chemokines  exert  their  biological  function  binding  their  receptor  (or  receptors),  that  is  a  7  
transmembrane   protein,   of   the  Υ-­‐‑subfamily   of   the   rhodopsin-­‐‑like   receptors.   Chemokine  
receptors   can   be   divided   in   the   following   groups:  G-­‐‑protein   coupled   receptors   (GPCR),  
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which   are   usually   coupled   to   αi   (but   also   αq   and   α11)   Gα-­‐‑subunit,   and   non-­‐‑signaling  
atypical  chemokine  receptors.  
  
1.2.3.  Regulatory  mechanisms  of  chemokine  signaling  
  
The  signal  triggered  by  the  binding  of  a  chemokine  to  its  own  receptors  involves  a  series  
of  molecules,   that  vary  depending  on  the   identity  of   the  G  protein  α  subunit.  Generally,  
GPCR  activation  causes   the  dissociation  of   the  α  and   the  βγ  subunits:  βγ   (but  also  α,   in  
case  of  a  αi-­‐‑coupled  receptor)  can  thus  activate  phosphatidil   inositol  3-­‐‑kinase  (PI3K)  and  
phospholipase   C   (PLC),   eliciting   calcium  mobilization   from   intracellular   compartments  
and  diacylglycerol  (DAG)  production  from  membrane  phosphatidil  inositol  trisphosphate  
(PIP3).   In   addition,   PLC   activates   RAP1   guanine-­‐‑nucleotide   exchange   factors   (GEFs)  
CALDAG-­‐‑GEFs   (calcium-­‐‑   and   diacylglycerol-­‐‑regulated   GEFs).   Furthermore,   G   proteins  
containing  αi  activate  DOCK2   (dedicator   of   cytokinesis   2),  while   those   that   contain  α12/13  
can  activate  the  small  GTPase  RHO-­‐‑A  (RAS  homologue  A)127.  These  events  lead  to  a  wide  
range  of  cellular  responses,  for  example  the  integrin  activation  on  the  cell  surface,  due  to  
the   actin   cytoskeleton   remodeling,   a   process   called   inside-­‐‑out   signalling.   Chemokine  
stimulation   through   its   receptor   can   also   trigger   gene   transcription   (pro-­‐‑inflammatory,  
pro-­‐‑survival  or  anti-­‐‑apoptotic  genes),  cell  polarization,  formation  of  a  leading-­‐‑edge  and  of  
a  uropod128.  
  
Intracellular   pathway.   The   fine   tuning   of   chemokine   signalling   is   ensured   by  multiple  
levels  of  control:  in  first  place,  after  receptor  engagment  and  consequent  cell  activation,  the  
stimulation  is  terminated  by  the  intrinsic  GTPase  activity  of  α  subunits,  that  can  hydrolyze  
GTP   and   reunite  with  βγ   to   return   to   the   initial   conformation  of   inactive  heterotrimers.  
This   process   can   be   controlled   by   proteins   known   as   regulators   of   G-­‐‑protein   signaling  
(RGS)129,  and  can  both  enhance  and  inhibit  GTPase  activity  of  the  α  subunit,  depending  on  
the  chemokine  receptor.  
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Another  mechanism  that  regulate  chemokine  signaling  is  receptor  desensitization,  which  
consists   in   the   lack   of   the   activity   of   the   receptor   due   to   the   excessive   phosphorylation  
mediated   by   G-­‐‑protein-­‐‑coupled   receptor   kinases   (GRKs)   of   serine   residues   on   the   C-­‐‑
terminal   portion   of   the   receptor130.   Following   prolonged   exposure   to   its   ligands,   a  
chemokine   receptor   can   also   be   downregulated,   through   the   internalization   in   clatrin-­‐‑
coated  pits  (CCP)  or  in  caveolae  by  β-­‐‑arrestin  or  adaptin1131,  132,  133.  As  with  desensitization,  
the   molecules   mediating   internalization   recognize   and   dock   to   phosphorylated   serines  
(and   threonines)  on   the   carboxy-­‐‑terminal  portion  of   the  GPCR,  even   though   the   specific  
aminoacids  recognized  are  different,  allowing  a  distinct  regulation.  
  
Association   with   GAGs.   In   vivo,   chemokine   effects   are   further   modulated   by   the  
association  to  glycosamminoglicans  (GAGs).   In   fact,  chemokines  are  seldom  present   in  a  
“nude”   state,   but   are   instead   associated   to   carbohydrate   structures   such   as   heparan  
sulfate,  chondroitin  sulfate,  dermatan  sulfate  or  keratan  sulfate,  which  are  believed  to  be  
important   in   processes   like   the   formation   of   the   chemotactic   gradient134,   chemokine  
halflife135,   haptotaxis   or   chemokine   neutralization129.   Although   every   chemokine   can  
virtually  bind  every  GAG,  specific  associations  have  been  shown  to  be  preferred,  probably  
depending  on  the  chemokine  tridimensional  structure  and  on  the  compartment  in  which  
the   chemokine   is   produced   and   secreted.   GAG   “decoration”   has   been   shown   to   affect  
important  features  like  receptor  affinity,  and  can  consequently  be  included  in  the  group  of  
the  regulators  of  chemokine  activity.  
  
Tertiary   structure.   Although   the   great   majority   of   chemokines   exist   only   as   soluble  
proteins,   there   are   two   exceptions,   CX3CL1   and   CXCL16,   that   are   also   present   in   a  
membrane-­‐‑bound   form,   and  are   thus   tethered   to   the   cell   surface.  Both  proteins  have   an  
extracellular   chemotactic   domain,   a   transmembrane  domain   and   a   cytoplasmic   tail,   and  
can   be   shed   by   different   enzymes136,   137.   The   two   forms   in   which   those   CX3CL1   and  
CXCL16  are  presented  to  responsive  cells  can  influence  cell  migration  differently,  and  the  
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degree  of  their  shedding  by  metalloproteases  represents  an  additional  level  of  chemokine  
modulation.  
  
Quaternary   structure.   The   ability   of   a   given   chemokine   to   bind   to   its   receptor   is   also  
determined  by   their  quaternary   structure.   It   is  widely  documented   that  both   chemokine  
and  chemokine   receptors  can   form  homodimers  and  heterodimers,  or  even  higher  order  
multimers,  alone  in  solution  or  in  association  with  GAGs138,  139,  140  although  it  is  still  unclear  
what   are   the   exact   consequences   for   this   phenomenon.   It   has   been   shown   that   the  
formation  of  chemokine  oligomers  in  vivo  can  enhance  leukocyte  recruitment141,  142,   likely  
because   of   an   association   to   GAG   binding.   Other   groups   have   reported   the   synergistic  
action   of   heteromeric   chemokine   aggregates,   increasing   chemotactic   activity   and   cell  
activation143,   144,   145.   At   the   same   time,   chemokine   receptors   oligomerization   is   not   well  
understood,  but  it  is  known  that  it  can  influence  their  surface  expression  or  their  binding  
and  signalling  capacity  through  allosteric  modulation146.  At  any  rate,  it  is  believed  that  this  
superior   structural   organization   and   interaction   will   introduce   a   further   degree   of  
complexity  into  chemokine-­‐‑induced  signaling129.  
  
Post-­‐‑translational   modifications.   In   the   delicate   balance   of   the   chemokine   system,  
particular   attention   should   be   paid   to   chemokine   alternative   forms,   derived   by   the  
proteolitic  action  of  dipeptidylpeptidase  IV  (DPPIV,  or  CD26).  This  enzyme  is  expressed  
by   many   hematopoietic   cells,   and   is   highly   selective   for   peptides   containing   a   Proline  
residue   at   position   2   of   the  N-­‐‑terminus,  which   is   a   common   feature   of   one   third   of   the  
known   chemokines147.   There   are   also   other   proteases   able   to   cut   chemokines,   such   as  
Cathepsins   (G   and  D)   and   elastases,   and   they   can   cleave   in   the   core   or   even   in   the   C-­‐‑
terminal   region   of   peptidic   sequence.   The   products   of   the   protease   action   can   have  
antagonistic  effect,  enhanced  agonistic  effect,  loss  of  receptor  binding  capacity,  or  even  no  
effect129.   For   example,   proteolitic   cleavage   of   CXCR3   ligands   CXCL10   and   CXCL11   by  
CD26   results   not   only   in   a   10-­‐‑fold   reduction   of   chemotactic   potency148,   but   also   in   an  
antagonistic  effect  of  CXCR3  signaling.  Conversely,   the   truncated   forms  of  CCL6,  CCL9,  
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CCL15  and  CCL23  have  an   increased  affinity   for  CCR1  as   compared   to   their   full-­‐‑lenght  
form149,   and   CCL4   can   even   acquire   specificity   for   CCR1   (although   as   an   antagonist)  
following  N-­‐‑terminus   cleavage,  while   its   full-­‐‑lenght   form  does  not   bind   this   receptor   at  
all150.  
  
1.2.4.   Atypical   chemokine   receptors:   from   walk-­‐‑on   to   main  
characters  
  
During   inflammation,   great   amounts   of   pro-­‐‑inflammatory   factors   are   released   in   the  
extracelluar  space,  and  chemokines  make  no  exception.  An  important  role  in  maintaining  
acceptable  chemokine  concentrations  in  inflamed  tissues  is  played  by  atypical  chemokine  
receptors   (ACKRs),   which   in   the   past   have   been   also   known   as   decoys,   interceptors,  
scavengers   or   chemokine-­‐‑binding.   Recently   there   has   been   growing   interest   concerning  
their  function  in  many  pathological  contexts,  such  as  microbial  infection  and  tumors,  but  
also   in  physiological  processes,   for   example   leukocyte   recirculation   to  peripheral   lymph  
nodes.  ACKRs  differ   from  classical   signalling   chemokine   receptors  under  many  aspects:  
structurally,  the  sequence  motif  DRYLAIV,  highly  conserved  in  the  former  ones,  is  either  
absent   or   poorly   conserved   in   the   latter   ones.   This   parameter   is   currently   used   (among  
others)   to   identify   new   putative   ACKRs   (such   as   the   new   entries   ACKR6   and   C5L2).  
Another  distinctive  property  of  ACKRs  is  their  different  signaling  pathway,  that  does  not  
pass   through  a  G  protein,  but   is  still  able   to   internalize   the  bound  ligand:   this  process   is  
called   “scavenging”,   and   represents   the   most   important   feature   of   these   proteins.   For  
ACKRs,  ligand  internalization  by  endocytosis  is  β-­‐‑arrestin-­‐‑dependent,  and  can  lead  to  the  
phosphorylation  of  the  actin-­‐‑binding  protein  cofilin  through  the  Rac-­‐‑p21-­‐‑activated  kinase  
1-­‐‑LIM  kinase  1  cascade151.  However,  following  chemokine  recognition  no  ACKR  is  able  to  
induce  cytoplasmic  calcium  release,  activation  of  PI3K  pathway,  or  any  other  G  protein-­‐‑
dependent   signaling   cascade,   and   this   is   another  paradigm  of  ACKR   function,  useful   in  
the  identification  of  new  members  of  this  protein  family.  
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The  majority   of  ACKRs   degrade   the   internalized   chemokines   through   the   fusion   of   the  
endocytic   vesicle   with   a   lysosomial   vesicle,   resulting   in   the   complete   clearance   of   the  
protein   from  the  environment.  ACKR1-­‐‑mediated  sequestration,   though,  does  not   lead   to  
chemokine   degradation,   suggesting   a   different   regulatory   mechanisms   for   chemokine  
scavenging  in  specific  compartments  or  for  specific  chemokines152.  
Being  their  function  opposite  to  signaling  chemokine  receptors,  it  is  also  conceivable  that  
different  cell  types  express  ACKRs.  In  fact,  ACKR1  is  not  found  on  leukocytes,  but  only  on  
endothelial   cells   of   venules   and   small   veins,   and   costitutively   on   erithrocytes153,   154.  
Similarly,  ACKR2   is  widely  expressed   in  “barrier”   tissues,   such  as  skin,  gut,  placenta  or  
lung119.  
ACKRs   can   bind   broad   spectra   of   chemokines,   but   usually   belonging   to   the   same  
functional  class:  for  instance,  ACKR1  is  highly  promiscuous  as  it  presents  affinity  for  more  
than  20  chemokines  (CC  and  CXC  chemokines),  primarily  of  the  inflammatory  group155,  156,  
while   ACKR4   binds   only   homeostatic   chemokines   (CCL19,   CCL21   and   more   weakly  
CXCL13)157.   The   existence   of   ACKR   that   are   able   to   specifically   bind   homeostatic  
chemokines   reflects   the   importance  of   this   chemokine   regulation   system  also  during   the  
steady  state,  and  specifically  during  development.  ACKR3  recognizes  CXCL12  and,  as  for  
CXCR4,  ACKR3-­‐‑deficiency,  particularly  in  endothelial  cells,  is  lethal  in  mice158,  indicating  
an  important  function  in  the  formation  of  normal  cardiac  structures  for  ACKR3.  Evidences  
for  ACKR3  role  in  other  developmental  programs  have  been  found  in  zebrafish,  where  it  
regulates  CXCL12  gradient,  necessary  for  primordial  germ  cell  migration159.  Interestingly,  
it  has  also  been  shown  that  ACKR3  can  heterodimerize  with  CXCR4,  downmodulating  the  
G  protein-­‐‑dependent  signaling  activity  after  CXCL12  ligation,  and  shifting  the  towards  the  
arrestin  axis160.  Differently,  ACKR4  targeted  disruption  generates  healthy  mice,  although  
they   display   a   more   rapid   onset   of   the   multiple   sclerosis   model   EAE   (experimental  
autoimmune  encephalomyelitis)161,  likely  attributable  to  the  impaired  capacity  of  DCs  and  
thymic  precursors  to  home  to  lymph  nodes  and  to  thymus,  respectively162.  
Furthermore,   the   “silent”   chemokine   receptors   are   involved   in   cancerogenesis,   being  
relevant  in  the  control  of  cancer-­‐‑related  inflammation,  especially  ACKR3,  which  has  been  
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related   to   tumors   of   both   hematopoietic   (lymphomas)   and   mesenchymal   (sarcomas,  
prostate  and  breast  cancer)  origin119.  
  
1.2.5.  The  tight  link  between  chemokines  and  cancer  immunology  
  
Inflammation   has   recently   been   recognized   as   a   hallmark   of   cancer   163,   164,   for   several  
reasons:   first,   inflammatory   diseases   increase   tumor   susceptibility   (extrinsic   pathway),  
and,  secondly,  in  epidemiologically  unrelated  cancers  induced  by  genetic  events  (intrinsic  
pathway)   there   is   a   common   inflammatory   signature165,   166.   Chemokines   are   part   of   the  
network   of   inlammatory   mediators   associated   to   neoplastic   events,   especially   those  
belonging  to  the  inflammatory  group  (CC  and  CXC,  mostly),  and  their  involvement  can  be  
deduced   from   a   pletora   of   evidences.   For   instance,   the   degree   of   tumor   associated  
macrophages  (TAMs),  which  often  is  proportional  to  the  disease  severity,  is  unequivocally  
linked   to   CCL2/CCR2   axis.   Moreover,   while   at   first   the   tissue   where   blood-­‐‑borne  
metastatic  cells  homed  to  was  believed  to  be  regulated  uniquely  by  mechanical  factors,  it  
has   been  proven   that  many   types   of   cancer   preferentially  metastasize   to   specific   organs  
(BM,   lymph  nodes,   lung,   liver),  while   other   organs  were   rarely   interested   by  metastatic  
events   (stomach,   kidneys)167.   In   addition,  mice  deficient   for   the   aforementioned  ACKR2,  
which  scavenges  most  of   inflammatory  CC  chemokines,   showed   increased  susceptibility  
to   skin   carcinogenesis   and   colitis-­‐‑associated   cancer   (a   paradigmatic   example   of  
inflammation-­‐‑cancer  connection)168,  169.  
Generally  speaking,  chemokines  can  influence  tumor  growth,  the  tissue  of  metastasis,  and  
anti-­‐‑tumor  immune  responses  in  two  ways:  directly  acting  on  cancer  cells  or  modulating  
the   behavior   (i.e.   migratory   properties)   of   tumor-­‐‑infliltrating   leukocytes,   but   it   is   likely  
that  in  vivo  both  phenomena  might  be  observed  at  the  same  time.  
  
Chemokines   and   cancer   cells.   Regarding   the   former   mechanism,   the   acquisition   of  
chemokine  receptor  expression  is  intrinsic  in  the  molecular  pathways  that  characterize  the  
tumorigenesis.   In   fact,   it   has   been   shown   that   downstream   of   RET   (papillary   thyroid  
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carcinoma),  beta-­‐‑catenin  (breast  cancer),  Ras,  mutant  p53,  Myc  and  Notch1170,  171,  172,  173,  174,  175  
several  chemokines  and  related  receptors  are  targeted:  for  example  in  acute  myelogenous  
leukemia   high   levels   of   the   transcription   factor   MEF2C   causes   upregulation   of   the  
expression   of   CCL2,   CCL3   and   CCL4176,   directing   invasiveness   of   cancer   cells.  
Additionally,   through   a   GWAS   (genome   wide   association   scan)   it   was   evidenced   that  
genetic   instability   at   cxcr4   locus,   with   functional   consequences   at   the   protein   level,  
correlated   with   incidence   of   familial   forms   of   chronic   lymphocytic   leukaemia   (CLL)177.  
Conversely,  when   a   tumor-­‐‑suppressor   gene   expression   such   as  TGFβ  was   lost   in   breast  
cancer  cells,  it  resulted  in  increased  secretion  of  inflammatory  chemokines  CXCL1,  CXCL5  
and  CCL20178,  179.  
  
Being   neoangiogenesis   fundamental   for   tumor   progression,   as   it   provides   oxygen   and  
nutrients   to   the   highly   demanding   cancer   cells,   many   studies   have   been   conducted   to  
assess  CXC  chemokines’  role  in  this  process.  The  pro-­‐‑angiogenic  signals  can  directly  come  
from   tumor   cells   or   indirectly   from   leukocytes   recruited   by   the   tumor  
microenvironment180.  
As   already   mentioned   above,   ELR+   CXC   chemokines   display   a   proangiogenic   effect,  
especially   on   CXCR1+/CXCR2+   endothelial   cells:   the   formation   of   new   blood   vessels   is  
promoted   increasing   endothelial   cells   resistance   to   pro-­‐‑apoptotic   stimuli   or   enhancing  
their   proliferative   potential,   after   CXCL5   and   CXCL8   ligation.   CXCR2   activation   can  
induce  production  and  secretion  of  metalloproteases   like  MMP-­‐‑2  and  MMP-­‐‑9,  which  are  
responsible  for  extracellular  matrix  remodeling,  but  also  of  key  molecules  for  angiogenesis  
such   as   VEGF   and   FGF2181.   A   synergistic   effect   of   CXCL12   and   VEGF   in   angiogenesis  
enhancement  has  been  evidenced  by  Kryczek  and  colleagues   in  human  ovarian   cancers,  
and  CXCR4  triggering  by  CXCL12  has  been  related  to  augmented  endothelial  cell  survival  
and  consequent  increase  of  vascularization182.  Besides,  CXCL12  can  attract  endothelial  cell  
precursors  from  blood  or  BM,  father  expanding  CXCR4  involvement  in  vessel  formation183.    
An   opposite   role   has   been   proven   for   CXCR3   ligands   CXCL9,   CXCL10   and   CXCL11,  
which  block  endothelial  cell  proliferation  in  several  tumors184.  
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Proangiogenic   chemokines   can   as   well   exert   their   functions   indirectly,   for   example  
recruiting   neutrophils   at   the   early   stage   of   the   disease185,   TAMs,   myeloid-­‐‑derived  
suppressor   cells   (MDSCs),   DCs   and   Tie-­‐‑2-­‐‑expressing   macrophages.   These   cells   can  
synthetize  a  great  variety  of  pro-­‐‑tumoral  moieties,   among  which   there  are  VEGF,  PDGF  
(platelet-­‐‑derived  growth  factor),  TGFβ,  metalloproteases  and  CXCL8  itself186,  187.  
Despite  the  great  number  of  strategies  used  by  transformed  cells  to  create  new  routes  for  
oxygen   and   nutrients   delivery,   one   of   the   most   common   features   of   tumor  
microenvironment  is  hypoxia,  mainly  because  of  the  disruption  of  tissue  architecture  and  
for  the  high  metabolic  request  of  dividing  cells.  Hypoxia-­‐‑inducible  factor-­‐‑1  α  (HIF-­‐‑1α)  is  
rapidly   expressed   when   the   oxygen   pressure   decreases   under   normoxic   levels,  
determining   several   responses,   including   promotion   of   vascularization.   CXCR4   is  
activated  downstream  the  signaling  pathway  initiated  by  HIF-­‐‑1α,  and  is  thus  upregulated  
in   hypoxic   conditions188,   but   is   also   induced   in   case   of   gene   mutations   of   von   Hippel-­‐‑
Lindau  (VHL),  a  negative  regulator  of  HIF-­‐‑1α189.  
In   ovarian   cancer,   it   has   been   shown   that   HIF-­‐‑1α   stimulates   secretion   of   CCL28,   a  
chemoattractant  for  T  regulatory  cells  (Tregs)  (and  type-­‐‑2  polarized  cells,  generally),  thus  
estabilishing   an   immunosuppressive   environment   and   increasing   intratumoral   vascular  
density  through  production  of  VEGFA190.  
  
The  concept  of  “cellular  highways”  emerged  recently191,  and  takes  into  account  the  pivotal  
role   played   by   homeostatic   chemokine   receptors   in   directing   the   normal   leukocytic  
trafficking,   in   physiological   conditions.   As   a   result,   there   are   tissue-­‐‑specific   chemokinic  
axes   (e.g.   CXCR4/CXCL12   in   the   CNS   and   BM,   CCR7/CCL19-­‐‑CCL21   in   secondary  
lymphoid   tissues,   CCR9/CCL25   in   the   small   intestine   and   CCR10/CCL27   in   the   skin),  
which  can  univocally  address  responsive  cells  if  needed.  Tumor  cells  evolved  mechanisms  
to  exploit  this  system,  hijacking  the  highways  to  metastasize  in  distant  tissues192.  The  most  
common  chemokine  receptors  expressed  by  the  great  majority  of  tumor  cell   types  are  by  
far  CXCR4  and  CCR7191.    
Introduction	  
38	  
The   first   case   was   reported   by   Muller   and   colleagues193,   and   since   then   CXCR4   was  
extensively   investigated,   and   found   upregulated   on   more   than   20   different   tumor  
histotypes166,   where   almost   invariably   represents   a   poor   prognostic   sign   and   correlates  
with  lung,  liver  and  BM  metastasis192.  CXCR4  is  also  the  only  chemokine  receptor  whose  
expression   was   found   on   cancer   stem   cells   (CSCs),   in   glioblastoma   and   in   pancreatic  
cancer,  and   in   the   latter  case  CD133+/CXCR4+  cells  were   identified  at   the   front  of   tumor  
invasion,  and  determined  the  metastatic  phenotype  of  individual  tumors194,  195.  Besides  the  
ability  to  follow  chemokine  gradients  displayed  by  metastatic  cancer  cells,  it  was  reported  
that   at   certain   stages   of   tumor   development   and   spread,   malignant   cells   produce  
chemokines   (CXCL12,   primarily)   for   which   they   express   the   appropriate   receptor196,   197,  
endowing   them   with   a   survival   advantage   over   non-­‐‑transformed   cells   present   in   the  
microenvironment192,   generating   an   autocrine   signaling   loop   that   confers   resistance   to  
chemotherapy-­‐‑induced  apoptosis,  and  promotes  proliferation198.    
CCR7  expression   in  breast,  melanoma,  gastric   and  non-­‐‑small   cell   lung   cancer,  head  and  
neck  tumor  and  colorectal  carcinomas  are  associated  with  lower  survival  rates  in  patients  
and  higher  risk  of   lymph  nodal  metastasis.  CCR7  mRNA  levels  are  also   linked  to   tumor  
stage,  while  CCR7  was  demonstrated  to  mediate  brain  colonization  of  leukemic  cells  in  T-­‐‑
cell  acute  lymphoblastic  leukemia  (T-­‐‑ALL)175,  193.  
Other  CXC   chemokine   receptors   have   been   involved   in   the   promotion   and   guidance   of  
tumor   infiltration   and   metastatic   process,   such   as   CXCR1   and   CXCR2   in   malignant  
melanoma199,   CXCR3   in   B-­‐‑cell   chronic   lymphocytic   leukemia   (B-­‐‑CLL)200,   CXCR5   in   liver  
metastasis   of   colorectal   carcinoma201,   and   CXCR6   in   prostate   cancer202.   Similarly,   CC  
receptors   promote  metastasis   to   skin   (CCR4   and   CCR10),   to   intestine   (CCR9)   and   liver  
(CCR6),   while   CX3CR1   is   associated   to   bone   colonization   and   perineural   invasion   of  
pancreatic  adenocarcinoma166.  
  
The  chemokine  ability  to  trigger  pro-­‐‑survival  signals  in  cancer  cells  through  the  activation  
of  MAP/Erk  kinase  pathway  has  already  been  mentioned  for  CXCR4,  but  it  has  also  been  
reported   for   other   chemokine   receptors,   in   a   wide   array   of   oncologic   diseases.  
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Interestingly,   even   the   opposite   phenomenon   was   observed,   as   CCR5-­‐‑mediated   p53  
activation   inhibited   in  vitro  proliferation   in  breast  carcinoma  samples  and  cell   lines,  and  
furthermore   the   nonsense  CCR5Δ32  mutation   frequency   in   humans   is  more   frequent   in  
patients  with  larger  tumor  size  and  lower  disease-­‐‑free  survival203.  
  
Shaping  the  immune  response  in  the  tumor  microenvironment.  The  other  side  of  the  coin  in  
the  bond  between  chemokines  and  cancer  refers  to  leukocyte  recruitment  at  the  tumor  site.  
While  the  immune  system  is  supposed  to  appropriately,  specifically  and  quickly  respond  
to  neoplastic  hazard,  tumor  cells  can  contribute  to  the  shaping  of  the  infiltrate,  recruiting  
more  convenient  and  tolerant  cell  types.    
  
In  this  regard,  an  important  contribution  to  tumor  promotion  and  progression  is  given  by  
TAMs,  which   are   associated   to   advanced   stage  of  disease,   induction  of  neoangiogenesis  
and   inhibition  of  T  cell   response187,  204.  CC  chemokines,   in  particular  CCL2,  CCL5  and,   in  
some   cases   CCL7,   are   the   main   actors   in   TAMs   trafficking   to   tumor   site,   and   strongly  
correlate   with   number   and   frequency   of   TAMs   in   situ.   Both   neoplastic   cells   and  
surrounding  stromal  cells  are  responsible  for  CC  chemokines  production,  and  high  levels  
of  CCL2   and  CCL5   are   indeed  present   also   in   sera   of   carcinoma  patients205.  Among   the  
roles  played  by  TAMs   in   tumor  growth,   there   is   also   the   recruitment   of   other   immune-­‐‑
suppressive   cell   types,   such  as  Tregs,   through   the   release  of  CCL22   in  ovarian   cancer206,  
CCL20   in   colorectal   cancer207,   or   CCL1,   CCL17   and   CCL22   in   other   pathological  
conditions208.  
CCL2/CCR2   axis   has   been   proven   to   be   important   even   for   the  migration   of  MDSCs   to  
tumor   site209,   together   with   CXCR4/CXCL12   and   CXCR2/CXCL5179,   and   in   some   cases  
(melanoma)  CCL21210.  
  
Less  clear  is  the  effect  of  the  neutrophils,  as  their  presence  in  the  leukocytic  infiltrate  has  
been  associated  to  poor  prognosis,  as  happens  for  TAMs,  MDSCs  and  Tregs211,  and  thus  a  
polarization   towards   the   so   called   N2   phenotype   has   been   hypothesized.   Sideways,  
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tumors   that   artificially   over-­‐‑express   CXCL8,   the  major   neutrophil-­‐‑attractant   chemokine,  
show  better  clinical  outcomes  when  injected  into  recipient  mice212.  
  
DCs  are  found  in  several  types  of  tumors,  and  are  generally  considered  beneficial  for  the  
anti-­‐‑tumor  response,  though  they  often  display  an  immature  state  and  a  refractoriness  to  
activation/maturation  signals.  CCL20,  CCL5,  CCL19  and  even  CXCL12  are  the  chemokines  
known  to  be  important  for  DC  recruitment  in  tumors,  like  pancreatic  carcinoma,  papillary  
thyroid  carcinoma,  breast  carcinoma  and  ovarian  carcinoma210.  
  
As  opposed  to  ELR+  CXC  and  many  CC  chemokines,  CXC  ELR-­‐‑  chemokines  such  as  CXC3  
ligands  CXCL9,  CXCL10  and  CXCL11  are  in  many  cases  responsible  for  the  promotion  of  
NK   cell   and   T   cell  migration   to   tumor   site,   generally   resulting   in   antitumor   responses.  
These  chemokines  are  induced  by  type  I  and  type  II  IFNs,  and  are  thus  symptomatic  of  a  
functional  type  1  polarization  of  the  cancer-­‐‑related  inflammation210.  Their  levels  within  the  
tumor  correlates  with  effector  cell  number,  creating  a  positive  feedback  loop,  as  NK  cells,  
CD4+  and  CD8+  T  cells  are   strong  producers  of   these  proteins  upon  activation.  CX3CL1  
and   CXCL16   are   other   recruiters   of   NK,   T   and   NKT   cells,   and   are   expressed   in   renal  
cancer,   neuroblastoma   and   colorectal   carcinoma213,   214.   CCR5-­‐‑specific   chemokines   like  
CCL3,   CCL4   and   CCL5   play   an   important   role   in   antitumor   imunity,   more   or   less  
overlapping  the  function  of  CXCR3  ligands.  
A   different   strategy   employed   by   the   immune   system   to   oppose   tumor   growth   is   the  
formation  of  tertiary  lymphoid  structures  (TLS),  where  an  efficient  adaptive  response  has  
been  observed   in   lung  cancers,  and  associated  with  patient   long-­‐‑term  survival215.  The  de  
novo  synthesis  of  TLS   is  promoted  by  CCL19,  CCL21,  CCL17,  CCL22  and  CXCL13,   that  
can  additionally  be  involved  in  the  interplay  between  B  cells,  T  cells  and  DCs  to  produce  a  
specific  antitumor  response.  
  
ACKRs   in   tumor   immunology.   Given   the   multifaceted   role   of   chemokines   in   tumor  
immunology,   it   is   not   surprising   that   atypical   chemokine   receptors   could   significantly  
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influence   cancer-­‐‑related   inflammation.   As   of   now,   data   concerning   the   most   studied  
ACKRs   are   available   in   the   literature   at   this   regard   (ACKR1,  ACKR2   and  ACKR3),   and  
interestingly  show  that  ACKRs  involvement   is  non  redundant  and  varied.   It   is  currently  
known   that   ACKR1,   that   acts   as   “chemokine   sink”216,   clears   from   the   circulation   the  
chemokines  that  recruit  immune  suppressive  cells,  such  as  TAMs  (CCL2)  or  MDSC  (CXC  
ELR+),   to   tumor   site;   consequently   when   in   a   melanoma   murine   model   ACKR1   was  
overexpressed   on   endothelial   cells,   cancer   cell   apoptotic   rate   was   increased,   while  
angiogenic   rate   significantly   diminished217.   Besides   its   inflammatory   and   proangiogenic  
chemokine  scavenging  function,  it  has  ben  proposed  that  ACKR1  might  favour  anti-­‐‑tumor  
response  as  well  by  directly  inducing  apoptosis  in  neoplastic  cells  through  the  interaction  
with   the   tetraspanin  molecule  KAI1/CD82218.   Collectively,  ACKR1   role   is   believed   to   be  
befeficial  for  tumor  immune  response.  
The  function  of  ACKR2  is  on  the  same  lines  of  ACKR1,  as  its  expression  frequently  results  
inversely   correlated   with   TAMs   infiltrate,   and   directly   correlated   with   disease-­‐‑free  
survival219.  
In   contrast,  ACKR3   role   seems   to  be   likely  pro-­‐‑tumoral,   as   its   overexpression  on   cancer  
cells  promotes  adhesion  molecule  production  (such  as  cadherin-­‐‑11  and  CD44),  enhancing  
invasion  and  angiogenesis220.  ACKR3,   like   its   functional  counterpart  CXCR4,   is   found  on  
several  tumor  types,  and  it  is  a  direct  target  in  the  pathway  of  Hypermethylated  in  Cancer  
1  (HIC1),  a  tumor  suppressor  gene  early  inactivated  during  tumor  progression221.  
  
Chemokine   post-­‐‑translational  modifications.   An   additional   control   level   that   might   be  
regulated   by   cancer   cells   to  manipulate   immune   response   is   represented   by   chemokine  
post-­‐‑translational   modifications.   As   mentioned   above,   chemokines   can   be   cleaved   by  
proteases,  citrullinated,  deiminated,  nitrated  and  glycosilated222,  and  although  this  issue  is  
still  quite  unexplored,  recent  data   indicate   that   tumor  progression  can  also  pass   through  
chemokine   processing.   For   example,   the   soluble   form   of   CXCL16   has   been   shown   to  
promote  CXCR6+  cell  proliferation  and  migration,  while  reduced  cancer  cell  proliferation  
and  detachment  rate  if  present  in  its  transmembrane  form223.  
Introduction	  
42	  
Furthermore,   CCL2   nitration/nitrosylation   induced   by   reactive   nitrogen   species   (RNS)  
within  the   tumor  has  been  found  to   impair  cytotoxic  T   lymphocytes   (CTLs)  recruitment,  
while  TAMs  capacity  to  migrate  to  the  chemokinic  gradient  was  unaffected224.  Indeed,  this  
novel   tumor   immune   escape   strategy   could   be   of   interest   for   future   therapeutic  
intervention  protocols.  
  
Chemokine  and  tumors  –  the  example  of  HHV8  and  perspectives.  A  paradigmatic  case  of  
the   importance   of   the   chemokine   system   in   tumor   progression   is   represented   by   the  
mechanism  of  action  of  the  etiologic  agent  of  Kaposi  sarcoma  (KS)  and  other  hematologic  
malignancies,   the   human   herpesvirus   8   (HHV8).   Viral   proteins   divert   host   immune  
response   in   two  ways:   the   first   through   the   costitutive   production   of   the   viral   receptor  
vGPCR,   which   interacts   with   both   ELR+   and   ELR-­‐‑   CXC   chemokines,   enhancing  
autonomous   cell   proliferation   and   promoting   the   classic   KS   lesions.   The   second  
mechanism  of   action   is  mediated  by   three  viral  proteins   (vMIP-­‐‑I,   vMIP-­‐‑II   and  vMIP-­‐‑III)  
that  mimic  the  structure  of  endogenous  CC  chemokines,  and  are  able  to  bind  CCR3,  CCR8  
and  CCR4,  recruiting  Tregs  and  other  type  2  polarized  immune  cells225.  
Collectively,   it  appears  clear  that  cancer  related  inflammation  might  be,  and  currently  is,  
an   optimal   target   for   the   oncologic   therapy.   Efforts   are   being   made   to   test   chemokine  
receptor   antagonists   (i.e.   AMD3100226),   or   neutralizing   mAbs   specific   for   certain  
chemokines  (i.e.  αCCL2227),  but  it  appears  likely  that  the  study  of  alternative  mechanisms  
of  immune  evasion  orchestrated  by  cancer  cells,  such  as  the  proliferative  advantage  given  
by   the   autocrine   chemokine/chemokine   receptor   loop,   or   the   promotion   of   chemokine  
post-­‐‑translational   processing,   can   contribute   to   the   understanding   of   the   link   between  
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1.3.  Multiple  myeloma  
1.3.1.  General  information,  disease  stages  and  molecular  markers  
Multiple  myeloma   (MM)   is   a   neoplastic   plasma-­‐‑cell   disease,   characterized   by   the   clonal  
proliferation   of   malignant   plasma   cells   prevalently   in   the   bone   marrow228,   and   less  
frequently  in  extramedullary  tissues.  Among  the  signs  of  this  disorder,  the  most  important  
are   the   presence   of   monoclonal   protein   in   the   blood   and   urine   and   associated   organ  
disfunction.    
MM  represents  about  1%  of  total  neoplastic  diseases,  and  13%  of  hematologic  cancers,   is  
usually  diagnosed  later  in  life  (around  70  years  of  age),  and  currently  the  treatments  rely  
on   autologous   stem   cell   transplantation   and   subministration   of   several   classes   of  drugs,  
such  as  alkylating  agents   (melphalan),   IMiDs  (thalidomide,   lenalidomide)  or  proteasome  
inhibitors  (bortezomib).  New  treatment  protocols  have  improved  the  managment  of  MM  
course,   and   extended   patients   survival229,   though   this   pathology   is   still   classified   as  
incurable.  
Commonly,   the   pathology   evolves   from   an   initial   age-­‐‑dependent   pre-­‐‑malignant   stage  
known  as  monoclonal  gammopathy  of  undetermined  clinical  significance  (MGUS),  which  
affects  2%  of  the  population  above  the  age  of  50230,  with  a  risk  of  progression  to  MM  of  1%.  
MGUS   displays   abnormal   monoclonal   spike,   but   not   organ   disfunction,   and   usually  
precedes  the  phase  of  smoldering  MM  (SMM),  in  which  the  involvement  of  bone  marrow  
plasma  cells  can  reach  30%  of  total  cells,  and  the  risk  of  advancement  to  symptomatic  MM  





Figure   9   –  Pathogenesis   and   stages   of  Multiple  Myeloma.  MM   arises   from   a  
germinal  centre-­‐‑B  cell,   in  30-­‐‑50%  of  cases  passing  by   the  benign  MGUS  phase  
and  often  by  the  Smouldering  phase.  With  MM  progression,  tumor  cells  obtain  
the   ability   to   colonize   extramedullary   tissues   (blood,   pleural   fluid,   skin)   and  
thus  to  metastasize.  Below,  the  most  important  features  of  each  MM  stage,  such  
as  angiogenetic  and  osteolytic  bone  resorption  potential  are  shown.  Moreover,  
some   of   the   extramedullary   MM   can   estabilish   immortalized   cell   lines   in  
vitro232.  
  
The  transition  to  the  terminal  stage  of  MM  is  due  to  many  oncologic  events:  probably  the  
earliest  one  is   the  dysregulation  of  the  cyclin  D  gene233,  which  is  already  observed  at  the  
MGUS  step.  Indeed,  many  genetic  abnormalities  occur  in  plasma  cells,  and  can  be  divided  
in  primary  and  secondary,  depending  on  the  phase  in  which  they  most  frequently  occur.  
Primary   translocations   are   early   observed   in   MM   pathogenesis,   and   involve   the  
juxtaposition  of  the  immunoglobulin  switch  region  on  oncogenes,  like  c-­‐‑MAF  and  MMSET  
on  chromosome  14,   in  which  case  resulting   in   the  deregulation  of  MMSET  and,   in  some  
cases,  FGFR3.    
Differently   from   other   B-­‐‑cell   malignancies,   this   kind   of   chromosomal   modifications  
simultaneously  dysregulates  a  great  variety  of  genes.  Secondary  events  are  characterized  
by  c-­‐‑Myc  dysregulation,  activating  mutations  in  NRAS  and  KRAS2,  as  well  as  monosomy  
of   chromorome   13,   inactivation   of   cyclin-­‐‑dependent   kinase   inhibitors   CDKN2A   and  
CDKN2C232.   Moreover,   epigenetic   alterations   (i.e.   gene   methylation)   and   microRNA  
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expression  have  been  related  to  MM  pathogenesis.  Besides,  MM  patients  can  be  classified  
also   according   to   a   transcriptional   signature,   as   recently   evidenced   by   Zhan   and  
colleagues234.  
  
1.3.2.  The  importance  of  bone  marrow  microenvironment  
  
The   almost   exclusive   localization   of   MM   cells   in   bone   marrow   is   due   to   the   peculiar  
microenvironment   present   in   this   organ,   both   in   terms   of   cellular   and   non   cellular  
components.  
As   an   example,   bone   marrow   highly   expresses   CXCL12,   which   represents   a   pivotal  
chemotactic   cue   for   CXCR4+   MM   cells,   whose   organ   retention   and   capacity   to   grow  
significantly   relies   on   this   receptor.   Within   bone   marrow   cellular   component,  
hematopoietic  and  non  hematopoietic  cells  can  be  found,  the  former  consisting  in  T,  B,  NK  
and   NKT   lymphocytes,   DCs,   and,   during   MM   progression,   MDSCs.   In   turn,   the   latter  
includes   adypocytes,   bone   marrow   stromal   cells   (BMSCs),   endothelial   cells   (ECs),  
osteoclasts  (OCs)  and  osteoblasts.  
MM   cells   are   able   to   generate   significant   modifications   in   their   surroundings,   actively  
contributing   to   the   formation   of   bone   lesions   and   neovascularization   through   the  
interaction   with   BMSCs   and   ECs,   while   they   inhibit   osteoblasts   thus   impairing   bone  
neosynthesis.   In  parallel,   the  normal   immune   response   is   shifted   towards   tolerance  or   a  
type  2,  or  as  recently  shown,  type  17  cancer-­‐‑related  inflammation.  These  condition  leads  to  
the  formation  of  the  so  called  “MM  niche”,  or  in  other  words  an  environment  that  allows  
tumor  growth,  cell  survival  and  drug  resistance235.  
  
Non-­‐‑hematopoietic  components  of  the  MM  niche.  A  great  variety  of  adhesion  molecules  
are   expressed   by   myeloma   cells   and   enable   them   to   interact   with   BMSCs   and   the  
components  of   the   extracellular  matrix   (ECM):  very   late   antigen-­‐‑4   (VLA-­‐‑4)  on  MM  cells  
binds  to  vascular  cell  adhesion  molecule  1  (VCAM1)  on  BMSCs,  while  the  VLA-­‐‑4  together  
with   CD138,   also   known   as   syndecan-­‐‑1   mediate   the   interaction   of   MM   cells   to   ECM  
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components,  such  as  collagen  I  and  fibronectin.  Other  important  proteins  involved  in  MM  
adhesion   are   CD44,   LFA-­‐‑1,   CD56   and  MPC-­‐‑1,   besides   the   fundamental   role   played   by  
CXCR4236.  This  complex  set  of  connections  triggers  anti-­‐‑apoptotic  signals  in  MM  cells  and  
upregulates  cell-­‐‑cycle  regulating  proteins237,  favoring  tumor  growth.    
  
Upon  interaction  with  MM  cells,  BMSCs  activate  the  NFkB  pathway  and  produce  IL-­‐‑6:  this  
cytokine   upregulates   the   expression   and   secretion   of   pro-­‐‑angiogenic   factors,   such   as  
VEGF,   which   acts   on   MM   cells,   creating   a   paracrine   loop   that   optimizes   MM   growth  
conditions238.   IL-­‐‑6   release,   combined  with  VEGF  and   insulin-­‐‑like  growth   factor-­‐‑1   (IGF-­‐‑1)  
production,  is  also  induced  in  MM  cells  and  BMSCs  following  Notch  pathway  activation,  
which   is   correlated   to  MM  proliferation  and   survival239.  Besides,   IL-­‐‑6  plays  a   role   in   the  
formation  of  bone  lesions240,  it  is  induced  by  pro-­‐‑inflammatory  cytokines  such  as  TNFα  in  
BMSCs,   and   determines   the   polarization   of   CD4+   T   cells   towards   a   Th17   phenotype,  
further  contributing  to  disease  progression.  Collectively,  IL-­‐‑6  stands  out  as  a  key  molecule  
in  the  MM  milieu,  as   it   is  produced  by  paracrine  (BMSCs  and  osteoblasts)  and  autocrine  
mechanisms,   and   accordingly   its   serum   levels   inversely   correlate   with   disease-­‐‑free  
survival241.  
Interestingly,   it  has  been  shown  that   IL-­‐‑6  and  TNFα,   together  with  bFGF  and  TGFβ,  are  
potent   inducers   of   VEGF   in   BMSCs   and  MM   cells,   demonstrating   once  more   the   close  
relation  among  the  several  factors  involved  in  tumor  pathogenesis242.  
  
As   previously   mentioned,   bone   lesions   are   a   hallmark   of   multiple   myeloma,   and   are  
caused   by   a   large   number   of   factors.   The   balance   between   bone   production   and  
mineralization  (osteoblasts  activity)  and  bone  resorption  (OCs  activity)   is  frequently  lost,  
because   of   osteoclast   formation   and/or   hyperactivation.   Perhaps   the   most   important  
molecule   involved   in   this   process   is   Receptor   activator   of   NK-­‐‑kB   ligand   (RANKL),   a  
member  of  TNF  family,  produced  by  MM  cells.  RANKL  is  an  essential  growth  factor  for  
OCs,   since   through   the   binding   to   its   receptor   RANK   on   OCs,   it   mediates   OC  
differentiation   and   inhibits   apoptosis243.   The   action   of   RANKL   is   attenuated   by  
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osteoprotegerin   (OPG),   a   soluble   decoy   for   RANKL   produced   by   BMSCs,   whose  
concentration  in  BM  plasma  is  found  decreased  in  MM  patients,  resulting  in  OC  activation  
and  bone  destruction244.    
Besides   RANKL,   the   chemokine   CCL3   was   identified   as   an   important   player   in   OC  
activation  for  the  first  time  by  Choi  and  colleagues245,  as  it  stimulates  osteoclastogenesis,  in  
concert  with  RANKL  and  IL-­‐‑6246.  Another  CC  chemokine,  CCL5,  has  been  demostrated  to  
mediate  osteoclastogenesis,  thus  suggesting  a  broader  role  for  CCR1  and/or  CCR5  ligands  
in  the  process  of  bone  destruction247.  Moreover,  CCL3  and  CCL4  might  influence  contact-­‐‑
dependent   MM   cells-­‐‑mediated   osteoclastogenesis,   since   CCR1   and   CCR5   binding   on  
BMSCs   induces   the   expression   of   adhesion   molecules   such   as   VCAM-­‐‑1,   that,   in   turn,  
upregulates  RANKL  and  downmodulates  OPG248.  
Among  the  factors  that  trigger  the  formation  of  bone  lesions  IL-­‐‑3  might  be  important,  as  it  
exerts  its  function  in  a  dual  mode.  From  one  hand  it  activates  OCs,  while  on  the  other  it  
impairs  osteoblastogenesis  through  an  indirect  mechanism,  which  involves  the  monocytic  
lineage249.   Additionally,   TNFα,   CXCL12,   hepatocyte   growth   factor   (HGF)   and  
thrombospondin-­‐‑1  have  been   reported   to  be  upregulated   in  bone   lesions,   and  are   likely  





Figure   10   –  MM   cells   deeply   influence   and   shape   BM   microenvironment.   Tumor   cells  
promote  a  wide  array  of  affects  within  the  BM,  for  example  modulating  osteoclast  activity  
and   differentiation   through   IL-­‐‑6,   RANKL   or   CCL3.   Their   effects   on   osteoblast   activity  
(DKK1)   and   on   stromal   cells   (VCAM1)   are   also   displayed,   resulting   in   bone   resorption,  
neoangiogenesis  and  MM  cell  survival228.  
  
The  contribution  of  osteoblasts  to  MM  pathogenesis  is  probably  less  clear;  in  fact,  they  can  
support   myeloma   growth   through   the   production   of   IL-­‐‑6   and   OPG,   which   can   inhibit  
TRAIL-­‐‑mediated  MM  cell  apoptosis  by  binding  to  RANKL  and  to  TRAIL253.  At  the  same  
time,  osteoblastic  differentiation  is  blocked  by  several  factors,  including  the  Wnt-­‐‑signaling  
antagonist   DKK1   (produced   by   MM   cells),   secreted   frizzled   protein-­‐‑2   (sFRP2),   sFRP3,  
TNFα  and  sclerostin254,  255,  256,  257,  but  also  osteoblastic  proapoptotic  molecules,  such  as  IGF-­‐‑
BP4,  IL-­‐‑7  and,  as  recently  suggested,  TGFβ  and  activin  A258,  259,  260,  261.  
Introduction	  
	   49	  
It   is   likey   for   those  mechanisms   that   the   total   osteoblast   number  within   bone   lesions   in  
MM  patients   is  most   frequently  reduced  as  compared   to  healthy  subjects,  and  correlates  
negatively  with  tumor  progression  and  disease  stage262.    
  
How  the  leukocytes  (try  to)  respond:  role  of  the  immune  system.  The  other  half  of  the  story  
is   related   to   the   influence   that   MM   cells   have   on   what   should   be   an   efficient   and  
productive  anti-­‐‑tumor  response.   Indeed,   the  concept  of  MM  niche   is  defined  also  by   the  
presence  of  tolerant  leukocytes  and  the  exclusion  of  most  dangerous  ones  (or  even  by  their  
functional  impairment),  a  process  that  is  referred  to  as  tumor  immuno-­‐‑editing.  
  
A  great  deal  of  the  immune  response  against  cancer  is  carried  out  by  T  lymphocytes:  the  
bone  marrow   is   an   important   reservoir   for   effector/memory  T   lymphocytes   (TEM),   and   a  
DC-­‐‑based   cell   vaccine   has   shown   that   bone   lesions   contain   tumor-­‐‑specific,   potentially  
active,  T  cells263.  Moreover,  other  groups  have  focused  on  the  role  of  marrow-­‐‑infiltrating  
lymphocytes   (MILs),   that   are   able   to   produce   high   levels   of   IFNγ,   thus   blunting   OC  
outgrowth,   when   cocoltured   in   vitro264,   and   to   display   a   higher   tumor   specificity   than  
PBLs  stimulated  with  anti-­‐‑CD3/anti-­‐‑CD28  beads265.  
Nevertheless,  many  T   cell   dysfunctions  have  been  described   in   relation   to  MM,   such   as  
CD4+  T  cell  lymphopenia,  which  represents  a  marker  of  advanced  disease,  lower  survival  
rate  and  increased  risk  of  relapse266  267.  In  addition,  the  normal  proportion  of  CD4  and  CD8  
T  cells  has  been  found  inverted,  while,  within  CD4  T  cell  population,  an  abnormlly  high  
Th1:Th2  cell  ratio  has  been  reported268.    
Furthermore,   soluble   molecules   like   TGFβ   can   suppress   CD8   T   cell   effector   function,  
including  the  production  of  perforin,  granzyme  A  and  B,  FasL,  and  IFNγ,  through  a  IL-­‐‑2  
autocrine   pathway269,  while   the   impaired   expression   of   co-­‐‑stimulatory  molecules   (CD28  
and   CD40L)   and   signal   trasduction   proteins   (CD3ξ   and   ZAP-­‐‑70)   is   associated   to   more  
advanced  stages  of  the  disease270.  
An   important  role   in  MM  progression   is   thought   to  be  played  also  by  other  CD4+  T  cell  
subpopulations,  specifically  Th17  and  Tregs.  IL-­‐‑6  is  among  the  cytokines  that  induce  both  
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of   those  phenotypes;   for   instance,   IL-­‐‑6   in   combination  with   IL-­‐‑23   and  TGFβ  determines  
Th17   differentiation,   via   a  MM   cell   STAT3-­‐‑dependent  mechanism271.   As   for   Tregs,   their  
actual   function   in  MM  has  not  been   clearly  determined  yet.  Contrasting  data   evidenced  
either  the  paucity272  or  the  increase273  of  this  population  in  MM  patients,  and  at  least  some  
of  those  differences  could  be  possibly  due  to  the  examined  compartment  or  to  the  criteria  
used   to   define   Tregs   241.  At   any   rate,  MM   cells   are   able   to   induce  Tregs   formation   both  
directly,   through   the   expression   of   ICOS-­‐‑L274,   and   indirectly,   in   an   APC-­‐‑dependent  
manner,  often  mediated  by  DCs275,  suggesting  that  Treg  contribution  might  be  significant.  
  
Another  key  component  of  BM  infiltrate  in  MM  are  the  dendritic  cells,  whose  primary  task  
shoud  be  to  cross-­‐‑present  tumor  related  antigens  (TRA),  activate  effector  cells  and  recruit  
leukocytes   to   the   tumor   site.   As   described   for   other   types   of   malignancies,   the  
dysregulation   of   DC   function   mainly   consists   of   low   maturation   capacity,   with  
consequential   impairment   of   T   cell   activation,   and   in   reduced   number   of   circulating  
precursors,   both   of  myeloid   (CD11c+)   and   plasmacytoid   (CD11c-­‐‑   CD123+)   lineage.   This  
results  in  an  immature  phenotype  displayed  by  in  situ  DCs,  with  lower  expression  levels  
of  HLA-­‐‑DR,  CD40  and  CD80,  and  lower  capacity  to  induce  allogeneic  T  cell  proliferation  
and  to  present  tumor  antigens  to  specific  lymphocytes276.  Besides,  DCs  from  MM  patients  
with   stable   disease   fail   to   upregulate   CD80/CD86   expression   in   response   to   IL-­‐‑2   and  
CD40L277.  
The   factors   that   promote   DC   maturative   and   functional   impairment   include   IL6,   since  
IL6Rα-­‐‑deficient   DCs   have   been   shown   to   be   functionlly   competent   and   to   mediate  
protective  immunity278,  but  also  IL-­‐‑10  and  TGFβ,  through  a  p38-­‐‑dependent  mechanism279.  
Moreover,  HGF,  VEGF   and   β2-­‐‑microglobulin   have   been   reported   to   be   involved   in  DC  
functional  inhibition280.    
A  deeper  understanding  of  the  processes  that  lead  to  DCs  functional  defect  is  fundamental  
for   the   development   of   novel   therapeutic   vaccination   approaches,   which   so   far   have  
proven  to  produce  interesting  results  in  vivo241.  
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Figure  11  –  Immune  response  is  modulated  by  tumor  cells.  Schematic  representation  
of  the  interplay  between  MM  cells  and  leukocytes  within  BM.  TGFβ  and  PD-­‐‑1L  can  
suppress  T  and  NK  cell  effector  response,  together  with  high  expression  of  MHC-­‐‑I  
(which   blocks  NK   cells)   and   the   impairment   of  DCs  maturation   (thus   interfering  
with  T  cell  activation).  In  parallel,  T  regs  and  Th17  are  actively  induced  from  MM  
cells,  favouring  a  tolerant  environment280.  
  
Accumulating   evidences   link   NK   cells   to  MM,   portraying   those   innate   lymphocytes   as  
important  sentinels   in  myeloma-­‐‑related   immune  response.  The  ability  of  NK  cells   to  kill  
MM   cells   in   vitro   has   been   documented   years   ago   by   Frohn   and   colleagues281,   and   has  
been  further  investigated  by  other  groups,  in  search  for  an  alternative  strategy  to  treat  this  
disease.  
On  a  molecular  level,  NK  cells  recognize  and  are  able  to  mediate  cytotoxicity  against  MM  
cells  mainly  through  activating  receptors,  such  as  NKG2D  and  DNAM-­‐‑1,  since  it  has  been  
described   that  myeloma   cells   express   high   levels   of  MIC-­‐‑A,  MIC-­‐‑B   (NKG2D   ligands)282,  
PVR   and   Nectin-­‐‑2283.   Intriguingly,   it   has   been   described   that   different   clones   of   MM  
express  either  NKG2D  or  DNAM-­‐‑1  ligands,  but  not  both  at  the  same  time,  suggesting  an  
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immune   selection   of   the   NK   cells   during   tumor   progression282.   In   fact,   while   NKG2D  
ligands  are  generally  present  solely  on  the  surface  of  transformed  cells,  DNAM-­‐‑1  ligands  
can  be  found  also  on  the  membrane  of  healthy,  normal  cells,  adding  further  complexity  to  
the   mechanisms   underlying   NK   cell-­‐‑MM   interaction.   Moreover,   NCRs   (NKp46   in  
particular)   are   involved   in   MM   recognition   and   clearance   by   NK   cells,   although   the  
specific  ligands  that  mediate  the  binding  have  not  been  defined  yet283.  
Besides,  tumor  cells  can  escape  the  immune  control  exerted  by  NK  cells  even  by  increasing  
the  membrane  shedding  of  NKG2D  ligand  MIC-­‐‑A284.  This  process  is  mediated  by  ERp5,  a  
disulphydic   isomerase   whose   expression   is   induced   in   MM   patients.   MIC-­‐‑A   cleavage  
generates  a  soluble  form  of   the   ligand,   that   is  able   to   impair  NKG2D-­‐‑dependent  NK  cell  
activation   and   degranulation,   representing   an   important   form   of   defense   for  MM   cells.  
Nevertheless,   the   immune   system  has   accordingly   adapted   to   this   strategy,   through   the  
formation  of  antibodies  specific  for  MIC-­‐‑A  soluble  form  (sMIC-­‐‑A),  and  indeed  the  titer  of  
these   antibodies   has   been   found   increased   in   patients   with   active  MM   as   compared   to  
subjects  with  MGUS284.  
An   important   regulator  of  MIC-­‐‑A  expression  on  MM  cells   is  glycogen  synthase  kinase-­‐‑3  
(GSK-­‐‑3),   that  downmodulates  MIC-­‐‑A   through   the   activation  of   the   signaling   transducer  
STAT3285.   In   this   work,   the   authors   proposed   that   the   inhibition   of   GSK-­‐‑3,   a  
serine/threonine  kinase  on  which  many  signaling  pathways  converge,  might  be  exploited  
in  vivo  to  enhance  NK  cell-­‐‑mediated  cytotoxicity.    
In   the   last   years,   a   line   of   research   focused   on   the   role   of   chemotherapeutic   drugs  
administered  at  low  doses  on  the  upregulation  of  NK  cell  activating  ligands.  Indeed,  it  has  
been  demonstrated   that  sublethal  doses  of  melphalan  and  doxorubicin,  genotoxic  agents  
currently   used   in  MM   therapy,   induce  NKG2D   and  DNAM-­‐‑1   ligand   overexpression   on  
tumor   cells   in   vitro,   through   an  ATM   (Ataxia-­‐‑Telangectasia  mutated)/  ATR   (ATM-­‐‑   and  
RAD3-­‐‑  related)-­‐‑dependent  mechanism,  associated  to  cellular  senescence286.  
As   emerging   data   support   the   importance   of   NK   cell   control   on   MM   progression,   it  
appears  clear  that,  for  some  reason,  endogenous  BM  and  peripheral  NK  cells  are  unable  to  
efficiently   counter   tumor   growth.   At   this   regard,   NK   cell   adoptive   transfer   therapeutic  
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protocols  are  being  tested,  in  order  to  have  an  appropriate  number  of  functional  (primed)  
NK  cells.  This  strategy  could  be  used  after   the  classic  chemotherapy,   thus  exploiting   the  
MIC-­‐‑A,  MIC-­‐‑B  and  DNAM-­‐‑1  overexpression  on  MM  cells,  or  could  completely  bypass  it  
in   the   future.  Alici   and   colleagues   tried   successfully   to   expand   and   activate  NK   cells   in  
vitro  with  IL-­‐‑2  stimulation,  before  transplanting  them  in  a  murine  model  of  MM,  reporting  
a   significant   achievement   in   terms   of   tumor   growth   and   survival287.   The   same   group  
attempted   to   expand   in   vitro   human  NK   cells   derived   from   peripheral   blood   of   newly  
diagnosed  MM  patients,  and  tested  their  functionality  ex  vivo  against  primary  MM  cells,  
in  an  autologous  setting,  obtaining  encouraging  results288.  The  same  strategy  has  proven  to  
be  successful  in  a  humanized  murine  model  of  multiple  myeloma,  where  transplanted  NK  
cells   derived   from   human   healthy   donors  were   able   to   reduce   tumor   growth   and   bone  
lesion289.  
A  different  approach  bases  on  the  capacity  of  the  NK  cells  to  detect  the  “missing  self”:  in  
other  words,  NK   cells   from  haplo-­‐‑identical   donors   can   be   transplanted   in   patients   after  
autologous   stem   cell   transplantation   (ASCT)   exploiting   the  HLA   (recipient)/KIR   (donor)  
mismatch.  In  this  condition,  NK  cells  display  a  strong  graft  versus  leukemia  (GvL)  effect,  
and  a  lower  Graft  versus  Host  disease  (GvHD).  That  aside,  the  quantity  of  haploidentical  
NK  cells  was  not   sufficient   to  obtain  a   complete   remission   in   that   conditions;  moreover,  
the  difficulty  in  finding  an  appropriate  HLA/KIR  mismatched  donor  make  this  therapeutic  
approach  quite  demanding290.  
  
1.3.3.  5TMM  –  A  reliable  murine  model  of  Multiple  Myeloma  
  
SCID-­‐‑hu  models.  Several  murine  model  for  MM  are  described  in  literature,  and  a  group  of  
them   involves   SCID   (severe   combined   immunodeficiency)   mice,   which   present   the  
advantage   of   having   human   myelomatous   cells   transplanted291,   292,   293,   294,   295:   SCID-­‐‑hu  
(humanized)   mice   can   be   useful   to   test   in   vivo   the   cellular   response   and/or   systemic  
toxicity  of  novel  pharmacological  compounds,  but  present  evident  limits  in  relation  to  the  
interaction   between   human   MM   cells   and   the   environment,   or   with   the   endogenous  
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immune   system.  Moreover,   commonly   these  models   are   heterotopic,   as   tumor   cells   are  
often   injected   sottocutaneously,   or   even   in   artificial   scaffolds   that   mimic   human   bone  
structure.  
  
Transgenic  models.  An  alternative  approach  of  development  for  murine  models  of  MM  is  
represented  by  mice  with  genetic  mutations  that  cause  the  overexpression  of  oncogenes,  in  
particular   the   ones   related   to   B   cell   lineage.  MAF,  XBP-­‐‑1s   and   c-­‐‑Myc   are   some   of   these  
genes,  and  have  been  targeted  for   the  generation  of  such  models296,  297,  298.  Although  these  
genetically   modified   mice   reproduce   some   features   of   human   multiple   myeloma,   the  
causal   relationship   between   gene  mutation   and   disease   estabilishment   has   not   yet   been  
demonstrated,  thus  the  genetic  alteration  may  not  fully  represent  the  MM  progression.  
  
The  5TMM  model.  The  5TMM  model   in  mice  was  first  described  by  Radl  and  colleagues  
several   years   ago   (in   fact   it   is   also   called   Radl   model)299,   and   consists   in   the   i.v.  
transplantation  in  young  C57BL/KaLwRij  mice  (6-­‐‑10  weeks  old)  of  a  cell  line  derived  from  
the  BM  of  syngeneic  elderly  mice,  that  spontaneously  develop  a  pathology  very  similar  to  
human  MM.    
About  33%  of  MM  patients  develop  the  pathology  passing  first  by  the  MGUS  phase,  while  
the   remaining   cases   present   de   novo  myelomas,   or,   in   other  words,  MM   caused   by   the  
direct   transformation  of  plasma  cells   into  over  myeloma300,  and  5TMM  model  belongs  to  
the  latter  category301.  
Many   of   the   characteristics   of   human   MM   heva   been   detected   in   5TMM   models,   for  
example  osteolytic  bone  lesions,  increased  angiogenesis  and  the  presence  of  paraprotein  in  
serum302,  303,  304,  305.   Several   cell   lines  have  been  derived   from  C57BL/KaLwRij  MM-­‐‑bearing  
mice,  and  have  been  used  for  5TMM  models,  the  most  studied  of  which  are  5T2  and  5T33.  
The   first   induces   a   slower,   less   aggressive   and  more   BM-­‐‑tropic  MM   (clinical   symptoms  
detectable    
12  weeks  after   injection),  while   the  second  grows  more  rapidly,  and  displays   the   typical  
hallmarks  of  MM  already  at  the  4th  week  after  transplantation303.  
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In   this   work   the   5TMM  model   was   used,   with   the   i.v.   transplantation   of   5TGM1   line,  
which   derives   from   5T33,   and   presents   the   advantage   of   proliferating   easily   in   vitro  
without  IL-­‐‑6  (like  5T33)  or  feeder  cells  (like  5T2)306.  Being  even  more  aggressive  than  5T33  
cell  line,  5TGM1  are  capable  of  colonize  spleen  and  liver,  probably  for  their  hematopoietic  
nature  in  mice,  besides  of  course  BM.  Several  studies  reported  that  the  homing  preferences  
of   transplanted   MM   cells   can   be   distinguished   after   the   first   18   hours,   when   they  
accumulate   in   BM,   spleen   and   liver,   while   decreasing   in   blood   and   lung307.   Many  
molecules  have  been   involved  with   the   initial  homing  process  of  5TGM1  to  BM,  such  as  
CCL2,  CCL3,  IGF-­‐‑1,  CD44v,  CXCL12  and  CXCR3  ligands308,  309,  310,  311,  312,  and  have  provided  
important  insights  in  MM  pathogenesis.    
Overall  the  5TGM1  5TMM  model  represents  a  useful  tool  to  characterize  the  multi-­‐‑organ  
progression  and  estabilishment  of  Multiple  Myeloma,  and  also  to  evaluate  its  interactions  
with  the  numerous  components  of  the  immune  system.  
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2.  Aim  of  the  thesis  
  
BM  is  the  organ  where  NK  cell  development  mainly  occurs,  and  thus  where  virtually  all  
NK  cell  differentiation  stages  can  be  found.  There  are  several  factors  influencing  NK  cell  
development,   including   transcription   factors,   cytokines   and   interaction  with   other   cells,  
belonging  both  to  the  hematopoietic  and  to  the  stromal  compartment.  
The   role   of   chemokines   and   chemokine   receptors   has   recently   emerged   as   part   of   the  
components   that   drive   NK   cell   maturation   process,   likely   driving   the   positioning   of  
responsive   subsets   in   the   correct   BM   niche.   In   particular,   homeostatic   chemokine   axes  
seem  to  be  significantly  involved  in  this  phenomenon,  as  for  example  CXCR4  expression  is  
progressively   downregulated   in   various   NK   cell   subsets   during   development313,   while  
S1P5,   one   of   the   five   receptors   for   the   chemotactic   lipidic   molecule   sphingosine-­‐‑1  
phosphate  (S1P),  is  strongly  expressed  by  NK  cells  prevalently  during  the  terminal  phase  
of  their  maturation  in  the  BM116.    
  
The   role   of   CX3CR1   in  NK   cells  was   previously   investigated   in   inflammatory   contexts,  
such  as  NK  cell   recruitment   to   the  brain   in  experimental  autoimmune  encephalomyelitis  
(EAE)314   and   CMV   infection315.   Besides,   CX3CL1   was   found   to   induce   NK   cell  
cytotoxicity316,  to  mediate  melanoma  lung  metastasis  clearance  by  NK  cells  in  vivo317,  and  
to  enhance  cardiac  allograft  rejection318.  Lastly,  CX3CR1  has  been  demonstrated  to  have  a  
role  in  NK-­‐‑DC  interaction  during  inflammatory  conditions319.  
  
In  the  steady  state  CX3CR1  has  been  studied  mainly  in  relation  to  the  myeloid  lineage,  as  
it   has   been   reported   to   play   an   important   role   in   DCs   development   and   monocyte  
biology320,321,322.  So  far,   there  are  no  data  regarding  CX3CR1  role   in  NK  cell  development,  
trafficking  or  functional  properties  in  homeostatic  conditions.  
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Through  the  use  of  a  transgenic  mouse  model,  our  group  focused  its  attention  on  CX3CR1  
on  NK  cells,  where  it  has  a  similar  expression  pattern  to  that  of  S1P5,  as  it  is  preferentially  
expressed  by  the  CD11b+/KLRG1+  subset323,  which  is  abundantly  located  in  the  sinusoidal  
compartment   of   the   BM.   As   this   receptor   expression   is   developmentally   and   spatially  
regulated,   in  the  first  part  of  this  thesis  the  phenotypical  and  functional  consequences  of  
CX3CR1  deficiency  on  murine  NK  cells  will  be  described,  with  a  particular  emphasis  on  
the  BM  trafficking  capacities  of  different  NK  cell  subsets.  The  effect  of  CX3CR1  absence  on  
NK   cells  was   investigated   both   during   steady   state   conditions   and   in   a  model   of   acute  
hepatic   inflammation,   namely   Poly(I:C)   subministration.   The   results   obtained   in   this  
framework  shed  light  on  the  involvement  of  CX3CR1  in  NK  cell  retention  within  the  BM.  
  
While   the   trafficking   capacities   to   BM   and,   eventually,   to   metastatic   sites   of   multiple  
myeloma   cells   have   been   extensively   studied241,   308,   309,   so   far   little   is   known   about   the  
migratory   properties   of   immune   cells   during   tumor   growth,   both   in   situ   and   in   the  
peripheral  organs.  The  level  of  several  chemokines  has  been  found  altered  in  MM324,  325,  but  
the   direct   consequences   of   these   environmental   modifications   on   leukocytic,   and   more  
specifically,  on  NK  cell  recruitment  to  tumor  site  have  not  been  assessed  yet.  
  
Thus,  given  the  notable  importance  of  the  BM  microenvironment  for  NK  cell  development  
and   functional   maturation,   and   considering   the   modifications   induced   by   multiple  
myeloma   growth   in   the   same   organ,   the   second   part   of   this   work   will   deal   with   the  
reciprocal   influence   between   NK   cells   and   MM   cells   during   tumor   progression   in   BM  
microenvironment.   To   this   aim,   a   murine   model   of   multiple   myeloma   was   first  
characterized   and   validated,   and   then   used   to   evaluate   several   features   of   NK   cell  
behavior,   including   their   killing   efficacy   against   tumor   cells,   their   expression   of  
maturation  markers  and  their  capacity  to  reach  and  reside  within  the  BM.  
  
The  balance  between  chemokine   receptor  expression,  both  homeostatic   (i.e.  CXCR4)  and  
inflammatory   (i.e.   CXCR3)   ones,   and   the   environmental   concentration   of   the   respective  
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ligands   has   a   critical   relevance   in   this   latter   aspect.   Moreover,   the   knowledge   of   the  
mechanisms   that  guide   lymphocyte  retention  within   the   tumor  site  at  different  stages  of  
MM  progression  will   be   extremely   valuable   in   light   of   a   future  NK   cell-­‐‑based   adoptive  
transfer  therapy  for  this  incurable  disease.  
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3.  Methods  
  
Mouse   Models.   Male   and   female   CX3CR1+/GFP   and   CX3CR1GFP/GFP   mice   were   purchased  
from  JAX  Mice  and  Services  (Bar  Harbor,  Maine,  USA),  and  were  bred  and  housed  in  the  
animal   facility  of   the   Istituto  Nazionale  Tumori  Regina  Elena,   in  Rome.  For   all  CX3CR1  
experiments,   female   mice   between   6   and   12   weeks   of   age   were   used.   Female  
C57BL/KaLwRij  mice  were  housed  in  the  animal  facility  of  the  Istituto  Superiore  di  Sanità  
(ISS),  in  Rome.  At  the  age  of  5  weeks  mice  were  injected  with  2x106  5TGM1-­‐‑LUC  cells,  and  
then  sacrificed  after  2,  3  or  4  weeks  of  tumor  growth.  Multiple  myeloma  progression  was  
assessed   at   the   moment   of   the   animal   sacrifice   by   staining   BM   and   splenic   cells   with  
IgG2b-­‐‑specific   antibodies.   Wild   type   C57BL/6   mice   Ly5.1   (CD45.1)   and   Ly5.2   (CD45.2)  
were   purchased   from   Charles   River   (Calco,   Italy)   and   used   for   adoptive   transfer  
experiments.  Animals  were   kept   under   specific   pathogen-­‐‑free   conditions,   in   accordance  
with   institutional   guidelines   for   animal   care   and   use.   Mice   were   killed   by   cervical  
dislocation  and  BM,  spleen,  liver,  blood  and  inguinal  LNs  were  collected.  
  
Cell   preparation   and   NK   cell   enrichment.   For   FACS   staining   experiments,   BM,   spleen,  
liver,  LNs  and  blood  were  processed  as  described  in  323:  briefly,  BM  cells  were  isolated  by  
extensive   flushing  of   femurs  and  tibias  with  PBS,  while  cells   from  spleen,   liver  and  LNs  
were   obtained   by   mechanical   disruption   on   a   70-­‐‑µμm   cell   strainer   (Falcon,   Becton  
Dickinson)   with   a   rubber   syringe   plunger   in   RPMI   10%   FBS.   Hepatic   white   cells   were  
further   separated   using   Lympholyte   (CL5031,   Cedarlane   Labs)   and   then   washed   and  
resupended   in  RPMI  10%  FBS.  Peripheral  blood   samples  were  obtained  by   tail  bleeding  
and  collected  in  heparin  containing  tubes.  
The  NK  cell  enrichment  from  BM  and  spleen  was  performed  in  two  steps:  first,  CD3+  and  
CD19+   (and  Gr-­‐‑1+   only   for   BM)   cells  were   depleted  with  Dynabeads   Biotin   Binder  Kit,  
Invitrogen   (Paisley,   UK)   according   to  manufacturer’s   instructions.   Secondly,   DX5+   cells  
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were  positively  selected  using  CD49b  (DX5)  MicroBeads  Kit,  Miltenyi  (Bergisch  Gladbach,  
Germany).  NK  cell  frequency  was  always  >  80%  of  total  cells.  
  
Antibodies,  cytokines  and  reagents.   Several  antibodies  directly   conjugated   to   fluorescein  
isothiocyanate   (FITC),   phycoerythrin   (PE),   peridinin   chlorophyll   protein   (PerCP)   5.5,  
allophycocyanin   (APC),  PE-­‐‑cyanine   (cy)7,  APC-­‐‑eFluor  780,  or  biotin,  and  specific   for   the  
following  antigens   (clone  name   in  parentheses)  were  used   in   this   study:  NK1.1   (PK136),  
CD3ε   (145-­‐‑2C11),   CD49b   (DX5),   CD11b   (M1/70),   KLRG1   (2F1),   CD19   (6D5),   c-­‐‑Kit(2B8),  
DNAM-­‐‑1  (TX42.1),  CD127  (A7R34),  IFN-­‐‑γ  (XMG1.2),  CD45.1  (A20),  CD45.2  (104),  CXCR4  
(2B11),   CXCR3   (220803),   CCR1   (643854),   CCR5   (C34-­‐‑3448),   CD107a   (1D4B),   BrdU   (3D4),  
CD138  (281-­‐‑2),  IgG2b  (RMG2b-­‐‑1)  and  respective  isotype  controls.  Abs  and  Pe-­‐‑cy7,  and  PE-­‐‑
conjugated  streptavidin  were  purchased  from  Pharmingen  (Becton  Dickinson,  San  Diego,  
CA),   eBioscience   (San   Diego,   CA),   Biolegend   (San   Diego,   CA)   and   R&D   Systems  
(Minneapolis,   MN).   Alexa   Fluor   647-­‐‑   and   FITC-­‐‑conjugated   Annexin   V   was   purchased  
from   Biolegend.   PE-­‐‑conjugated   mouse   anti-­‐‑human   IgG   was   purchased   from   Jackson  
Immunoresearch  Laboratories.  Purified  rat  anti-­‐‑mouse  Ly49G2  (4D11),  mouse  anti-­‐‑mouse  
Ly49C/I  (5E6)  mAb  were  from  Pharmingen.  
Recombinant  mouse   IL-­‐‑12  and  human  CXCL12,   IL-­‐‑15  and   IL-­‐‑2  were   from  Peprotech  EC  
(London,  UK).   Bovine   Serum  Albumin   (BSA),   Polyinosinic-­‐‑Polycytidylic   acid   (Poly-­‐‑I:C),  
bromo-­‐‑deoxyuridine   (BrdU),   saponin,   AMD-­‐‑3100   and   PKH26  were   from   Sigma-­‐‑Aldrich  
(St.  Louis,  MO).  
  
In   vitro   functional   assays.   In   order   to   perform   degranulation   assays,   BM   and/or  
splenocytes  from  CX3CR1+/GFP,  CX3CR1GFP/GFP  or  healthy  C57BL/KaLwRij  female  mice  were  
collected,   washed   in   PBS   and   incubated   overnight   in   complete   medium   supplemented  
with   IL-­‐‑15   (100   ng/ml)   at   106   cells/ml.   Stimulated   cells  were  washed   in   RPMI   10%   FBS,  
Hepes   10  mM,   and   5x105   cells  were   resuspended   alone,  with   the  mouse   lymphoma   cell  
line   YAC-­‐‑1   or   with   5TGM1   MM   cell   line   in   the   same   medium   supplemented   with  
monensin   (0.1  M)   and   IL-­‐‑2   (500   U/ml)   at   1:2   effector:target   (E:T)   ratio.   Cells   were   then  
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incubated  at  37°C,  5%  CO2  4  h  in  96  well-­‐‑plate.  During  the  last  3h,  PE-­‐‑  or  FITC-­‐‑conjugated  
anti-­‐‑mouse  CD107a  or  IgG  was  added  directly  into  each  well.  Next,  cells  were  harvested  
and   stained   with   anti-­‐‑CD3ε,   anti-­‐‑NK1.1   and   anti-­‐‑KLRG1   mAbs,   and   then   analyzed   by  
FACS.    
Intracellular  staining  for  IFN-­‐‑γ  was  performed  as  described  in  323  with  cells  isolated  from  
BM  and  spleen  and  cultured  for  18  h  in  complete  medium,  in  presence  of  IL-­‐‑2  (500  U/ml)  
and   IL-­‐‑12   (100   ng/ml)   or   of   IL-­‐‑2   alone   (500   U/ml).   Brefeldin   A   (10   mg/ml)   was   added  
during  the  last  6  hours  of  incubation.    
In  competitive  in  vitro  experiments,  splenocytes  from  Ly5.1+/Ly5.2+  CX3CR1+/GFP  mice  and  
Ly5.1-­‐‑/Ly5.2+   CX3CR1GFP/GFP   mice   were   mixed   at   1:1   ratio   before   cytokine   stimulation.  
Cells  derived  from  the  two  mouse  strains  were  identified  by  anti-­‐‑CD45.1  mAb  staining.  
Chemotaxis  assays  of  BM  (5  x  105)  and  spleen  (1  x  106)  cells  were  performed  in  5  µμm-­‐‑pore  
Transwell  insert  using  the  indicated  concentrations  of  CXCL12  as  described  in  323.    
For  the  cytotoxicity  assay,  YAC  cells  were  treated  for  1h  at  37°C  with  1mCi/mL  of  51Cr  per  
106   cells;   target   cells  were   then  washed   and   co-­‐‑incubated  with   enriched   (or   sorted)  NK  
cells   from   BM   or   spleen   for   4   hours   at   different   effector-­‐‑target   ratio   in   MW96.  
Radioactivity   was   analysed   with   a   β-­‐‑counter,   and   spontaneous   51Cr   release   was   also  
assessed.  Killing  frequency  was  evaluated  by  dividing  the  number  of  killed  targets  by  the  
number  of  effector  cells  for  each  E:T  ratio.  
  
Immunostaining  and  FACS  analysis.   Cells   from   the   indicated   organs  were  washed   and  
resuspended  in  staining  buffer  (PBS  without  Ca2+  Mg2+,  BSA  0,2%,  EDTA  2mM  and  NaN3  
0,025%).  The  anti-­‐‑CD16/32  (clone  24G2)  mAb  was  added  for  10  minutes  on  ice  to  prevent  
non-­‐‑specific  and  Fc-­‐‑mediated  binding.  Then,  cells  were  stained  with  the   indicated  mAbs  
diluted  in  staining  buffer  for  20  minutes  on  ice.    
Staining   for   CXCR4   was   performed   after   cell   incubation   for   2   h   at   37°C   in   5%   CO2   to  
optimize  membrane  expression  of  the  potentially  internalized  receptor.  For  all  chemokine  
receptor  staining,  cells  were  incubated  40  minutes  on  ice.  
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Intracellular  staining  for  IgG2b  was  performed  by  fixing  cells  with  1%  paraformaldehyde  
(PFA)  in  PBS,  and  by  permeabilizing  them  with  0,2%  TWEEN  in  PBS.  Cells  were  incubated  
with   biotinilated   anti-­‐‑IgG2b   specific   mAb,   washed,   and   stained   with   PE-­‐‑conjugated  
streptavidin.  
Samples  were  analyzed  using  a  FACSCanto  II  (BD  Biosciences)  and  data  were  elaborated  
using  Diva  Version  6.1.3  (BD  Biosciences)  or  FlowJo  Version  7.6  software  (TreeStar).  
  
ELISA  assay.   Several   chemokine  concentration   levels  were  assessed   in  BM  supernatants  
and   sera.   BM   supernatants   were   obtained   flushing   BM   cells   in   ice-­‐‑cold   PBS,   and  
centrifuging   cells   twice,   at   200   and   8000   rcf,   and   were   stored   at   -­‐‑80°C.   To   assess   the  
concentration  of  CXCL12,  CXCL9  and  CXCL10  we  made  use  of  specific  DuoSet  Kits  (R&D,  
Minneapolis,   US)   according   to   manufacturer’s   instruction.   For   BM   supernatants,  
chemokine   concentrations  were   normalized   to   total   protein   concentration  present   in   the  
extracellular  fluid,  assessed  with  Bio-­‐‑Rad  Protein  Assay  Kit,  Biorad  (Hercules,  CA).    
BM   supernatants   data   are   expressed   as   pg   of   protein/mg   of   total   extracellular   proteins,  
while  as  pg  of  protein/mL  for  serum  chemokine  level.  
  
Adoptive  transfer  experiments  
CX3CR1-­‐‑related   experiments.   Sorted   KLRG1+/CX3CR1+   and   KLRG1+/CX3CR1-­‐‑   (purity   >  
95%)   splenic   NK   cells   from   CX3CR1+/GFP   mice   were   adoptively   transferred   by   i.v.   tail  
injection  into  CD45.1/.1  C57BL/6  WT  female  mice,  and  BM,  spleen  and  liver  were  collected  
after  12  days.  Similarly,  total  splenocytes  from  CX3CR1+/GFP  mice  were  i.v.  injected  into  WT  
recipients,   and   organs   were   collected   after   18   hours   to   detect   the   localization   of   GFP-­‐‑
expressing  NK  cells.  
Splenocytes  from  CD45.1/.2  CX3CR1+/GFP  and  CD45.2/.2  CX3CR1GFP/GFP  mice  were  collected,  
mixed   at   1:1   ratio   and   stained  with   the   cell   fluorescent   dye   PKH26.   15x106   splenocytes  
were   i.v.   injected   in  C57/BL6  recipient  mice.  An  aliquot  was  saved  and  stained   to  assess  
the  input  ratio  (calculated  as  [CD45.1-­‐‑]cells/[CD45.1+]cells).  
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After  150  minutes,  24  and  36  hours,  BM,  spleen,  liver,  LN  and  blood  cells  were  collected,  
and   transferred  NK   cells  were   identified   by   immunofluorescence   and   FACS   as   PKH26+  
NK1.1+   CD3-­‐‑   cells.   To   discriminate   between   CX3CR1+/GFP   and   CX3CR1GFP/GFP,   PKH26+  
donor   cells   were   identified   as   CD45.1+   (CX3CR1+/GFP)   or   CD45.1-­‐‑   (CX3CR1GFP/GFP).   The  
homing   index   was   calculated   dividing   the   [CD45.1-­‐‑]organ/   [CD45.1+]organ   cell   ratio   by  
[CD45.1-­‐‑]input/  [CD45.1+]input  ratio  among  the  PKH26  labeled  cells.    
In  another  set  of  experiments,  106  sorted  PKH26–labeled  KLRG1+GFP-­‐‑  (purity  >  85%,  no  
GFP+  cell)  or  KLRG1+GFP+  splenic  NK  cells  (purity  >  95%)  from  CX3CR1+/GFP  (CD45.1/.2)  
and  CX3CR1GFP/GFP   (CD45.2/.2)  donor  mice  were  i.v.   injected  into  C57/BL6  recipient  mice.  
After  12h  and  36h,  BM,  spleen,  liver  and  blood  were  collected,  and  transferred  cells  were  
identified  as  PKH26+  CD45.1+  (CX3CR1+/GFP)  or  PKH26+  CD45.1-­‐‑  (CX3CR1GFP/GFP).  
In  a  third  set  of  experiments,  C57/BL6  recipient  mice  were  i.v.  injected  with  5x106  enriched  
splenic  NK  cells   from  CX3CR1+/GFP  CD45.1/.2  and  CX3CR1GFP/GFP  CD45.2/.2  donor  mice  at  
1:1  ratio.  Enrichment  of  NK  cells  was  performed  by  depleting  CD3+  and  CD19+  cells  with  
Dynabeads  Biotin  Binder  (Life  Technologies),  and  NK  cell  percentage  ranged  around  40-­‐‑
45%.    
  
MM-­‐‑related  experiments.  Total  splenocytes   from  8  weeks  old  female  C57BL/KaLwRij  were  
stained   intracellular   fluorescent   dye   PKH26,   and   12x106   PKH+   cells   were   injected   in  
control  and  tumor-­‐‑bearing  mice,  after  3  weeks  of  tumor  growth.  BM,  spleen,  lymph  nodes,  
liver  and  blood  cells  were   collected  after  18  hours,   and  were   stained  with  CD3-­‐‑,  NK1.1-­‐‑  
and  KLRG1-­‐‑specific  conjugated  antibodies.  
Alternatively,  C57BL/6  splenic  NK  cells  were  enriched  with  Dynabeads  Biotin  Binder  Kit,  
were   stained  with  CFSE   2  µμM,   and   transferred   in   control   and   tumor-­‐‑bearing  mice.   BM,  
spleen,   lymph  nodes,   liver  and  blood  cells  were  collected  after  150  minutes  or  18  hours,  
and  stained  with  CD3-­‐‑,  NK1.1-­‐‑,  KLRG1-­‐‑,  CXCR4-­‐‑  or  CXCR3-­‐‑specific  antibodies.  
In  a   third  set  of  experiments,  15x106   splenocytes   from  CD45.1/.1  C57BL/6J  WT  and   from  
CD45.2/.2  CXCR3-­‐‑/-­‐‑  mice   in  a  1:1   ratio  were   stained  with  CFSE  2  µμM  and   i.v.   injected   in  
control  or  tumor-­‐‑bearing  mice.  After  150  minutes  or  18  hours  BM,  spleen,  liver  and  blood  
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cells  were  collected  and  stained  as  before.  Donor-­‐‑derived  cells  were  identified  according  to  
their  CFSE-­‐‑  expression  and  CD45  allelic  variant.    
Data  were  analyzed  as  percentage  of  NK  cells  or  NK  cell  subsets  in  the  organ  compared  to  
total   injected   counterpart,   and   as   KLRG1-­‐‑/KLRG1+   ratio  within   the  NK   cell   transferred  
population,  corrected  for  the  KLRG1-­‐‑/KLRG1+  ratio  detected  in  the  input.  
To  assess  whether  KLRG1-­‐‑  NK  cells  acquired  KLRG1  expression  during   the  18  hours  of  
adoptive  transfer  in  vivo,  splenic  NK  cells  were  first  enriched  depleting  CD3+  and  CD19+  
cells,  and  then  KLRG1-­‐‑  cells  were  sorted,  stained  with  CFSE  and  injected  into  control  and  
tumor-­‐‑bearing  mice.  After  18  hours,  BM,  spleen  and  liver  were  collected,  and  transferred  
cells  were  analyzed  for  KLRG1+  expression.  
  
Labeling   of   sinusoidal   BM   NK   cell   populations   and   in   vivo   mice   treatments.   BM  
sinusoidal   NK   cells   were   identified   using   the   procedure   described   by   Pereira   and  
colleagues326.  Briefly,  2  minutes  before  sacrifice,  recipient  mice  were  i.v.  injected  with  1  µμg  
of   PE-­‐‑conjugated   anti-­‐‑CD45   or   anti-­‐‑α2   integrin   chain   (DX5)   mAb   diluted   in   PBS   as  
described   in   323.  After   cell   collection   and   staining,   parenchymal   and   sinusoidal  NK   cells  
can  be  identified  as  PE-­‐‑  and  PE+  cells,  respectively.  
AMD-­‐‑3100   (100  µμg  diluted   in   50  µμL  of  PBS)  was   subcutaneously   injected,   as  previously  
described113.  At   the  end  of   the   treatment,  mice  were  sacrificed  and  their  organs  collected  
for  immunostaining  and  FACS  analysis.  
For  MM  experiments,  NK  cell  depletion  was  obtained  by  intraperitoneally  injecting  anti-­‐‑
NK1.1   mAb   (clone   PK136)   (100   µμg/mouse/injection)   at   day   -­‐‑2   before   5TGM1  
transplantation,  and  the  depletion  was  maintained  with  subsequent  injections  2,  7  and  14  
days  after  5TGM1  infusion.  
  
In  vivo  proliferation  and  survival  assays.  One  milligram  of  BrdU  diluted  in  200  µμl  PBS  was  
in  vivo  administered   to  mice  by   intraperitoneal   (i.p.)   injection  every  8  h   for   three   times.  
Mice  were  sacrificed,  and  BM  and  spleen  cells  were  collected  and  stained  with  anti-­‐‑NK1.1,  
-­‐‑CD3ε,  and  -­‐‑KLRG1  specific  mAbs.  Following  fixation  and  permeabilization,  samples  were  
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washed  and  treated  with  0.45  µμg/ml  DNase.  Samples  were  then  incubated  for  1  h  at  room  
temperature  (RT)  with  anti-­‐‑BrdU  specific  mAb,  washed  and  analyzed  by  flow  cytometry.  
Annexin  V  staining  was  performed  on  BM  and  splenic  cells  following  the  manufacturer’s  
instructions.  
  
Bone   marrow   chimeras.   Eight   week-­‐‑old   female   C57BL/6   (CD45.1+/CD45.2-­‐‑)   mice   were  
irradiated  with   900   rads   (in   two   450   rad   doses  with   an   interval   of   3   h).   For   single   BM  
chimeras,   irradiated  mice  were   reconstituted   by   i.v.   injection   of   2x107   BM   cells   derived  
from   either   CD45.1/.2   CX3CR1+/GFP   or   CD45.2/.2   CX3CR1GFP/GFP   mice.   For   mixed   BM  
chimeras,   2x107   BM   cells   from   CD45.1/.2   CX3CR1+/GFP   and   CD45.2/.2   CX3CR1GFP/GFP   or  
CD45.2/.2  CX3CR1+/GFP  mice  were   i.v.   injected   in   irradiated   hosts   in   a   1:1   ratio.   In   some  
experiments,   irradiated   mice   were   reconstituted   with   BM   cells   from   NK   cell-­‐‑depleted  
mice.  Depletion  of  NK  cells  was  here  obtained  in  vivo  by  i.p.  injection  of  anti-­‐‑NK1.1  mAb  
(clone  PK136)  (100  µμg  /mouse/injection)  at  day  -­‐‑2  and  -­‐‑1  in  donor  mice  before  sacrifice.  NK  
cell   depletion   was   always   controlled   by   FACS   staining   for   CD3/NK1.1   the   PBMCs   of  
donor  mice  before   reconstitution.  Organs  of   recipient  mice  were  collected  after  5  weeks,  
and  donor-­‐‑derived  cells  were  identified  with  anti-­‐‑CD45.2  and  anti-­‐‑CD45.1  mAbs.  
  
Poly-­‐‑(I:C)  treatment.  CX3CR1+/GFP  and  CX3CR1GFP/GFP  mice  were  i.p.  injected  with  150  µμg  of  
Poly-­‐‑(I:C),  diluted  in  PBS.  BM,  spleen  and  liver  cells  were  collected  at  6,  18  and  72  hours  
after  the  injection.  The  total  number  of  BM  cells  corresponded  to  the  cell  count  from  two  
tibias   and   femurs.   Cells   were   stained   with   anti-­‐‑NK1.1-­‐‑,   anti-­‐‑KLRG1-­‐‑,   and   anti-­‐‑CD3ε-­‐‑
specific  mAbs  to  enumerate  total  NK  cells  (CD3-­‐‑  NK1.1+)  and  subsets  of  NK  cells.  NK  cell  
tissue   redistribution   during   inflammation  was   then   quantified   as   percentage   of  NK   cell  
number  in  Poly-­‐‑(I:C)-­‐‑treated  versus  untreated  control  mice.  
  
Statistics.  Unpaired   student’s   t   test  was  used   to   compare  experimental  groups,   and  a  p  
value  below  0.05  was  considered  statistically  significant.  To  analyze  competitive   in  vitro  
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assays   or   adoptive   transfers,   paired   student’s   t   test   was   used   to   compare   experimental  
groups,  and  likewise  a  p  value  below  0.05  was  considered  statistically  significant.  
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4.  Results  
  
4.1  First  part  –  CX3CR1   in  NK  cell  development  and  
function  
4.1.1.  Terminally  differentiated  NK  cells  express  CX3CR1  in  BM  and  
in  peripheral  organs  
  
We  initially  evaluated  CX3CR1  expression  on  NK  cells  using  a  genetically  modified  mouse  
model,   in   which   GFP   cDNA   replaced   one   copy   of   cx3cr1   gene,   but   was   still   under   its  
original   transcriptional   promoter327.   This  model   allowed   us   to   track  CX3CR1-­‐‑expressing  
cells  by  analysing  GFP  positivity  with  a  flow  cytometric  approach,  distinguishing  NK  cells  
as   CD3-­‐‑/NK1.1+   lymphocytes,   and   within   this   population   cell   subsets   were   defined  
according  to  CD11b  and  KLRG1  expression.  
Figure  12b  shows  the  CX3CR1+  NK  cell  frequency  is  high  in  peripheral  organs  (liver  and  
spleen),  while  their  proportion  is  much  lower  within  BM.  Likewise,  adoptively  transferred  
CX3CR1-­‐‑expressing  NK   cells   preferentially   localized   in   extramedullary   organs   18   hours  
after  injection  (Figure  12c).  When  BM  NK  cell  subsets  were  analysed,  CX3CR1  expression  
was   found   to   be   developmentally   regulated,   as   it   progressively   increased   from  
CD11blow/KLRG1-­‐‑   (6.3±1.5   %)   to   CD11bhigh/KLRG1-­‐‑   (10.8±2.3   %),   reaching   its   maximum  
levels   in   the  CD11bhigh/KLRG1+  subset   (27.8±4.1  %),   although   the   latter   subset   expressed  
much   higher   levels   of   CX3CR1   in   spleen   (43±3.2   %)   and   liver   (50±3  %).   Conversely,   in  
spleen   and   liver   the   frequency   of   CX3CR1-­‐‑expressing   NK   cells   was   equal   in  
CD11blow/KLRG1-­‐‑   and   CD11bhigh/KLRG1-­‐‑   subsets,   but   was   markedly   increased   in  





Figure  12  –  CX3CR1  is  preferentially  expressed  by  peripheral  NK  cells  and  more  mature  
NK   cell   subsets.   CD3-­‐‑/NK1.1+   lymphocytes   (a)   from   BM,   inguinal   lymph   nodes,   spleen  
and   liver   of   CX3CR1+/GFP   mice   were   analyzed   for   GFP   expression   (b).   CX3CR1+/GFP-­‐‑
derived  splenocytes  were  stained  with  PKH-­‐‑26  and  adoptively  transferred  into  WT  hosts.  
The  frequency  of  GFP+  cells  among  PKH-­‐‑26+  cells  was  assessed  18  hours  after  transfer,  in  
the  represented  organs  (c).  Representative  dot  plot  of  a  staining  for  CD11b  and  KLRG1  (d)  
to  analyze  GFP  expression  within  NK  cell  subsets  (e).  Data  are  expressed  as  mean  values  ±  
SEM.   At   least   6   CX3CR1+/GFP   and   WT   donor   mice   were   used   in   three   independent  
experiments.  
  
4.1.2.  CXCR4  and  CX3CR1  expression   levels   inversely  correlate  on  
NK  cells  
  
Given   the   heterogeneous   levels   of   CX3CR1   within   NK   cell   subpopulations   and   their  
different   trafficking   capacities,   the   following   experiments   were   aimed   at   determining  
whether   other   chemokine   receptors   could   be   differentially   regulated   in   the   subsets   of  
interest.  In  accordance  with  the  previous  literature,  KLRG1-­‐‑  BM  NK  cells  (that  from  here  
on  will   include  CD11blow/KLRG1-­‐‑  and  CD11bhigh/KLRG1-­‐‑  NK  cells)  had  a  higher  CXCR4  
expression   levels   in   comparison   to   KLRG1+   cells,   but   an   additional   difference   was  
recorded   between   KLRG1+/CX3CR1-­‐‑   and   KLRG1+/CX3CR1+   NK   cells   (Figure   13a,b),  
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suggesting   a   further   level   of   CXCR4   regulation.   This   phenotypic   variation   was   also  
functionally   significant,   as   in   in   vitro   chemotaxis   assay   against   CXCL12   the   NK   cell  
subpopulations   behaved   accordingly   to   their   CXCR4   expression,   displaying   a   higher  
migration   index   in   the   KLRG1-­‐‑   subset   and   a   lower   responsiveness   to   CXCL12   in  
KLRG1+/CX3CR1+  subset  (Figure  13c).  
This   functional   feature   identified   two   additional   NK   cell   subsets   that   differed   for   their  
distinct  trafficking  capacities,  within  the  KLRG1+  NK  cell  population.  
The   differential   CXCR4   expression   might   indeed   suggest   a   dissimilarity   in   BM  
compartmentalization   of   the   two   subsets,   as   CXCL12   is   highly   produced   on   CXCL12  
abundant   reticular   (CAR)   cells,   which   are   present   in   the   marrow   parenchymal  
compartment,   while   are   absent   in   the   vascular   part,   also   known   as   BM   sinusoidal  
compartment.  By  means  of  a  novel  method  that  allows  the  identification  of  sinusoidal  vs  
parenchymal  BM  cells326,  we  show  that  NK  cell  subsets  are  differentially  distributed  in  the  
two  BM  compartments,  as  within  KLRG1-­‐‑,  KLRG1+/CX3CR1-­‐‑  and  KLRG1+/CX3CR1+  NK  
cells  11%,  44%  and  87%,  respectively,  were  localized  in  the  sinusoidal  space  (Figure  13d).  
Notably,   the  KLRG1-­‐‑   subset   represents   the  vast  majority  of   total  BM  NK  cells,  meaning  
that   about   86%   of   BM   NK   cells   are   parenchymal,   while   only   a   little   proportion,  
substantially  consisting  of  KLRG1+  fraction,  is  sinusoidal.  
Considering  the  data  obtained  so  far,  we  hypothesized  that  the  differential  BM  positioning  
of   the   three   NK   cell   subsets   in   analysis   might   be   regulated,   at   least   partially,   by   their  
diverse   expression   levels   of   CXCR4.   To   test   this   hypothesis,   we   s.c.   administered  
AMD3100,  a  pharmacologic  inhibitor  of  CXCR4,  which  is  known  to  mobilize,  among  other  
cell   types,   BM   NK   cells   to   the   peripheral   blood113.   To   analyse   changes   in   NK   cell   BM  
compartimentalization,  PE-­‐‑conjugated  anti-­‐‑DX5  antibody  was  i.v.   injected  one  hour  after  
AMD3100   administration,   and   mice   were   then   sacrificed.   Figure   13g,h   shows   how   the  
CXCR4   inhibitor   administration   induced   a   significant   shift   in   KLRG1-­‐‑   NK   cell   subset  
localization   from   parenchyma   to   the   sinusoid,   while   both   KLRG1+/CX3CR1-­‐‑   and  
KLRG1+/CX3CR1+  NK  cells  were  unaffected  by  the  treatment.  Taken  together,  these  data  
demonstrate   that   CXCR4   function   is   fundamental   for   NK   cell   retention   in   BM  
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parenchyma,   particularly   for   KLRG1-­‐‑   subset,   while   it   seems   to   be   irrelevant   for   their  
positioning   in   the   sinusoids.  This   conclusion   suggests   the  existence  a  CXCR4-­‐‑dependent  
directional   transfer   from   parenchymal   to   sinusoidal   space   to   take   place   during  NK   cell  
maturation,  which  preludes  to  the  definitive  exit  of  terminally  differentiated  NK  cells  (i.e.  
KLRG1+  cells)  from  BM  to  the  peripheral  circulation.  
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Figure   13   –   KLRG1+/CX3CR1+   NK   cells   express   low   levels   of   CXCR4   and   mainly  
localize  in  BM  sinusoids.  Overlay  of  CXCR4  expression  (a)  and  representation  of  mean  
values   of   median   fluorescence   intensity   (MFI)   on   NK   cell   subsets   (b).   In   vitro  
chemotaxis   assays  were   performed  with  CX3CR1+/GFP   splenocytes,   against  medium  or  
CXCL12   (200   ng/mL),   for   2   hours.  Data   are   displayed   as   frequency   of  migrated   cells  
over   input  cells   (c).  d  and  e   show  representative  histograms  and   the  quantification  of  
the   sinusoidal   fraction   of   NK   cell   subsets.   The   relative   contribution   of   the   NK   cell  
subsets  was   then   considered  within   total   parenchymal   or   sinusoidal  BM  NK   cells   (f).  
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AMD-­‐‑3100  was  subcutaneously  administered  to  CX3CR1+/GFP  mice,  and  1  hour   later  
PE-­‐‑conjugated  anti-­‐‑DX5  mAb  was   i.v.   injected,  before  mice   sacrifice.  Parenchymal   (g)  
and  sinusoidal  (h)  localization  of  NK  cell  subsets  was  then  assessed  by  FACS.  Data  are  
expressed  in  number  of  cells  for  each  subpopulation.  Each  bar  graph  show  data  from  at  
least  6  mice  from  3  independent  experiments.  *  =  p  <  0.05.  
  
4.1.3.   CX3CR1   identifies   a   terminally   mature   KLRG1+   NK   cell  
subset  with  reduced  effector  capacities  
  
The   distinct  migration   properties   of   the   two  KLRG1+  NK   cell   subsets   identified   by   the  
CX3CR1   expression   could   also   imply   the   presence   of   functional   differences,   in   terms   of  
IFNγ  production  upon  cytokine  stimulation  or  cell   cytotoxicity  against  NK  cell-­‐‑sensitive  
targets,  such  as  YAC-­‐‑1  thymoma  line.  Thus,  BM-­‐‑  and  spleen-­‐‑derived  cells  were  cultured  
overnight  with   IL-­‐‑2   +   IL-­‐‑12   or   IL-­‐‑2   alone   as   a   negative   control,   to   assess  NK   cell   IFNγ  
production.  Figure  14  shows  that  KLRG1+/CX3CR1-­‐‑  NK  cells  from  both  organs  displayed  
a  higher  cytokine  production  rate  than  their  KLRG1+/CX3CR1+  counterpart.  Nevertheless,  
this   experimental   approach   takes   into   account   also   the   effect   of   other   cell   types,   both  
hematopoietic   and   non-­‐‑hematopoietic,   upon   the   stimulation  with   IL-­‐‑2   ±   IL-­‐‑12.   Thus,   to  
assess  unequivocally  the  intrinsic  NK  cell  functional  properties,  splenic  KLRG1+/CX3CR1-­‐‑  
and  KLRG1+/CX3CR1+  NK   cells  were   sorted   and   treated   overnightwith   IL-­‐‑2   ±   IL-­‐‑12   or  
with  IL-­‐‑15,  to  study  IFNγ  production  and  their  ability  lo  kill  target  cells,  respectively.  Both  
assays  showed  the  reduced   functionality  of  KLRG1+/CX3CR1+  NK  cells,  as  compared   to  
the  KLRG1+/CX3CR1-­‐‑  counterpart.  
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Figure  14  –  Distinct  functional  properties  of  CX3CR1+  and  CX3CR1-­‐‑  KLRG1+  NK  cells.  
a)   Previously   activated  with   IL-­‐‑2  with   or  without   IL-­‐‑12  BM  cells   or   splenocytes   from  
CX3CR1+/GFP   mice   were   incubated  with   Brefeldin   A   for   6   hours   and   then   stained   for  
intracellular   IFNγ.   KLRG1+   NK   cells   were   analysed   for   their   expression   of  
CX3CR1/GFP   and   IFNγ   (a).   Histograms   in   b   represent   the   quantification   of   three  
separate   experiments   shown   in   a   for  BM  and   spleen.  Then,   the   two  KLRG1+  NK   cell  
subsets  were  sorted   from  CX3CR1+/GFP   splenocytes,  and   tested   for   IFNγ  production   (c,  
left)   and   for   cytotoxicity   against   the   lymphoma   line   YAC-­‐‑1   (c,   right).   Data   are  
representative  of  1  of  at  least  3  performed  experiments.  *  =  p  <  0.05.  
  
The   more   pronounced   sinusoidal   localization,   the   reduced   CXCR4   expression   and   the  
upregulation  of  CX3CR1  on  NK  cells  during  maturation  suggested  that  KLRG1+/CX3CR1-­‐‑  
and   KLRG1+/CX3CR1+   subsets   might   be   developmentally   related.   Thus,   we   set   up   an  
adoptive   transfer   experiment   where   we   injected   purified   KLRG1+/CX3CR1-­‐‑   or  
KLRG1+/CX3CR1+  NK  cells,  derived  from  the  spleen  of  CD45.2+  CX3CR1+/GFP  donors,  into  
WT  CD45.1+  recipients.  After  12  days,  organs  were  collected  from  recipient  mice,  and  the  
phenotype   of   donor-­‐‑derived   NK   cells   was   analyzed.   As   represented   in   Figure   15,  
KLRG1+/CX3CR1-­‐‑  NK  cells  gave  rise  to  KLRG1+/CX3CR1+  cells,  but  not  the  opposite.  This  
result  clearly  indicates  that  high  levels  of  CX3CR1  are  acquired  at  later  stages  of  NK  cell  
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differentiation,   being   KLRG1+/CX3CR1+   population   a   more   mature   stage   than  
KLRG1+/CX3CR1-­‐‑   cells.   In   addition,   once   CX3CR1   expression   is   acquired   by   KLRG1+  
cells,  is  stably  maintained  on  their  cell  surface.  
  
  
Figure  15  –  KLRG1+/CX3CR1-­‐‑  cells  give  rise  to  KLRG1+/CX3CR1+  cells,  but  not  vice  
versa.   Highly   purified   KLRG1+/CX3CR1-­‐‑   or   KLRG1+/CX3CR1+   from   CD45.2+  
CX3CR1+/GFP   spleen   were   injected   into   CD45.1   WT   mice,   and   their   frequency   was  
assessed   by   FACS   in   the   recipient   BM,   spleen   and   liver   after   12   days,   staining   for  
CD3/NK1.1/CD45.1/CD45.2.   Number   in   plots   indicate   the   mean   frequency   of   GFP+  
cells   among   transferred  KLRG1+  NK   cells.  Data   are   representative   of   1   of   at   least   3  
experiments  performed.  
  
To  further  characterize  the  two  subsets,  we  also  determined  the  surface  expression  level  of  
several   markers,   many   of   which   are   produced   at   different   times   during   NK   cell  
development,   like   c-­‐‑kit   and   CD127   (on  more   immature  NK   cells)   or   Ly49  MHC   class   I  
receptors   (on   functional   NK   cells).   In   agreement   with   the   data   obtained   so   far,  
KLRG1+/CX3CR1+  NK  cells  expressed  lower  levels  of  c-­‐‑kit  and  higher  levels  of  Ly49  C/I  as  
compared   to   KLRG1+/CX3CR1-­‐‑   and   more   so   when   compared   to   KLRG1-­‐‑   NK   cells,  
although   no   differences   between   the   two   KLRG1+   subsets   were   observed   concerning  
CD94,  DNAM-­‐‑1,  Ly49H  and  Ly49G2  (Figure  16).    
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Figure  16  –  Surface   receptor  profile  of  NK  cell   subsets.  Splenocytes   from  CX3CR1+/GFP  
mice  were  stained  CD3,  NK1.1  and  KLRG1,  and  for  the  extracellular  receptors  indicated  
above.   Control   for   m157-­‐‑Fc   (Ly49H)   staining   was   NKG2D-­‐‑Fc   followed   by   PE-­‐‑
conjugated  anti-­‐‑human  IgG,  while  anti-­‐‑Ly49C/I  and  anti-­‐‑Ly49G2  staining  controls  were  
PE-­‐‑conjugated  anti-­‐‑mouse  IgGa/b  and  anti-­‐‑rat  IgG,  respectively  (not  shown).  Numbers  
in   the   histograms   represent   the   positive   cells   for   each   subset,   of   a   representative  
analysis  out  of  3  separate  experiments  performed.  
  
Taken   together,   these   data   evidenced   the   existence   of   two   functionally   and  
developmentally   distinct   NK   cell   subsets   within   the   KLRG1+   subpopulation,   that  
differently   localize   in   BM   compartments.   Albeit,   the   actual   function   of   the   receptor  
CX3CR1,   and   how   and   whether   it   contributes   to   these   differences   remained   to   be  
determined.  
  
4.1.4.  KLRG1+  NK  cells  accumulated  in  BM  and  LNs  of  mice  lacking  
CX3CR1  
  
The  next  issue  to  tackle  was  the  biologic  role  of  the  CX3CL1  receptor  on  NK  cells,  and  to  
this  aim  we  adopted  a  so  called  “loss  of  function”  approach,  using  CX3CR1GFP/GFP  mice,  in  
which  both  alleles  of  cx3cr1  gene  were  replaced  by  two  copies  of  GFP  cDNA  as  compared  
to   the   heterozygous   CX3CR1+/GFP  mice,   considered   as   controls.   The   interpretation   of   the  
data  deriving   from   the   study  of   these  knock-­‐‑in  mice   is   complex,   since   the   expression  of  
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GFP   does   not   identify   cells   with   a   functional   CX3CR1   anymore,   but   instead   cells   that  
mantain  the  CX3CR1  trascriptional  activity  (GFP  cDNA  is  placed  under  cx3cr1  promoter).  
Moreover,  being  most  of  experimental  techniques  described  in  this  thesis  related  to  FACS,  
the   issue   of   GFP   fluorescence   intensity  must   be   taken   in   consideration  when   analyzing  
changes  of  GFP+  cells  frequency:  in  fact,  having  one  gfp  allele  instead  of  two,  CX3CR1+/GFP-­‐‑
derived  GFP+  cells  display  a  lower  GFP  fluorescence  intensity  than  CX3CR1GFP/GFP-­‐‑derived  
GFP+  cells.  Nevertheless,  our  experiments  were  adequately  controlled  not  to  be  biased  by  
this  difference.  
  
The  first  step  taken  was  to  analyse  total  NK  cell  frequency  and  number  in  BM,  spleen,  liver  
and  peripheral  lymph  nodes  (LNs)  (Figure  17a).  No  differences  were  reported  in  the  first  
three   organs,  while   a   significant   increase   of  NK   cell   number   in   LNs  was   found   (105   vs  
5x105  cells).  Interestingly,  this  increase  was  mainly  attributable  to  the  total  LN  cell  count,  
which  was  higher  in  CX3CR1-­‐‑deficient  mice,  while  NK  cell  frequency  within  lymphocytic  
population   was   not   significantly   altered.   Furthermore,   the   phenotype   evidenced   an  
increased   proportion   of   GFP-­‐‑expressing   NK   cells   in   CX3CR1GFP/GFP   mice   in   all   the  
considered  organs  but  the  liver  (not  shown).    
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Figure   17   –   Tissue   distribution   of   NK   cell   and   NK   cell   subsets   in   CX3CR1+/GFP   and  
CX3CR1GFP/GFP   mice.   Single-­‐‑cell   suspensions   were   collected   from   several   organs   of  
CX3CR1+/GFP  and  CX3CR1GFP/GFP  6  to  10-­‐‑week-­‐‑old  mice.  BM  was  collected  from  one  tibia  
and   femur.   After   staining  with   selected  mAbs,  NK   cells  were   gated   as   CD3-­‐‑/NK1.1+  
among   lymphocytes.   (a)   Circles   represent   NK   cell   number   in   the   indicated   organ   of  
each   mouse.   Among   NK   cells,   subsets   were   identified   as   CD11blow/KLRG1-­‐‑,  
CD11bhigh/KLRG1-­‐‑,  and  CD11bhigh/KLRG1+  (B),  and  among  KLRG1+  as  GFP+  and  GFP-­‐‑  
cells   (c).   (b)  Dot   plots   showing  NK   cell   subset   composition   in   BM   (upper   panel)   and  
LNs  (lower  panel)  of  CX3CR1+/GFP  and  CX3CR1GFP/GFP  mice  are  representative  of  at  least  
eight   animals   for   each   genotype   in   five   independent   stainings.  Numbers   in   dot   plots  
indicate  the  frequency  of  each  subset  within  the  NK  cell  population.  Each  column  of  the  
graphs   represents   the   average   frequency   ±   SEM   of   the   indicated  NK   cell   population  
among  NK   cells   in  BM   (upper  panel)   and  LNs   (lower  panel).   (c)  Histogram  overlays  
compare   the   frequency  of  GFP+  cells  within  KLRG1+  population   into  BM  and  LNs  of  
CX3CR1+/GFP   and   CX3CR1GFP/GFP   mice.   Graphs   represent   the   average   frequency   (left  
panels)  and  the  number  (right  panels)  ±  SEM  of  GFP-­‐‑  and  GFP+  cells  among  KLRG1+  




When  NK  cell  population  was  dissected  into  cell  subsets,  according  to  their  expression  of  
CD11b  and  KLRG1,  we  registered  an   increased  number  of  CD11bhigh/KLRG1+  fraction   in  
the  BM   (about   1.5   fold),   and  of  CD11bhigh  population   (both  KLRG1-­‐‑  and  KLRG1+)   in   the  
LNs   of   CX3CR1-­‐‑deficient   mice,   when   compared   to   heterozygous   controls   (Figure   17b).  
Notably,  KLRG1+  increase  in  BM  was  balanced  only  by  the  reduction  in  CD11blow/KLRG1-­‐‑  
cell  frequency,  the  most  immature  subset,  as  the  functionally  competent  CD11bhigh/KLRG1-­‐‑  
population  did  not  change.    
As  CX3CR1  is  mainly  expressed  by  mature  NK  cell  subsets,  the  increase  of  GFP+  NK  cells  
observed  in  BM  and  LNs  was  likely  related  to  the  augmented  proportion  of  KLRG1+  and  
CD11bhigh  cells   in  these  organs.  In  turn,  KLRG1+  cell  number  increase  in  BM  of  CX3CR1-­‐‑
deficient   mice   was   entirely   due   to   the   expansion   of   the   GFP+   fraction,   while   the  
KLRG1+/GFP-­‐‑  cell  number  was  unchanged  (Figure  17c).  
  
4.1.5.   Neither   CXCR4   expression   nor   its   function   are   altered   by  
CX3CR1  deficiency  
  
Because   our   previous   data   showed   that   KLRG1+/CX3CR1-­‐‑   and   KLRG1+/CX3CR1+   NK  
cells   expressed   different   levels   of   CXCR4   and   migrated   differently   towards   a   CXCL12  
gradient   in   vitro,  we   stained  BM  cells   from  CX3CR1-­‐‑deficient   and   –sufficient  mice  with  
anti-­‐‑CXCR4  mAbs  and  tested  them  in  in  vitro  chemotaxis  assay.  The  graphs  in  Figure  18  
make  clear  that  CXCR4  expression  levels  were  unchanged  in  the  two  strains,  and  also  that  
no   difference   could   be   detected   in   terms   of   CXCL12-­‐‑directed   migration.   Thus,   the  
alteration  of  NK  cell  subset  proportion  in  the  BM  of  CX3CR1-­‐‑deficient  mice  could  not  be  
linked  to  modifications  in  CXCR4-­‐‑CXCL12  axis.  
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Figure  18  –  CX3CR1  deficiency  does  not  impair  CXCR4  expression  and  function  on  NK  
cells.  Immunofluorescence  staining  of  BM  cells  with  anti-­‐‑NK1.1-­‐‑,  anti-­‐‑CD3-­‐‑,  anti-­‐‑KLRG1-­‐‑  
and   anti-­‐‑CXCR4-­‐‑specific   (black   line)   or   isotype   control   (dotted   gray   line)   mAbs   was  
performed,  followed  by  FACS  analysis  (a).  Histogram  overlays  show  CXCR4  expression  
as   compared   to   isotype   control   staining   and   number   represents   mean   fluorescence  
intensity   (MFI)   of   CXCR4   expression   subtracted   of   isotype   control   MFI   in   KLRG1-­‐‑  
KLRG1/GFP-­‐‑   and   KLRG1+/GFP+   NK   cells.   One   representative   experiment   of   3  
performed   is   shown.  b)  Chemotaxis  assays   to  different  concentrations  of  CXCL12  were  
performed  in  5µμm  pore  Transwell  insert.  After  90  min,  migrated  cells  were  collected  and  
stained  with   anti-­‐‑NK1.1-­‐‑,   and   anti-­‐‑CD3-­‐‑specific  mAbs   and   counted   by   FACS   analysis.  
Shown   is   the   chemotactic   response   of   BM   (left)   and   splenic   (right)   total   NK   cells   in  
response   to   migration   medium   with   no   chemokine   or   containing   CXCL12.   Data   are  
expressed  as  percentage  of  input  cells  and  represent  the  mean  values  ±  SD  from  a  total  of  
6  animals  analyzed  in  3  independent  experiments.  
  
4.1.6.  NK  Cell-­‐‑intrinsic  mechanism  of  action  of  CX3CR1  
  
The  unbalanced  proportion  of  NK  cell  subsets,  in  particular  within  the  BM,  might  indeed  
reflect  a  modulatory  role  for  CX3CR1  in  the  process  of  NK  cell  development.  At  the  same  
time,   since  other  cell   types  have  been  described   to  express  CX3CR1,   it  was  possible   that  
the   altered   phenotype   found   in   CX3CR1-­‐‑deficient   animals   could   be   due   to   an   indirect  
effect  exerted  by  other  CX3CR1-­‐‑expressing  cells  on  NK  cells  in  the  BM.    
To  test  this  possibility,  bone  marrow  chimera  experiments  were  performed,  in  which  WT  
CD45.1+  mice  were   sublethally   irradiated   and   then   reconstituted  with  CD45.1+/CD45.2+  
CX3CR1+/GFP  or  CD45.2+  CX3CR1GFP/GFP  BM-­‐‑derived  cells.  Five  weeks  after   reconstitution,  
organs  were  collected  and  NK  cell  phenotype  was  analysed  by  FACS.  Donor-­‐‑derived  cells  
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were   identified   as  CD45.2+   cells,   in   contrast   to   the   residual   amount  of   recipient-­‐‑derived  
cells,  which  anyway  were  CD45.1+.  
Figure  19  shows  the  slight  but  significant   increase  in  frequency  of  CX3CR1GFP/GFP-­‐‑derived  
KLRG1+  NK  cells,  as  compared  to  CX3CR1+/GFP-­‐‑derived  counterpart  in  BM,  but  not  in  the  
spleen.   As   observed   in   adult   mice,   only   the   GFP+   fraction   was   accountable   for   this  
alteration,  being  the  BM  KLRG1+/GFP-­‐‑  cells  almost  unchanged  in  the  two  chimeras.  
  
  
Figure  19  –  KLRG1+  NK  cell  accumulation  is  due  to  CX3CR1  effect  on  hematopoietic  
compartment.   CD45.1+   WT   mice   were   irradiated   and   reconstituted   with   either  
CX3CR1+/GFP  or  CX3CR1GFP/GFP  BM  cells.  After  5  weeks,  donor-­‐‑derived  NK  cell  and  NK  
cell   subset   frequency   in   BM   and   spleen   was   evaluated   by   staining   with   anti-­‐‑CD3,  
NK1.1-­‐‑,  KLRG1-­‐‑,  CD45.1-­‐‑  and  CD45.2-­‐‑specific  mAbs.  In  the  left  panels,  the  percentage  
of  KLRG1+  cells  within  total  NK  cells  is  shown  for  BM  and  spleen,  while  on  the  right  
the   frequency   of   KLRG1+/GFP-­‐‑   and   KLRG1+/GFP+   is   represented.   Bar   graphs   are  
representative  of  at  least  5  reconstituted  mice  for  each  genotype.  *  =  p  <  0.05;  **  =  p  <  
0.01.  
  
The  bone  marrow  chimeric  reconstitution  allows  to  estabilish  whether  the  effect  observed  
is,  or  is  not,  determined  by  the  hematopoietic  compartment,  since  the  stroma  in  this  case  
belongs  to  a  WT,  CX3CR1-­‐‑sufficient  mouse.  These  data  demonstrate  that  the  alteration  of  
BM  NK  cell  subset  frequencies  reported  in  CX3CR1-­‐‑deficient  mice  is  due  to  the  action  of  
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the   same   receptor   on   an   hematopoietic   cell,   either   resident   or   derived   from   BM  
environment.  
However,   as   other   hematopoietic   components   within   the   BM,   such   as   the   monocyte-­‐‑
macrophage   lineage327,   DCs328,   and   other   lymphocytes329,   have   been   reported   to   express  
CX3CR1,  an  indirect  effect  on  NK  cells  mediated  by  one  or  more  of  these  cells  could  not  be  
ruled  out  yet.  
Thus,  we  generated  mixed  BM  chimeric  mice,  by  the  infusion  of  equal  amounts  of  BM  cells  
from   both   CD45.1+/CD45.2+   CX3CR1+/GFP   and   CD45.2+   CX3CR1GFP/GFP   genotypes   into  
previously   irradiated   CD45.1+  WT   hosts.   In   this   condition,   any   phenotypical   alteration  
observed  would  indeed  be  due  to  the  direct  role  of  CX3CR1  on  NK  cells.  
The  graphs  presented  in  Figure  20b  confirm  that  KLRG1+  NK  cell  subset  expansion  in  the  
absence  of  CX3CR1  was  cell   intrinsic,  as   the  same  KLRG1+  increase  was  found  in  mixed  
BM  chimeric  mice,   after   5  weeks.   In   addition,   once   again   the  KLRG1+/GFP+  was   totally  





Figure  20  –  Tissue  accumulation  of  KLRG1+  NK  cells  is  associated  to  a  cell-­‐‑intrinsic  
defect.  BM  cells  fromCD45.1+/CD45.2+  CX3CR1+/GFP  mice  and  from  CD45.1-­‐‑/CD45.2+  
CX3CR1GFP/GFP  mice  were  collected,  mixed  at  1:1  ratio,  and  transplanted  into  lethally  
irradiated  CD45.1+/CD45.2-­‐‑  WT  recipients.  Organs  were  collected  after  5  weeks,  and  
donor-­‐‑derived  cells  were  identified  with  anti-­‐‑CD45.1  and  anti-­‐‑CD45.2  Abs,  with  the  
gating   strategy   illustrated   in   (a).   Donor-­‐‑derived   KLRG1-­‐‑   and   KLRG1+   NK   cell  
distribution  in  the  BM  of  the  recipient  mice  is  shown  in  (b).  c)  GFP-­‐‑  and  GFP+  NK  cell  
distribution   within   KLRG1+   population.   11   animals   per   group   were   used   in   5  
independent  experiments.  The  bar  graph  in  (d)  represents  the  total  CD45.1+/CD45.2+  
versus  CD45.1-­‐‑/CD45.2+  -­‐‑derived  cell  ratio  for  BM  and  spleen  after  5  weeks,  for  the  
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experiments   illustrated   in   (b)   and   (c).   e)   Circles   represent   the   percentage   of   the  
specified   subset   among   NK   cells   in   each   mouse.   The   number   of   total   NK   cells  
derived   from  donor  CX3CR1+/GFP   and  CX3CR1GFP/GFP  was  divided  by   the  number  of  
the   total   B   (CD19+)   cells   of   the   corresponding   donor   mice.   CX3CR1(D)GFP/GFP  
represents   donor  mice   that  were   deprived   of  NK   cells   using   anti-­‐‑NK1.1–depleting  
mAb.  Normalized  Ly5.1.2/Ly5.2  BM  and  spleen  NK  cell  ratios  (R)  of  Ly5.1  recipient  
mice   transplanted   with   the   Ly5.1+/Ly5.2+   and   Ly5.12/Ly5.2+   BM   indicated   in   the  
horizontal  axes  are  shown  for  3  experiments  performed  with  a  total  of  6  –  11  animals  
per  group.  *  =  p  <  0.05.  
  
Still,  it  was  possible  that  putative  long-­‐‑lived  mature  KLRG1+  NK  cells  present  in  the  BM  of  
CX3CR1GFP/GFP   donors   could   account   for   the   difference   observed   after   5   weeks   of  
reconstitution.  To  rule  out  this  potential  misinterpretation,  CX3CR1+/GFP  and  CX3CR1GFP/GFP  
donor  mice  were  first  depleted  of  NK  cells,  through  the  administration  of  the  anti-­‐‑NK1.1  
mAb  PK136,  then  BM  cells  were  collected  and  used  as  before  to  reconstitute  irradiated  WT  
hosts.  Similarly  to  what  was  found  with  non-­‐‑NK  cell  depleted  donors,  CX3CR1-­‐‑deficient  
KLRG1+GFP+  NK  cell  frequency  in  the  BM  was  increased.    
As  for  the  absolute  number  of  donor-­‐‑derived  cells  detected  in  BM  chimeras,  we  evidenced  
some   differences   in   the   reconstitution   rate   of   different   genotypes   being   CD45+   cells  
derived  from  CX3CR1GFP/GFP  1.5-­‐‑1.8  fold  than  CX3CR1+/GFP  cells  (Figure  20d).  To  solve  this  
discrepancy,  which  could  be  due  to  an  actual  difference  in  engraftment  potential  and/or  in  
BM   cell   maturation,   the   total   NK   cell   number   was   adjusted   to   total   B   cell   number  
(identified  as  CD19+   lymphocytes)  of  each  donor  genotype.  B  cells  were  considered  as  a  
control   population   because   they   do   not   express   CX3CR1,   and   thus   their   engraftment  
efficiency   should   not   be   affected   by   CX3CR1   absence.   The   NK/B   ratio   of   the   different  
donor   strains  were   then   confronted,   and   the   obtained   results   are   shown   in   Figure   20e.  
Being  the  total  ratio  equal  to  1,   it  can  be  concluded  that  there  were  no  differences  in  NK  






4.1.7.  CX3CR1  promotes  KLRG1+  NK  cell  egress  from  the  BM  
  
We   then   tested   the   possibility   that   the   expansion   of   a   selected  NK   cell   subset   could   be  
attributed   to   an   altered   homeostatic   rate   (proliferation/survival),   staining  NK   cells  with  
Annexin   V,   which   recognizes   the   phosphatidilserine   exposed   on   the   outer   side   of   cell  
membrane   in   apoptotic   cells,   or   administering   Bromo-­‐‑deoxy-­‐‑Uridine   (BrdU)   to  mice,   in  
order   to   detect   BrdU   incorporation   in   NK   cell   DNA   (Figure   21).   No   differences   were  
detected  in  the  frequencies  of  proliferating  and/or  apoptotic  NK  cells,  not  even  when  GFP-­‐‑  
and  GFP+  cell  subsets  were  considered.    
  
  
Figure  21   -­‐‑  NK  cell   turnover   rate   in  homeostatic   conditions   is  not  altered   in  absence  of  
CX3CR1.   a)   BrdU   (1mg)   was   administrated   to   7-­‐‑10   weeks   old   CX3CR1+/GFP   and  
CX3CR1GFP/GFP   mice   by   intraperitoneal   injection   every   8   hours   for   24   hours.   Mice   were  
sacrificed  and  BM  cells  were  isolated  and  stained  with  anti-­‐‑NK1.1-­‐‑,  and  anti  CD3-­‐‑specific  
antibody.  Histograms  show  the  fraction  of  BrdU+  cells  within  GFP+  and  GFP-­‐‑  among  total  
NK   cells.   A   total   of   five   animals   per   group   were   analyzed   in   3   independent  
experiments.  b)  Apoptosis  of  NK  cells   in   the  BM  was  measured  using  Annexin  V  assay.  
BM  cells  were  isolated  and  stained  with  anti-­‐‑NK1.1-­‐‑,  and  anti-­‐‑CD3-­‐‑specific  antibody  and  
APC-­‐‑conjugated   Annexin   V,   and   the   percentage   of   Annexin   V+   cells   among   GFP-­‐‑   and  
GFP+  NK  cells  was  calculated  by  gating  on  NK1.1+CD3-­‐‑  cells.  A  total  of  four  animals  per  
group  were  analyzed  in  2  independent  experiments  
  
Altogether,  these  data  rule  out  a  modification  of  NK  cell  turnover  rate,  thus  we  speculated  
that   the  NK  cell  population  enhanced  maturation  degree   in   the  BM  of  CX3CR1-­‐‑deficient  
mice   might   be   due   to   different   trafficking   capacities   to   this   organ   under   homeostatic  
conditions.   To   test   this   possibility,   competitive   adoptive   transfer   experiments   were  
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performed,   in   which   equal   amounts   of   CD45.1+/CD45.2+   CX3CR1+/GFP   and   CD45.2+  
CX3CR1+/GFP   -­‐‑derived   splenocytes   were   i.v.   injected   into   WT   hosts.   To   allow   their  
recognition   through   FACS   analysis,   transferred   cells   were   previously   marked   with   the  
fluorescent   dye   PKH-­‐‑26,   and   their   genotype   was   distinguished   according   to   the   CD45  
allelic  variant  expressed.  
The  localization  of  transferred  cells  was  assessed  in  BM,  spleen  and  liver  at  different  time  
points,  which   enabled  us   to  determine   each   organ’s  NK   cell   homing   attitude   (2.5   hours  
after  injection)  and  retention  capacity  (24  and  36  hours  after  transfer  injection).  
  
  
Figure   22   –   CX3CR1   deficiency   prolongs   NK   cell   maintenance   in   the   BM.  
Competitive   homing   experiments:   (a)   PKH26-­‐‑labeled   CD45.1+/CD45.2+  
CX3CR1+/GFP  and  CD45.1-­‐‑/CD45.2+  CX3CR1GFP/GFP  splenocytes  were   i.v.   injected  at  
1:1   ratio   in   wild-­‐‑type   Ly5.1-­‐‑/Ly5.2+  WT  mice.   After   2.5,   24,   and   36   hours,   BM,  
Results	  
88	  
spleen,  liver,  and  blood  were  collected,  and  transferred  NK  cells  were  identified  as  
NK1.1+/CD3-­‐‑/PKH-­‐‑26+   cells   by   FACS.   CD45.1-­‐‑specific   Abs,   which   selectively  
mark   cells   from   CX3CR1+/GFP   donors,   were   used   to   discriminate   between  
CX3CR1+/GFP  and  CX3CR1GFP/GFP   in  recipient  mice.  Subsequently,  we  identified  the  
GFP+  fraction  within  each  transferred  population.  The  gating  strategy  is  illustrated  
above,   whereas   the   graphs   in   (b)   represent   the   homing   index   expressed   as  
CX3CR1GFP/GFP/CX3CR1+/GFP   ratios   of   GFP+   NK   cells   in   the   different   organs   at  
different  time  points.  Data  are  mean  values  ±  SD  of  14  recipient  mice  analyzed  in  4  
independent   experiments.   *   =  p   <   0.01.   (c)  The  histogram   represents   the  homing  
index   expressed   as   CX3CR1GFP/GFP/CX3CR1+/GFP   ratios   of   sorted   KLRG1+GFP+  
donor  NK  cells   in   the  different  organs  of   recipient  mice  at  different   time  points.  
Data   are   mean   values   ±   SEM   of   six   recipient   mice   per   group   analyzed   in   two  
independent   experiments.   The   horizontal   line   in   the   graphs  defines   the   point   at  
which  the  CX3CR1GFP/GFP  and  CX3CR1+/GFP  populations  are  balanced  in  the  organs.  
*   =   p   <   0.05.   The   representation   of   GFP   expression   levels   (left)   and   their  
quantification  (right)  on  KLRG1-­‐‑  and  KLRG1+  splenic  NK  cells  from  CX3CR1+/GFP  
and  CX3CR1GFP/GFP  mice  are  shown  in  (d).  
  
No   significant   alteration   of   recruitment   was   observed   regarding   CX3CR1GFP/GFP-­‐‑derived  
total  NK  cells  in  any  of  the  tested  organs,  and  the  same  result  was  registered  for  GFP-­‐‑  NK  
cells.    
However,  GFP-­‐‑expressing  NK  cells  displayed  a  different  behavior,  as  for  what  concerned  
the   BM   retention   capacity.   In   fact,   as   shown   in   Figure   22b,  while   at   earlier   time   points  
CX3CR1-­‐‑sufficient  and  CX3CR1-­‐‑deficient  GFP+  NK  cells  equally  migrated  in  BM,  a  faster  
reduction   of   the   former’s   cell   number   was   observed   at   later   times,   resulting   in   the  
significant  increase  of  the  CX3CR1GFP/GFP/CX3CR1+/GFP  cell  ratio.  This  finding  might  indeed  
point   towards   an   impaired   capacity   of   CX3CR1-­‐‑deficient   cells   to   exit   from   the   BM   in  
homeostatic  conditions.  
Nonetheless,   in   this   experiment   only   GFP+,   and   not   KLRG1+/GFP+,   NK   cells   were  
analyzed,   so   there   was   the   chance   that,   though   present   in   limited   proportion,   KLRG1-­‐‑
/GFP+  NK  cells  could  influence  the  result  observed.  This  option  was  formally  excluded  for  
two  reasons:  first,  as  presented  in  Figure  22c,  the  competitive  adoptive  transfer  experiment  
was   repeated   injecting   purified   KLRG1+/GFP+   NK   cells   derived   from   the   two   mouse  
strains,  with  the  same  outcome  36  hours  after  injection.  Secondly,  the  histogram  in  Figure  
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22d   shows   that   KLRG1-­‐‑/GFP+   cells   cells   are  much   less   represented   than  KLRG1+/GFP+  
cells,   and   display   a   low   GFP   expression   intensity,   making   KLRG1-­‐‑/GFP+   contribution  
unlikely.  
Moreover,   the   study   of   the   trafficking   properties   of   purified   KLRG1+/GFP-­‐‑   and  
KLRG1+/GFP+  NK  cells  ruled  out  even  the  possibility  of  a  conversion  of  the  former  subset  
into  the  latter,  during  the  time  course  analysed,  given  no  newly  generated  GFP+  cells  were  
found   in  KLRG1+/GFP-­‐‑   transferred   recipients   (not   shown).  Accordingly  with   these  data,  
KLRG1+/GFP-­‐‑  cells  derived  from  the  two  strains  behaved  similarly  in  all  organs  and  at  all  
time  points  analysed  (Figure  22c).  
Altogether,   the   competitive   adoptive   transfer   experiments   indicate   a   more   pronounced  
capacity  of  CX3CR1-­‐‑deficient  GFP-­‐‑expressing  KLRG1+  NK  cells  to  be  retained  in  the  BM,  
or,   taken   backwards,   they   show   an   active   role   for   CX3CR1   in   driving  mature  NK   cells  
outside  the  BM,  towards  peripheral  circulation.  
  
4.1.8.   CX3CR1/CX3CL1   axis   regulates   NK   cell   distribution   within  
BM  
  
Based   on   the   evidence   that   KLRG1+/CX3CR1+  NK   cells  were   preferentially   localized   in  
BM   at   the   sinusoidal   level,   possible   differences   in   KLRG1+/GFP+   NK   cell  
compartimentalization  in  CX3CR1-­‐‑sufficient  and  CX3CR1–deficient  mice  were  then  tested.  
First,  adult  mice  were  analysed,  with   the  same  approach  described   in  Figure  13,   for  BM  
NK   cell   positioning   into   BM   compartments,   evidencing   a   significant   increase   in  
KLRG1+/GFP+  vs  KLRG1+/GFP-­‐‑  NK  cell   ratio   in   the  parenchyma  of  CX3CR1GFP/GFP  mice,  
but   not   in   their   sinusoids.   As   a   consequence,   when   parenchymal   compartment   was  
studied,   there   were   more   GFP+,   but   not   GFP-­‐‑,   cells   within   the   KLRG1+   NK   cell  
subpopulation  of  CX3CR1-­‐‑deficient  mice   (Fig.   23a   right  panel).  Hence,   the   sinusoidal  vs  
parenchymal   ratio   for   KLRG1+/GFP+   NK   cells   was   lower   for   homozygous   mice,   when  
compared   to   their  heterozygous   controls   (not   shown).  This   result  demonstrated   that   the  
accumulation  of  KLRG1+/GFP+  in  CX3CR1GFP/GFP  mice  is  more  pronounced  in  parenchyma  
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than   in   sinusoids.   Thus,   considering   the   data   obtained   so   far,   it   is   likely   that  
KLRG1+/GFP+  CX3CR1-­‐‑deficient  NK   cell   increased  BM   retention   could   be   associated   to  
this   subset   alterated   positioning   in   the   BM.   To   prove   this   assumption,   splenocyte  
competitive  adoptive   transfer  experiments  were   repeated,   this   time  assessing   the  donor-­‐‑
derived  cell   localization  at   the   time  points  analysed  (Figure  23b).  When  GFPhigh  NK  cells  
(which  for  the  85%  are  KLRG1+)  were  quantified  in  the  parenchyma,  a  differential  kinetics  
of  egress  was  observed  for  heterozygous  and  homozygous-­‐‑derived  cells.  In  fact,  CX3CR1-­‐‑
sufficient   cells   decreased   over   time   (from   2   to   36   hours   after   injection)   in   this  
compartment,  whereas  their  KO  counterpart  remained  more  or  less  unchanged  in  the  time  
course   considered.   This   finding  mirrors   the   behaviour   reported   in   Figure   22b,   strongly  
suggesting  that  not  only  CX3CR1  is  involved  in  mature  NK  cell  egress  from  the  BM,  but  it  
specifically  regulates  their  exit  from  parenchymal  to  the  sinusoidal  microenvironment.    
  
  
Figure  23  –  Endogenous  and  adoptively   transferred  CX3CR1-­‐‑deficient  GFP+  NK  cells  
are   preferentially   retained   in   BM   parenchymal   compartment.   (a)   To   test   whether  
CX3CR1+/GFP   and   CX3CR1GFP/GFP   NK   cells   were   differentially   localized   in   BM  
compartments,  sinusoidal  NK  cells  were  labeled  by  i.v.  injecting  1  mg  CD45-­‐‑PE  mAb  in  
300  ml   PBS.  Cell   suspensions   from  BM  were   then   quickly   collected   and   stained  with  
CD3-­‐‑,  NK1.1-­‐‑,  and  KLRG1–specific  mAbs.  The  percentage  of  CD45-­‐‑PE+  and  CD45-­‐‑PE-­‐‑  
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cells  within  KLRG1+/GFP-­‐‑  and  KLRG1+/GFP+  NK  cells  was  evaluated.  The  number  of  
parenchymal  (CD45-­‐‑PE-­‐‑)  NK  cells  (right  panel)  and  sinusoidal  (CD45-­‐‑PE+)  NK  cells  of  
the   indicated   phenotype   was   calculated.   Histograms   (left   panel)   represent   the  
KLRG1+GFP+/KLRG1+GFP-­‐‑  ratio  of  endogenous  NK  cell  number  in  CX3CR1+/GFP  and  in  
CX3CR1GFP/GFP  mice  inside  the  parenchyma  and  sinusoids.  The  average  values  ±  SEM  of  
two   experiments   performed   with   a   total   of   four   animals   per   group   are   shown.   (b)  
Enriched   splenic  NK   cells   from  CX3CR1+/GFP   and  CX3CR1GFP/GFP  were   transferred   into  
WT   recipient   mice   and   sinusoidal   NK   cells   were   labeled   by   i.v.   injection   of   DX5-­‐‑PE  
mAb  2  and  36  h  after  transfer.  Histogram  plot  shows  the  number  (left)  and  percentage  
(right)  of  parenchymal  GFPhigh  NK  cells  (representing  bona-­‐‑fide  KLRG1+GFP+  NK  cells)  
from  CX3CR1+/GFP  and  CX3CR1GFP/GFP  donor  mice  among  total  BM  GFPhigh  cells.  Data  are  
mean   values   ±   SEM   of   five   recipient   mice   per   group   obtained   in   two   independent  
experiments.  *  =  p  <  0.05.  
  
4.1.9.   Altered   functions   of   CX3CR1-­‐‑deficient   KLRG1+   NK   cells   in  
response  to  in  vitro  and  in  vivo  stimulation    
  
BM   parenchyma   is   a   complex   environment,   where   the   hematopoiesis   takes   place,   and  
residing   cells   are   exposed   to   a   great   variety   of   stimuli,   that   can   be   cellular   (i.e.   stromal  
cells,   osteoblasts,   etc.)   or   non-­‐‑cellular   (cytokines,   growth   factors,   or   proteins   of   the  
extracellular  matrix).  Consequently,  there  was  the  chance  that  the  prolonged  exposition  of  
NK  cells  to  these  powerful  environmental  cues  might  somehow  influence  their  functional  
capacities,  for  example  in  an  inflammatory  context.  
Two  different  approaches  were  adopted   to  verify   this   speculation,   the   first   in  an   in  vitro  
setting  and  the  second  in  an  in  vivo  model  of  acute  inflammation.  
Classical   features   of   NK   cell   function   were   then   tested,   in   particular   their   abiity   to  
degranulate  in  presence  of  tumor  cells  and  their  capacity  to  produce  IFNγ  upon  cytokine  
stimulation.  
The   results   obtained   are   represented   in   Figure   24a/b,   where   it   can   be   seen   that   while  
CX3CR1-­‐‑deficiency   does   not   affect   NK   cell   IFNγ   production   after   IL2+IL12   overnight  





Figure   24   -­‐‑   Functional   features   of   NK   cells   in   CX3CR1+/GFP   and  
CX3CR1GFP/GFP   mice.   (a)   Splenic   NK   cells   from   CX3CR1+/GFP   and  
CX3CR1GFP/GFP  mice  were  cultured  18  hours  in  presence  of  IL-­‐‑15  (100  ng/ml)  
and  used  as  effector   cells   in  a  4  hours  degranulation  assay  against  YAC-­‐‑1  
target   cells   in   the   presence   of   monensin   and   PE-­‐‑conjugated   anti-­‐‑CD107  
mAb.  Cells  were  then  collected  and  stained  with  NK1.1-­‐‑  and  CD3ε–specific  
mAbs.   Representative   FACS   dot   plots   (left)   show   NK1.1   and   CD107a  
expression  gated  on  NK1.1+/CD3-­‐‑  lymphocytes.  The  histogram  on  the  right  
shows  the  average  percentage  ±  SD  of  CD107+  NK  cells  in  a  representative  
experiment   out   of   5  performed   in  duplicate  with   a   total   of   seven   animals  
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per   group.   Frequency   of   CD107+   NK   cells   in   the   absence   of   target   was  
subtracted   to   each   treatment.   (b)   Freshly   isolated   cells   from   spleen   of  
CX3CR1+/GFP  and  CX3CR1GFP/GFP  mice  were   incubated  for  18  hours,  at  37   ̊C,  
5%  CO2   in  presence  of   IL-­‐‑2   (500  U)   and   IL-­‐‑12   (100  ng/ml).  Representative  
FACS   dot   plots   (left)   show  NK1.1   and   IFNγ   expression   gated   on  NK1.1+  
CD3-­‐‑   cells.   Histograms   show   the  mean   values   ±   SD   of   the   percentage   of  
IFNγ+  total  NK  cells  for  a  total  of  five  animals  per  group  analyzed  in  three  
independent  experiments.  *  =  p  <  0.05.  (c)  Equal  amount  of  freshly  isolated  
cells   from   spleen  of  CX3CR1+/GFP   and  CX3CR1GFP/GFP  mice  were  mixed   and  
stimulated  overnight  with  IL-­‐‑15  (100  ng/mL)  and  then  used  as  effector  cells  
as   in   (a).   The  histogram   shows   the  mean  percentage   ±   SD  of  CD107+  NK  
cells  from  the  two  strains,  in  two  performed  experiments  with  a  total  of  four  
animals  per  group.  Percentage  of  CD107a+  NK  cells  in  the  absence  of  target  
was  subtracted  to  each  treatment.  *  =  p  <  0.05.  
  
These   experiments  were   conducted   keeping   heterozygous   and  homozygous   splenocytes  
separate,   thus   it  was   impossible   to   state   if   there  was  a   contribution  deriving   from  other  
GFP-­‐‑expressing   “helper”   cells   in   CX3CR1GFP/GFP   mice.   Similarly   to   the   in   vivo   approach  
pursued  with  mixed  BM  chimeras  (Figure  20),  the  in  cys  effect  of  CX3CR1  absence  on  NK  
cells   was   investigated   by   mixing   equal   amounts   of   the   cells   from   the   two   strains,  
stimulating  them  overnight  with  IL-­‐‑15  and  then  incubating  them  with  the  target  cell  line  
in  a  1:2  effector:target  ratio  for  4  hours.  The  degree  of  degranulating  activity  was  higher  in  
CX3CR1-­‐‑deficient  NK  cells,  indicating  an  intrinsic  effect  of  CX3CR1  loss  on  NK  cells  as  for  
what  concerns  their  enhancement  in  degranulation  potential  (Figure  24c).  Some  intriguing  
findings  were  observed  when  NK  cell  population  was  dissected  into  cell  subsets:   in  fact,  
the  increase  of  CD107a  positivity  was  reported  not  only  on  KLRG1+,  but  also  on  KLRG1-­‐‑  
cells,   and   furthermore,   GFP-­‐‑   cells   were  mainly   responsible   of   this   increase  within   both  
KLRG1-­‐‑   and   KLRG1+   subpopulations.   Although   it   is   difficult   to   explain   such   a  
phenomenon,  since  GFP-­‐‑  cells  do  not  express  CX3CR1  in  control  mice  and  thus  should  not  
be  affected  by  its  deficiency,  it  is  still  possible  that  the  alteration  in  NK  cell  behavior  might  
arise  earlier  than  GFP  acquisition,  and  more  so  before  KLRG1  expression,  during  NK  cell  




As  anticipated,  the  following  step  was  to  evaluate  potential  differences  in  NK  cell  behavior  
during   an   in  vivo  model   of   acute   inflammation.   Specifically,  we  used  Poly(I:C)-­‐‑induced  
hepatic   inflammation   model,   in   which   a   TLR3   agonist   that   mimics   viral   dsRNA   is  
described  to  activate  NK  cells  and  to  provoke  their  redistribution  in  several  tissues,  such  
as   BM,   spleen,   and   blood,   finally   driving   them   to   the   liver330.   In   our   experimental  
conditions,  NK  cell   frequency  and  number   in   those  organs  were  monitored  during  a   72  
hours   long   time   course,  with   intermediate   time   points   at   6   and   18   hours   post-­‐‑Poly(I:C)  
subministration.  
CX3CR1+/GFPmice   displayed   a   substantial   mobilization   of   total   NK   cell   pool   in   BM   and  
spleen   (up   to  80%  reduction  of   the   initial  population  after   18  hours)   as   early  as   6  hours  
post  injection,  which  was  paralleled  by  a  corresponding  accumulation  in  the  liver,  where  
NK  cell  number  increased  even  by  3.5  fold.  The  initial  NK  cell  number  was  recovered  in  
the  BM  and  in  the  spleen  after  72  hours,  whether  at  that  time  point  the  liver  still  presented  
a  doubled  NK  cell  population,  compared  to  the  time  0  condition  (Figure  25a).  
Significant   differences   were   observed   between   the   two   strains,   inasmuch   CX3CR1-­‐‑
deficient  BM  NK  cells  exited  more  promptly  from  the  BM  (6  hours)  and  were  less  reduced  
in  the  spleen  at  intermediate  time  points  (6  and  18  hours).  It  is  difficult  to  adfirm  whether  
the  lower  mobilization  from  the  spleen  meant  a  slower  exit  rate  from  this  organ  or  either  a  
transitional   splenic   recruitment   after   BM   egress,   which   could   not   be   observed   in   the  
CX3CR1+/GFP   mice   (or   was   too   quick   to   be   detected).   Interestingly,   a   slight   but   not  
significant   increase   in   the   splenic   NK   cell   number   was   also   reported   after   72   hours,  
indicating  that  the  first  hypothesis  might  be  more  likely.  
When  specific  NK  cell  subset  contribution  to  Poly(I:C)-­‐‑induced  NK  cell  redistribution  was  
considered,  a  predominant  effect  on  KLRG1+  NK  cell  subset  was  observed,  in  accordance  
to   the   fact   that  CX3CR1   is  mainly   expressed   by  more  mature  KLRG1+  NK   cells   (Figure  
25b),   although   significant   but   less   important   changes   could   be   detected   also   for   the  
CD11blow/KLRG1-­‐‑  and  CD11bhigh/KLGR1-­‐‑  subsets   (not  shown).   Indeeed,  KLRG1+  NK  cell  
trafficking  reflected  what  was  remarked  for  total  NK  cells,  with  the  notable  difference  of  a  
decreased   number   of   CX3CR1-­‐‑deficient   KLRG1+   NK   cells   in   liver   after   18   hours,   as  
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compared   to   the   heterozygous   cells,  which  was   probably  masked   by   other   cell   subsets’  
behavior  when  total  NK  cells  were  considered.  
  
  
Figure  25  -­‐‑  Altered  poly(I:C)-­‐‑in-­‐‑  duced  tissue  redistribution  of  NK  cells  in  CX3CR1-­‐‑
deficient  mice.   CX3CR1+/GFP   and   CX3CR1GFP/GFP  mice   were   i.p.   injected   with   150   µμg  
Poly(I:C),  and  NK  cells  were  collected  from  BM,  spleen,  and  liver  after  6,  18,  and  72  
hours.  To  test  whether  the  differences  in  total  NK  cell  number  could  be  ascribed  to  a  
specific   cell   subset,   we   also   stained   our   samples   for   CD11b-­‐‑   and   KLRG1-­‐‑   specific  
mAbs.   The   histograms   represent   the   results   obtained   from   at   least   six   animals   per  
group  in  four  independent  experiments.  Data  are  expressed  as  percent  (mean  values  
±  SEM)  of  total  (a)  or  KLRG1+  (b)  NK  cell  counts  at  the  different  time  points  vs  the  
NK  cell  count  (total  and  KLRG1+,  respectively)  in  untreated  mice.  *  =  p  <  0.05.  
  
The  degree  of  hepatic  damage  resulting  from  NK  cell  recruitment  to  liver  can  be  assessed  
through   the   measurement   of   the   enzymatic   activity   of   hepatic   enzymes   present   in   the  
serum,  in  particular  the  Alanine  Transaminase  (ALT),  which  is  released  in  the  extracellular  
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medium  following  hepatocyte  apoptosis,  by  means  of  a  biochemical  assay  we  tested  ALT  
activity   in   blood   samples   of   CX3CR1+/GFP   and   CX3CR1GFP/GFP   animals   at   different   time  
points  after  Poly(I:C)  subministration,  in  order  to  determine  whether  the  alterated  NK  cell  
trafficking  could  result   in  differences   in   the  hepatic  damage  (not  shown).   In  preliminary  
experiments,  the  results  of  this  procedure  showed  a  similar  trend  for  the  two  strains,  as  in  
both  sera  no  ALT  activity  was  detected  until  48  hours  after   injection,  while  a   significant  
increase  was  observed  at  the  latest  time  point  (72  hours).  
  
4.2.  Second  part  –  NK  cell   trafficking  and  function   in  
Multiple  Myeloma  
  
Besides  CX3CR1,  NK  cell  capacity  to  reach  several  anatomical  compartments  is  conferred  
by  a  wide  array  of  chemokine  receptors  expressed  on  their  cell  surface113,  331,  332,  333,  such  as  
CXCR3,  CXCR4,  CXCR6,  CCR1,  CCR3,  CCR4  and  CCR5.  These  receptors  are  specific   for  
chemokines   secreted   in   diverse   physio-­‐‑pathological   conditions,   and   are   also   expressed  
heterogeneously  within  NK  cell  subpopulations.  
Being   the  most   important  district  of   their  development,  several  developmentally  distinct  
NK   cell   subsets   reside  within   the  BM,   also  displaying   a  differential   chemokine   receptor  
expression   pattern.   In   Figure   26   the   expression   profile   of   some   of   these   receptors   is  
presented,  on  total  NK  cells  and  on  KLRG1-­‐‑  and  KLRG1+  cell  subsets  localized  in  the  BM  
of   8   weeks-­‐‑old   healthy   mice.   Although   the   KLRG1-­‐‑   subset   is   not   an   homogeneous  
population,   which   includes   immature   CD11blow   NK   cells   as   well   as   fully   functional  
CD11bhigh  NK  cells,  it  can  be  seen  in  the  presented  histograms  that  most  of  the  chemokines  
receptors   analyzed   are   preponderantly   represented   on   this   fraction   of   NK   cells,   while  
CX3CR1  is  the  only  one  found  prevalently  on  mature  KLRG1+  cells.    
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Figure   26   –   Chemokine   receptor   expression   on   BM   NK   cells.   BM   cells   from   healthy  
C57BL/KaLwRij  mice  were   collected   and  NK  cells   and  NK  cell   subsets  were   stained   for  
with  CCR1-­‐‑,  CCR5-­‐‑,  CXCR3-­‐‑  and  CXCR4-­‐‑specific  mAbs  (red  lines)  and  respective  isotype  
controls   (blue   lines).  CX3CR1  expression   level  was  assessed  through  the  GFP  analysis   in  
BM  cells   from  CX3CR1+/GFP  mice,   in   a  C57BL/6J  background.  The   same  expression   levels  
were  detected  on  C57BL/KaLwRij  BM  NK  cells  using  human  CX3CL1  fused  with  human  
Fc,  and  then  staining  with  anti-­‐‑human-­‐‑Fc  mAb  (not  shown).  Numbers  in  histogram  plots  
represent  the  MFI  in  one  out  of  at  least  five  independent  experiments.    
  
In   paragraph   1.2.5.,   the   several   strategies   exploited   by   cancer   cells   to   divert   immune  
response   from   the   tumor   site   through   the  disregulation  of   the   chemokine  balance   in   the  
surrounding  microenvironment  were  described.  Because  of  the  major  role  played  by  NK  
cells   in  Multiple  Myeloma   (MM),   and   since   this   pathology  mainly   interests   the  BM,   the  
second   part   of   this   thesis   will   deal   with   the   interaction   of   MM   growth   and   NK   cell  
function  and  migration,  with  the  perspective  of  uncovering  new  aspects  of  NK  cell  biology  






4.2.1.  MM  cells  are  sensitive  to  NK  cell  action  in  vitro  and  in  vivo  
  
The   first   step   towards   this   objective   was   to   estabilish   and   characterize   an   appropriate  
murine  model  of  MM,  which  as  such  should  mimic  the  most  typical  features  of  the  human  
pathology.  The  murine  model  induced  by  transplantation  of  5TMM  cells  into  a  syngeneic  
mouse   strain   displays   the   classical   hallmarks   of   MM,   including   osteolitic   lesions,  
hypergammaglobulinemia,   and   angiogenesis,   and,   importantly,   grows   preferentially   in  
the  BM,  being  thus  classified  as  an  orthotopic  tumor  model.  
In  this  work,  5TGM1  cells,  a  5TMM-­‐‑derived  tumor  line,  were  used  to  estabilish  the  murine  
model:   2x106   cells   were   i.v.   transplanted   in   6-­‐‑10   weeks   old   syngeneic   C57BL/KaLwRij  
female   mice,   and   MM   growth   was   monitored   up   to   4   weeks   after   injection.   Tumor  
progression   was   evaluated   through   the   detection   of   intracellular   production   of   the  
monoclonal   paraprotein,   IgG2b,   which   is   expressed   exclusively   by   5TGM1   cells.   IgG2b  
levels  were  monitored  2,  3  and  4  weeks  after  5TGM1  injection  in  BM  and  in  spleen  (Figure  
28a).  
  
At   first,   in  vitro  NK  cell  capacity   to  react   to  5TGM1  cells  was  tested:   to   this  aim,  splenic  
and  BM-­‐‑derived  NK  cells  from  healthy  mice  were  previously  activated  by  cullturing  them  
overnight   with   IL-­‐‑15,   and   then   tested   through   51Cr-­‐‑release   cytotoxicity   assay   and  
degranulation   assay   against   5TGM1   cells.   Figure   27   shows   that  NK   cells   from  both   BM  
and   spleen   are   able   to   express   the   degranulation   marker   CD107a,   and   when   NK   cell  
subsets  were  considered,  KLRG1-­‐‑  fraction  was  observed  to  be  more  active   than  KLRG1+  
subpopulation.  Accordingly,   enriched   splenic  NK   cells  were   able   to   exert   up   to   20%   of  
cytotoxicity  towards  their  target.  These  results  demonstrate  the  sensitivity  of  MM  cells  to  
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Figure  27  –  5TGM1  activate  and  are  sensitive  to  NK  cells  in  vitro.  BM  and  splenic  cells  
from  healthy  C57BL/KaLwRij  mice  were  activated  overnight  with  IL-­‐‑15,  then  washed  and  
incubated  with  or  without  5TGM1  cells  for  4  hours,  in  presence  of  anti-­‐‑CD107a  mAb,  or  its  
isotype   control.  NK   cell   degranulation  was   then   assessed   by   FACS,   staining   for  NK1.1,  
CD3  and  KLRG1.  Data  are  expressed  as  percentage  of  CD107a+  cells,  and  CD107a  values  
obtained   in  absence  5TGM1  cells  were   subtracted   from   those  obtained  with   tumor  cells,  
and  are   representative  of  1  out  of  3   independent  experiments  performed   (left).  Enriched  
splenic  NK  cells  were  activated  overnight  with   IL-­‐‑15  and  used  as   effector,  while  YAC-­‐‑1  
cells  were  incubated  in  complete  medium  for  1  hour  in  presence  of  51Cr.  The  cytotoxicity  
lasted   4   hours,   and   the   radioactivity   present   within   supernatants   was   assessed   with   a  
TopCount-­‐‑NXT  counter  (right).  
  
Considered  the  in  vitro  data,  we  focused  on  the  analysis  of  NK  cell  anti-­‐‑tumor  activity  in  
vivo.  MM   growth  was   followed   in   a   4  week-­‐‑long   time   course,   during  which  we   could  
observe  a  slow  proliferation/engraftment  rate  until   the  3rd  week,   in  BM  and  spleen,  and  
after  that  a  marked  increase  in  the  speed  of  tumor  growth.  Nevertheless,  though  in  terms  
of  absolute  numbers  of  5TGM1  BM  and  spleen  may  appear  similar,  the  frequency  of  tumor  
cells  was  significantly  different  already  after  3  weeks  (2  ±  0.2%  in  BM  and  0.47  ±  0.03%  in  
spleen),  and  quite  distant  after  4  weeks  (8  ±  1%  in  BM  and  2.4  ±  0.3%  in  spleen).  At  four  
weeks,   the   alteration   in   the   equilibrium   in   the   BM   cellular   composition  was   far   deeper  
than  that  observed  in  the  spleen,  likely  having  a  strong  impact  on  several  aspects  related  
to   BM,   such   as   the   hematopoiesis   or   the   immune   response   exerted   by   the   BM-­‐‑residing  
leukocytes,  as  it  will  be  shown  later  on.  
Having  determined  the  kinetics  of  MM  progression   in  our  model,   the  next  question  was  
related  to  the  role  of  NK  cells  in  the  immune  response  against  it.  To  address  this  issue,  NK  
cells   of   MM-­‐‑bearing   mice   were   depleted   through   i.p.   administration   of   the   anti-­‐‑NK1.1  
Results	  
100	  
mAb  PK136   both   before   and   after   the   injection   of   5TGM1   cells.   This   depletion   protocol  
was  meant  to  measure  NK  cell  contribution  during  the  whole  course  of  MM  progression,  
since   the   initial   migration   to   and   colonization   of   BM   to   the   last   phase   of   estabilished  
disease.   As   it   is   shown   in   Figure   30b,   NK   cell   absence   determined   an   increase   of  MM  
growth   both   in   the   spleen   and   in   BM,   although   the   difference   was   not   statistically  
significant  after  4  weeks  in  the  BM,  whereas  it  was  evident  in  the  spleen.  This  effect  could  
likely  be   linked   to   the  different   role  played  by  NK  cells   in   the   two  different   anatomical  
compartments  during  MM  progression.  
At  any  rate,  the  induction  of  a  quicker  MM  growth  demonstrates  the  in  vivo  action  of  NK  
cells  in  the  immune  response  to  tumor.  
  
  
Figure  28  –  MM  growth  in  vivo  is  affected  by  NK  cells  in  BM  and  spleen.  BM  and  spleen  
cells  were  collected  from  healthy  and  tumor-­‐‑bearing  mice  2,  3  and  4  weeks  after  5TGM1  
injection,  and  were  intracellularly  stained  with  anti-­‐‑IgG2b  mAbs,  specific  for  tumor  cells.  
Kinetics  of  MM  growth  in  BM  and  spleen,  shown  as  mean  value  ±  SEM  (left).  Effect  of  NK  
cell  depletion  on  MM  progression  at  the  time  points  indicated  (right).  Data  are  expressed  
as  mean  number  of  IgG2b+  cells  in  organs  ±  SEM,  and  are  representative  of  at  least  8  mice  
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4.2.2.   NK   cell   response   in   vivo   is   impaired   early   during   tumor  
growth  
  
As  already  done  in  vitro,  NK  cell  degranulation  capacity  was  then  assessed  ex  vivo,  by  the  
evaluation  of  CD107a  expression  of  freshly  collected  cells  from  BM  and  spleen  of  healthy  
and  MM-­‐‑bearing   mice   (Figure   29).   Interestingly,   splenic   NK   cells   derived   from   tumor-­‐‑
bearing  mice  showed  an  increase  of  their  degranulation  rate,  at  all   time  points  analyzed,  
while  BM  NK  cells  were  activated  only   in   the  early  phases  of   tumor  growth.   Indeed,   in  
light   of   the   in   vitro   experiments,   NK   cells   naturally   react   against   5TGM1   cells,   thus  
suggesting   that   the   increase   of   CD107a+   cells   observed   in   the   spleen   could   reflectstheir  
normal  activity.  Conversely,  the  lack  of  degranulation  enhancement  reported  at  later  times  
in  the  BM  is  probably  due  to  the  dysregulation  or  suppression  of  NK  cell  function,  which  
is  related,  directly  or  indirectly,  to  MM  cell  extensive  proliferation.    
  
  
Figure   29   –  NK   cell   functionality   is   impaired   after   3   weeks   in   the   BM.   Expression   of  
degranulation  marker  CD107a  was  assessed  by  FACS  on  freshly  collected  NK  cells   from  
BM   (left)   and   spleen   (right)   of   healthy   and  MM-­‐‑bearing  mice   after   2,   3   and   4  weeks   of  
tumor  growth.  Each  symbol  represents  a  single  mouse,  analysed  in  at  least  2  independent  
experiments.  The  horizontal  bar  represents  the  mean  value.  *  =  p  <  0.05;  ***  =  p  <  0.001.    
  
To   insert   these   data   in   a  more   detailed   framework,   the  NK   cell   number   and   frequency  
among   lymphocytes   were   assessed   in   BM   and   spleen.   Mirroring   the   trend   of   MM   cell  
growth,   a   significant  NK   cell   number   decrease  was   reported   in   BM   as   early   as   the   3rd  
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week,  while  it  was  halved  by  the  following  week.  Of  note,  not  only  the  NK  cell  number,  
but  also  total  lymphocyte  count  and  even  total  BM  cell  count  was  reduced  after  4  weeks,  
but   were   normal   after   3   weeks   (not   shown).   The   situation   was   different   in   the   spleen,  
where   NK   cell   number   remained   unchanged   until   the   3rd   week,   but   suffered   a   strong  
reduction  at  the  4th  (decreasing  by  a  third).  
  
  
Figure  30  –  MM  growth  causes  the  reduction  of  BM  NK  cell  number  after  3  weeks.  CD3-­‐‑  
NK1.1+  lymphocytes  were  quantified  in  BM  (left)  and  spleen  (right)  of  healthy  and  tumor-­‐‑
bearing  mice  during  disease  progression.   In   the  upper  panels,   graphs   show   the  NK  cell  
number   in   each   group   (the   horizontal   bar   represents   the  mean   value),  while   below   the  
histograms  display  the  mean  NK  cell  frequency  among  lymphocytes  of  the  same  animals  ±  
SEM.  Each  circle  represent  a  single  mouse,  analysed  in  at  least  3  independent  experiments.  
*  =  p  <  0.05;  **  =  p  <  0.01;  ***  =  p  <  0.001.  
  
Comparing  the  result  obtained  from  NK  cell  phenotyping  and  MM  quantification,  a  fine  
correlation  between  those  two  parameters  was  found,  which  might  explain  the   impaired  
NK  cell  degranulation  capacity  observed  after  3  and  4  weeks  in  the  BM  (Figure  31).  
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Figure  31  –  NK  cells  are  overwhelmed  by  5TGM1  cells  in  BM  after  3  weeks.  Total  NK  cell  
number   in   BM   and   in   the   spleen   of   each   tumor-­‐‑bearing  mice   after   2,   3   and   4  weeks   of  
tumor   growth   was   divided   by   the   IgG2b+   cell   number   found   in   the   same  mouse.   The  
curve   shows   the   mean   values   of   the   resulting   NK:IgG2b+   (5TGM1)   cell   ratios.   Data  
represent  at  least  10  mice,  in  3  independent  experiments.  
  
In  fact,  dividing  each  animal’s  NK  cell  number  by  tumor  cell  number  detected  in  BM  (or  in  
the  spleen)  at  different  time  point  analyzed,  a  decreasing  curve  can  be  drawn,  indicating  
the  presence  of  4  MM  cells  per  NK  cells  in  BM  already  after  3  weeks,  and  of  about  20  MM  
cells  per  NK  cell  after  4  weeks.  Obviously,  NK  cells  are  not  the  only  players   involved  in  
MM-­‐‑directed  immune  response,  but   it   is   likely  that  the  unfavourable  effector:target  ratio  
might  put  them  at  a  strong  disadvantage.  In  comparison,  the  spleen  displays  a  far  better  
situation,  since  the  NK  cell/IgG2b+  cell  ratio  slighlty  goes  below  1  only  after  4  weeks.  
  
4.2.3.  Myeloma  cells  alter   the  proportion  of  NK  cell  subsets  within  
BM  
  
When  BM  NK  cell  subset  composition  was  analyzed,  a  preponderant  involvement  of  the  
less  mature  KLRG1-­‐‑  subset  was  found  after  3  weeks,  while  the  KLRG1+  subset  was  more  
or   less   maintained   intact.   Consequently,   considering   the   NK   cell   subset   frequencies  
CD11bhigh/KLRG1+   subset   was   doubled,   mainly   at   the   expense   of   CD11blow/KLRG1-­‐‑  
fraction.   If   added   to   NK   cell   number   decrease,   this   shift   in   NK   cell   phenotype   might  





Figure  32  –  NK  cell  decrease  in  BM  is  selectively  caused  by  KLRG1-­‐‑  subset.  CD3-­‐‑/NK1.1+  
lymphocytes  were  dissected  in  3  subsets  according  to  their  CD11b  and  KLRG1  expression.  
a)  Histograms  show  the  reduction  of  both  KLRG1-­‐‑  cell  subsets  in  the  BM  of  MM-­‐‑bearing  
mice  after  3  weeks  (left),  while  KLRG1+  cell  number   is  unchanged.  Conversely,  KLRG1+  
frequency  within   the  BM  NK  cells   in  presence  of  MM   is   augmented  1.5   fold   (b,   left),   as  
compared  to  healthy  mice.  Graphs  represent  mean  values  ±  SEM  of  at  least  15  mice,  from  
at  least  4  independent  experiments.  *  =  p  <  0.05;  **  =  p  <  0.01;  ***  =  p  <  0.001.  
  
Differently,   after   4   weeks   no   important   difference   in   NK   cell   subset   frequency   was  
evidenced  neither  in  the  BM  nor  in  the  spleen,  although  every  subpopulation  suffered  an  
important  reduction  in  both  organs,  probably  related  to  the  hematopoiesis  block  caused  by  
the   expansion   of   MM   cells.   Indeed,   the   slightly   reduced   transition   of   immature  
CD11blow/KLRG1-­‐‑  cells  into  fully  functional  CD11bhigh/KLRG1-­‐‑  cells  observed  in  BM  might  
be  in  agreement  with  this  speculation,  and  could  also  cause  the  similar  phenotype  in  the  
spleen  (Figure  33).  
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Figure  33  –  At  later  stages  of  MM  growth  BM  NK  cell  number  is  greatly  reduced.  All  NK  
cell   subsets   suffer   an   important   numeric   reduction   in   the   BM   after   4   weeks   of   tumor  
growth  (a,  left),  while  in  the  spleen  only  a  slight  tendency  can  be  observed  (a,  right).  NK  
cell   subset   balance   is   unaltered   in   the   BM   (b,   left),   while   a   decreased   frequency   of   the  
functional  CD11bhigh/KLRG1-­‐‑  subset  in  MM-­‐‑bearing  mice  is  shown  in  the  spleen  (b,  right).  
Graphs   represent   mean   values   ±   SEM   of   at   least   15   mice,   from   at   least   4   independent  
experiments.  *  =  p  <  0.05;  ***  =  p  <  0.001.  
  
The  individual  contribution  of  each  NK  cell  subpopulation  to  total  NK  cell  degranulation  
degree  ex  vivo  at  2,  3  and  4  weeks  was  in  line  with  the  results  shown  in  Figure  29,  and  did  









4.2.4.   KLRG1-­‐‑   NK   cell   trafficking   capacity   to   BM   is   impaired   in  
tumor-­‐‑bearing  mice  
  
The  results  obtained  so  far  described  a  developing  situation  regarding  NK  cells  in  the  BM:  
in   fact,   while   at   the   beginning   NK   cells   seem   to   be   functional   and   able   to   efficiently  
hamper   tumor  growth,  at   the  3rd  week   they  are   reduced   in  numbers  and   function,   thus  
paving   the   way   to   what   will   take   place   at   later   stages,   when   they   are   completely  
overpowered  by  MM  cells  in  the  BM.  Our  interest  then  focused  mainly  on  the  3rd  week,  
which   represents   an   asymptomatic,   intermediate   phase   of   tumor   progression,   that  may  
allow  to  dissect  early  mechanisms  of  subversion  of  NK  cell-­‐‑mediated  function.  
In  particular,  KLRG1-­‐‑  BM  NK  cell  decrease   in  numbers  evidenced  at   this  stage  could  be  
possibly  due   to   several,   non  mutually   exclusive,   phenomenons:   first,   a   reduction   of   cell  
survival,  which  should,  at  any  rate,  not  affect  KLRG1+  subset.  Another  option  would  be  
the   altered   NK   cell   development,   which   would   explain   KLRG1+   frequency   increase.  
Lastly,  there  might  be  a  disregulation  of  NK  cell  subsets  trafficking  capacities,  selectively  
impairing  the  entry  rate  of  specific  NK  cell  subsets  to  the  tumor  site.  
The  first  possibility  was  tested  by  staining  NK  cells  derived  from  BM  of  healthy  and  MM-­‐‑
bearing  mice  with  AnnexinV  (Figure  34a).  No  significant  differences  in  the  survival  rate  of  
total   NK   cells   and   of   KLRG1-­‐‑   or   KLRG1+   NK   cell   subsets   in   the   two   conditions   were  
observed,   suggesting   that,  at   least  at   this   stage  of  MM  progression,   the  apoptotic   rate  of  
NK  cells  did  not  affect  KLRG1-­‐‑  subset  numeric  reduction.  
Next,   the  hypothesis  of   the  altered   trafficking  was  examined,  by  adoptively   transferring  
PKH26-­‐‑marked   splenocytes   into   healthy   or   MM-­‐‑bearing   mice   to   evaluate   their   in   vivo  
migration   capacity   (Figure   34b).   The   graphs   display   the   reduction   in   total   NK   cell   BM  
recruitment   in   the  BM  of   tumor-­‐‑bearing  mice,   that  could  be  exclusively  attributed  to   the  
KLRG1-­‐‑  fraction  of  cells,  whereas  KLRG1+  capacity  to  traffick  to  BM  was  not  affected  by  
MM-­‐‑induced  BM  conditioning.  Conversely,  donor-­‐‑derived  NK  cells  were  normally  able  to  
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migrate  to  the  spleen,  even  in  presence  of  tumor  cells,  and  so  were  KLRG1-­‐‑  and  KLRG1+  
NK  cell  subsets.  
These   data   are   similar   to   those   related   to   endogenous   KLRG1-­‐‑   NK   cells,   displayed   in  
Figure  32  (there  separated  for  the  expression  of  CD11b),  and  indicate  that  the  equilibrium  
between  NK  cell  entrance  and  retention  in  BM  is  disrupted  after  3  weeks  of  tumor  growth.  
Furthermore,  this  evidence  weakens  the  hypothesis  that  the  reduced  representation  of  the  
KLRG1-­‐‑  subset   in  BM  might  be  due   to  altered  NK  cell  development,  as  18  hours  would  
definitely  be  insufficient  to  justify  such  a  phenomenon.  
Nevertheless,   it   could  be   still   conceivable   that  during   the   time  between   the   engraftment  
and  the  organ  collection  a  fraction  of  KLRG1-­‐‑  NK  cells  would  acquire  KLRG1  expression,  
thus  altering  the  interpretation  of  the  data  deriving  from  the  transfer  experiments.  To  rule  
out  this  hypothesis,  purified  KLRG1-­‐‑  cells  were  stained  with  PKH-­‐‑26  and  i.v.  transferred  
into  control  or   tumor-­‐‑bearing  mice.  After  18  hours,  BM  and  splenic   cells  were  collected,  
and   the  presence  of  newly  generated  KLRG1+  NK  cells  within   the  engrafted  population  





Figure   34   –  Altered   capacity   of  KLRG1-­‐‑  NK   cell   to  migrate   to  BM   in  MM-­‐‑
bearing   mice.   The   apoptotic   rate   of   BM   NK   cells   and   NK   cell   subsets   was  
measured  by  staining  for  AnnexinV,  as  shown  in  a  representative  experiment  
(a,  left).  Data  are  expressed  as  fold  increase  of  AnnexinV+  cells  in  MM-­‐‑bearing  
mice  vs  those  in  healthy  mice  (a,  right).  Being  the  ratio  close  to  1,  there  was  no  
alteration   in   the  measured  apoptotic   rate.  b)  12x106  splenocytes  were  stained  
with  PKH26  and  adoptively  transferred  in  healthy  or  tumor-­‐‑bearing  mice  after  
3   weeks.   Transferred   cells   were   detected   in   BM   (left)   and   spleen   (right)   of  
recipient   mice   18   hours   after   transplantation,   through   PKH-­‐‑26   expression  
analysis.   Histograms   represent   the   mean   values   ±   SEM   of   the   frequency   of  
transferred  cells  detected   in  each  organ  among  total   transferred  cells.  Highly  
purified   (>95%)   KLRG1-­‐‑   splenocytes   were   stained   with   PKH-­‐‑26   and  
adoptively   transferred   into   healthy   and  MM-­‐‑bearing  mice   after   3  weeks.   18  
hours  later,  KLRG1  expression  was  assessed  by  FACS  on  recipient’s  NK  cells  
(left  panels),  and  on   transferred  NK  cells   in  healthy  and   tumor-­‐‑bearing  mice  
(central  and  right  panels),  within  BM  (above)  and  spleen  (below).  Numbers  in  
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dot  plots  represent  the  frequency  of  newly  generated  KLRG1+  NK  cells  among  
the   total   transferred   NK   cells   in   the   organ   analysed,   from   one   over   two  
independent  experiments,  with  at  least  4  mice  per  each  group.  **  =  p  <  0.01.  
  
This  was  not  the  case,  at   least  for  the  BM-­‐‑residing  transferred  NK  cells,  and,  at  any  rate,  
the  process  of  acquisition  of  KLRG1  that  occurred  in  the  spleen  did  not  present  differences  
between   control   and  MM-­‐‑bearing  mice.   Taken   together,   these   experiments   demonstrate  
the   selective   reduction  of  KLRG1-­‐‑  NK  cell  homing   to  BM   in  presence  of  MM  at   the   3rd  
week  of  tumor  growth,  indicating  that  these  cells  are  probably  driven  outside  the  organ  at  
an  intermediate  phase  of  disease  progression.  
  
4.2.5.  The   chemokine   environment   is  unbalanced   in  BM  of   tumor-­‐‑
bearing  mice  
  
To   further   characterize   BM   NK   cell   trafficking   properties,   the   following   step   was   to  
analyze   the   expression   of   some   of   the   chemokine   receptors   known   to   affect   NK   cell  
function,   in   particular   those   involved  with   cancer-­‐‑related   inflammation   (CXCR3,   CCR1,  
CCR5)  and  with  BM  retention  (CXCR4).  Figure  35a,b  show  that  CXCR4,  CCR1  and  CCR5  
present  a  normal  expression  profile  on  BM  NK  cells  derived  from  MM-­‐‑bearing  mice,  while  
CXCR3   expression   was   found   to   be   significantly   reduced.   As   pictured   in   Figure   26,  
KLRG1-­‐‑   fraction   accounts   for   the  majority  of   the   chemokine   receptors   expressed  by  NK  
cells  (including  CXCR3),  and  thus  it  is  not  surprising  that  CXCR3  downregulation  within  
the  total  NK  cell  pool  is  prevalently  caused  by  a  marked  effect  on  KLRG1-­‐‑  subpopulation  
(Figure  35c).  To  portray  BM  microenvironment  in  relation  to  the  chemokine  system  more  
in  detail,  the  concentration  of  several  chemokines  in  BM  extracellular  fluids  of  healthy  and  
MM-­‐‑bearing   mice   was   assessed.   In   particular,   we   determined   the   concentration   of   the  
specific   ligands   of   the   same   chemokine   receptors   analysed   on   NK   cells   (Figure   35d,e).  
CXCR3  ligands  CXCL9  and  CXCL10  were  upregulated  in  BM  extracellular  fluids  of  MM-­‐‑
bearing  mice,  while  CXCL12  concentration  was  reduced  in  presence  of  MM.  Interestingly,  
an  increase  in  CXCL9  concentration  was  also  found  in  sera  of  MM-­‐‑bearing  mice,  whereas  
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neither  CXCL10  nor  CXCL12  were  altered.  Soluble  CX3CL1  was  not  detected  in  blood  of  
either   control   or   tumor-­‐‑bearing  mice   (not   shown).  Moreover,   preliminary  data   obtained  
through  Luminex  technology  indicate  a  tendency  to  increase  in  CCR1/5  ligands  CCL2  and  
CCL3  expression  in  MM-­‐‑bearing  mice,  while  CCL5  was  not  altered  (not  shown).  
While  CXCL12  decrease  in  BM  is  in  agreement  with  KLRG1-­‐‑  NK  cell  reduction  as  their  BM  
retention   is   supposed   to  be  more  dependent  on  CXCR4   function,   the   increase  of  CXCR3  
ligands  is  harder  to  explain,  especially  if  CXCR3  expression  on  NK  cells  is  downregulated.  
  
  
Figure  35  –  MM  produces  important  alterations  of  CXCR3  and  CXCR4  axes  
within  the  inflamed  BM.  a)  Overlay  of  chemokine  receptor  expression  on  BM  
NK   cells   from   healthy   (dotted   line)   and   tumor-­‐‑bearing   (black   line).   Filled  
gray   line   represents   isotypic   control.   b)   Quantification   of   CCR1,   CCR5,  
CXCR3  and  CXCR4  expression  on  total  NK  cells,  represented  as  mean  values  
of  MFI  ±  SEM.  CXCR3  downmodulation  was  assessed  also  on  KLRG1-­‐‑  and  
KLRG1+  NK  cell  subsets,  and  quantified  as  MFI  ±  SEM  (c).  BM  extracellular  
fluids   from   healthy   and   MM-­‐‑bearing   mice   were   collected   and   stored   as  
described   in  Methods.   In   (d)   are   displayed   the   results   of   ELISA   assays   for  
CXCL12,  CXCL9,  CXCL10  and  CX3CL1,  normalized  for  total  proteins  present  
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in   the   extracellular   fluid   tested.  Histograms   show   the  mean   values   ±   SEM.  
ELISA  assays   for  CX3CL1  (not  shown),  CXCL9,  CXCL10  and  CXCL12  were  
also  conducted  on  serum  samples   (e),   and  are  displayed  as  mean  values  of  
their   concentration   ±   SEM.   At   least   8   mice   per   group,   in   3   independent  




4.2.6.   Myeloma   impairs   CXCR3+   NK   cell   ability   to   reside   and  
migrate  to  BM  
  
Chemokine  receptor  downregulation  can  be  caused  by  several  mechanisms.  First,  it  can  be  
due   to   an   alteration   of   NK   cell   maturation   (especially   as   CXCR3   is   developmentally  
modulated);   secondly,   there  could  be  an  alteration   in   the   transcriptional,   translational  or  
even   post-­‐‑translational   control   of   the   receptor   expression;   finally,   it   is   possible   that  
CXCR3+   cells   are   excluded   from   the   analyzed   context,   reverberating   on   global   CXCR3  
expression  intensity.  
The  first  case  was  previously  discarded  as  unlikely  (Paragraph  4.2.4)  though  not  formally  
ruled   out,   and,  moreover,  we   observed   a  decrease   in   frequency   of  CXCR3-­‐‑positive   cells  
(not   shown),   which   pointed   towards   the   last   hypothesis.   Regardless,   to   hone   in   on   the  
exact  mechanism   of   CXCR3   downregulation   it   was   important   to   determine   its   kinetics:  
indeed,  transcriptional  and  post-­‐‑traslational  modifications,  and  developmental  alterations  
would  require  completely  different  lapses  of  time.  
To  address  this  issue,  a  variant  of  the  previously  shown  adoptive  transfer  experiment  was  
employed,   this   time   analyzing   CXCR3   expression   level   on   transferred   splenic   NK   cells  
after   i.v.   injection   into  control  and  tumor-­‐‑bearing  mice  at  different   time  points   (3  and  18  
hours).  The  results  represented  in  Figure  36  reveal  that  CXCR3  downregulation  occurs  on  
engrafted   cells   already  after   3  hours,   and  persists   over   18  hours,   thus   excluding  a   long-­‐‑





Figure   36   –  CXCR3   downmodulation   on   BM  NK   cells   from  MM-­‐‑bearing  mice   takes  
place  also  on  splenic  transferred  cells,  with  a  fast  kinetics.  Enriched  splenic  NK  cells  (≅  
30%   of   total   cells)   were   previously   stained   with   CFSE   and   then   i.v.   transferred   into  
control  or  tumor-­‐‑bearing  mice  after  3  weeks  of  MM  growth.  CXCR3  expression  level  on  
transferred  NK  cells  was  assessed  in  BM  of  recipient’s  mice  3  or  18  hours  after  injection.  
On  the  left  graph,  the  individual  values  of  MFI  for  each  mouse  analysed  are  displayed  
(horizontal  bars   represent   the  mean  value),   at   the   time  points   indicated.  At   least   four  
transferred   mice   were   used,   in   two   independent   experiments.   The   histogram   plots  
(right)  show  a  representative  experiment  CXCR3  downmodulation  in  MM-­‐‑bearing  mice  
(dotted  line)  as  compared  to  control  mice  (black  line).  The  isotypic  control  is  pictured  as  
the   filled   gray   line.   Numbers   in   the   plot   indicate   the   MFIs   of   the   representative  
experiment.  *  =  p  <  0.05  
  
Nevertheless,   it  remained  to  be  assessed  whether  post-­‐‑translational  mechanisms,  such  as  
ligand-­‐‑induced   receptor   internalization,   rather   than   the   direct   exclusion   of  CXCR3+  NK  
cells,  could  explain  the  observed  CXCR3  downmodulation.  To  prove  one  of  these  theories,  
we  made  use  of  CXCR3-­‐‑/-­‐‑  mice,  testing  the  BM  trafficking  properties  of  NK  cells  in  absence  
of  this  receptor.  
Competitive   adoptive   transfer   experiments  were  performed,   in  which   equal   amounts   of  
previously   marked   WT   CD45.1+   C57BL/6J   and   CD45.2+   CXCR3-­‐‑/-­‐‑-­‐‑derived   splenocytes  
were   i.v.   injected   in   control  and   tumor-­‐‑bearing  mice  after  3  weeks  of  MM  growth.  Cells  
from   recipient   organs  were   collected   after   3   and   18   hours,   and   donor-­‐‑derived  NK   cells  
were   distinguished   according   to   their   CD45   allelic   variant   (Figure   37a).   Surprisingly,  
CXCR3-­‐‑deficient  NK  cells  were  more  able  to  traffick  to  BM  than  their  WT  counterpart,  at  
both   time   points   tested,   in   healthy   mice   and   in   the   presence   of   the   tumor.   An   higher  
amount  of  transferred  CXCR3-­‐‑deficient  cells  was  also  observed  in  blood,  suggesting  that  
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the  receptor  was  needed  for  NK  cells  to  extravasate  to  selected  peripheral  tissues.  Indeed,  
CXCR3   absence   determined   a   reduced   migration   directed   towards   liver   and   spleen,  
although  in  the  former  the  differences  were  more  marked  than  in  the  latter.  
In  Figure  37b  the  data  concerning  KLRG1-­‐‑  NK  cell  subset  are  presented  as  ratio  of  WT  vs  
CXCR3-­‐‑/-­‐‑   cells   in  each  organ.  The  bar  graphs  show  that   the  altered  migration  of  KLRG1-­‐‑  
NK  cells  to  every  organ  in  absence  of  CXCR3  was  not  affected  by  MM  presence,  and  the  
same   can   be   said   for   the   BM   after   18   hours.  Notably,   spleen,   liver   and   blood   display   a  
different   trend   at   the   same   time   point:   in   fact,   the   presence   of   MM   cells   seems   to  
significantly  reduce  CXCR3-­‐‑sufficient  NK  cell  entry  in  those  organs  in  favour  of  their  KO  
counterpart.  Notwithstanding  this,  spleen  and  liver,  but  not  the  blood,  are  still  preferred  





Figure  37  –  CXCR3-­‐‑deficient  KLRG1-­‐‑  NK  cells  home  to  the  BM  better  than  their  WT  
counterpart.   Splenocytes   from   CD45.1+   WT   and   CD45.2+   CXCR3-­‐‑/-­‐‑   mice   were  
previously  stained  with  CFSE  and   then  adoptively   transferred   in  control  or   tumor-­‐‑
bearing   mice   in   1:1   ratio.   3   or   18   hours   later,   BM,   spleen,   liver   and   PBMCs   from  
recipient  mice  were  collected  and  transferred  cells  were  identified  as  CFSE+  cells.  WT  
and  CXCR3-­‐‑/-­‐‑   cells  were  distinguished  via   their  CD45  allelic  variant.   a)  Histograms  
show   the   frequency   of   NK   cells   from   WT   and   CXCR3-­‐‑/-­‐‑   in   the   analysed   organs,  
expressed   as   percentage   of   transferred   cells   in   the   organ   over   the   total   transferred  
cells  in  each  mouse.  In  (b)  histograms  represent  the  contribution  of  KLRG1-­‐‑  NK  cells  
of  both  genotypes,  expressed  as  WT:CXCR3-­‐‑/-­‐‑  transferred  KLRG1-­‐‑  NK  cell  ratio  in  the  
organ  at   the   indicated   time.  Each  value  was  normalized   for   the   initial  WT:CXCR3-­‐‑/-­‐‑  
ratio  present  in  input  cells.  Horizontal  dotted  line  represents  the  value  at  which  WT  
and   CXCR3-­‐‑/-­‐‑   cells   are   balanced   in   the   organ.   At   least   5   mice   per   group,   in   two  
independent  experiments  were  used.  *  =  p  <  0.05;  **  =  p  <  0.01;  ***  =  p  <  0.001.  
  
Altogether,   the   competitive   adoptive   transfer   experiments   demonstrate   that,   despite   the  
increase   of   CXCL9   and   CXCL10   concentration   observed   in   Figure   37b,   CXCR3   is   not  
requested  for  BM-­‐‑directed  NK  cell  migration.  On  the  contrary,  it  seems  to  mediate  NK  cell  
migration  towards  peripheral  organs,  like  spleen  and  liver.  
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5.  Discussion  
  
In   the   first   part   of   this  work   it  was  demonstrated   that   the   expression   of   the   chemokine  
receptor   CX3CR1   identifies   two   distinct   KLRG1+   NK   cell   subpopulations,   differing   in  
effector  responses  (Figure  14),  CXCR4  expression  and  CXCL12-­‐‑driven  chemotaxis  (Figure  
13a,b).   Besides,   KLRG1+CX3CR1-­‐‑   and   CX3CR1+   NK   cells   are   developmentally   related,  
marking  a  further  step  in  the  model  of  NK  cell  differentiation.  The  expression  analysis  of  
GFP   on  NK   cells   and  NK   cell   subsets   evidenced   a   preferential   distribution   of  CX3CR1-­‐‑
expressing  NK  cells  within   extra-­‐‑medullary   tissues,  particularly   spleen,   blood  and   liver,  
while   their   frequency   was   relatively   low   in   the   BM.   The   inverse   correlation   between  
CX3CR1  and  CXCR4  expression,  highlighted  on  the  two  KLRG1+  NK  cell  subsets,  recalls  
the  expression  pattern  described  for  S1P  receptor  S1P5  on  NK  cells116.  This  gradual  loss  of  
a  BM-­‐‑tropic  receptor  fits  well  in  the  model  of  progressive  loss  of  dependence  from  stromal  
CXCL12-­‐‑expressing  cells  during  NK  cell  development,   to  approximate   the  sinusoids,   the  
interface   between   the   BM   and   the   circulation.   Indeed,   CXCR4/CXCL12   axis   has   been  
reported   to   play   an   important   role   not   only   in   NK   cell   development114,   but   also   in  
hematopoietic   stem  cell,  B   cell   and  plasmocytoid  DC   (pDC)  BM  retention115,  334,  335,   so   the  
prevalently  parenchymal  KLRG1-­‐‑  NK  cell   subset  distribution   is  not   surprising,  given   its  
CXCR4  expression  levels.  At  the  same  time,  KLRG1+/CX3CR1+  cells  are  sinusoidal  for  the  
87%   (Figure   13d),   while   KLRG1+/CX3CR1-­‐‑   fraction   display   an   intermediate   phenotype  
(56%  of  parenchymal  cells).  
Furthermore,   the   distinct   degree   of   dependence   on  CXCR4   shown   by  KLRG1-­‐‑  NK   cells  
was  functionally  relevant,  as  demonstrated  by  the  different  outcomes  of  CXCR4  antagonist  
AMD-­‐‑3100   administration  on  NK  cell   subset  BM   retention.   Indeed,   the  KLRG1-­‐‑   fraction  
was   the  most   affected   by   CXCR4   blockage,   resulting   in   a   significant   reduction   in   their  
parenchymal   cell   number,   and   in   an   equivalent   increase   in   the   sinusoidal   compartment  
(Figure   13g,h)   as   well   as   in   the   peripheral   blood   (not   shown).   Conversely,   the   BM  
compartmentalization  of  KLRG1+,  both  CX3CR1-­‐‑  and  CX3CR1+,  NK  cells  was  not  affected  
Discussion	  
116	  
by  AMD-­‐‑3100.  Of  note,  CXCR4  expression  on  KLRG1+  subpopulation  is  only  reduced,  but  
not   abolished,  meaning   that  CXCR4  might   still   exert   an  effect  on   this   subset,   other   than  
BM  retention.  
Considering   the   most   important   function   of   a   chemokine   receptor,   the   most   logical  
hypothesis  to  make  for  CX3CR1  biological  function  would  be  related  to  cell  trafficking:  the  
adoptive   transfer   experiments   shown   in   Figure   12c   were   aimed   at   testing   the   homing  
capacity   of  CX3CR1+  NK   cell   population,  during   a  mid-­‐‑term   time   lapse   (18  hours).   The  
preferential   localization   in   peripheral   organs   such   as   spleen   and   liver,   might   be  
interpreted   differently:   on   one   hand,   it   would   suggest   that   CX3CR1   directs   NK   cells  
towards   those   districts,   implicating   the   high   expression   of   the   ligand   CX3CL1   on  
homeostatic  conditions.  This  interpretation  would  though  contradict  a  number  of  papers,  
where   CX3CR1-­‐‑deficient   NK   cells   were   normally   represented   in   spleen   and   liver336.  
Nevertheless,  Yu  and   colleagues   reported   that   in   a  different  model   of  CX3CR1-­‐‑deficient  
mice,   lung-­‐‑residing   NK   cells   (identified   in   this   work   as   CD3-­‐‑/DX5+)   were   reduced   in  
steady  state  conditions,  if  compared  to  WT  controls336.  In  contrast,  in  our  model  we  did  not  
detect   significant   differences   in   pulmonary   NK   cell   number   (not   shown),   but   this  
discrepancy   might   be   due   to   the   different   animal   models,   or   to   the   methods   used   to  
identify  NK   cell   population.  Another   report   described   that   there  were   no  differences   in  
NK  cell  number  within  LNs,  peripheral  blood  and  spleen  between  CX3CL1-­‐‑deficient  mice  
and   WT   mice337.   Besides,   while   CX3CL1   expression   has   been   traced   in   some   hepatic  
compartments  in  humans,  it  appears  that  its  production  is  notably  increased  only  during  
inflammatory   conditions   involving   liver,   such  as   cirrhosis  or  HCV-­‐‑induced   fibrosis338,  339.  
Of  note,  several  publications  indicated  an  important  role  for  CX3CR1/CX3CL1  axis  in  the  
lung,  since  epithelial  cells  in  respiratory  airways  express  high  levels  of  CX3CL1,  recruiting  
CX3CR1+  leukocytes  in  steady  state  and  inflammatory  conditions336,  340,  though  we  did  not  
assess  lung-­‐‑directed  CX3CR1+  NK  cell  homing  in  adoptive  transfer  experiments.  
At  the  same  time,  it  is  also  true  that  besides  its  biological  role,  our  data  show  that  CX3CR1  
is  a  marker  of  terminal  differentiation  on  NK  cells,  and  thus  it  is  conceivable  that  mature,  
CX3CR1+  NK   cells  would   preferentially   accumulate   in   peripheral   organs   rather   than   in  
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BM,  mimicking  the  distribution  of  endogenous  NK  cell  subset  in  the  different  anatomical  
compartments  (Figure  5).  
The   data   obtained   from   competitive   adoptive   transfer   experiments   of   CX3CR1+/GFP   and  
CX3CR1GFP/GFP   splenocytes  shed  more   light  on   this   issue:   in   fact,  no  difference   in   liver  or  
spleen-­‐‑directed   trafficking  was   observed   at   any   of   the   time   points   analysed,   suggesting  
that,  at  least  during  the  steady  state,  CX3CR1  does  not  play  a  role  in  NK  cell  positioning  in  
these   organs   (Figure   22b).   Conversely,   the   absence   of   CX3CL1   receptor   entailed   an  
increase   of   KLRG1+/GFP+  NK   cell   retention  within   the   BM,   and   specifically   in   the   BM  
parenchyma,   36   hours   after   transplantation.   Taken   together,   the   transfer   experiments  
point   out   a   non-­‐‑redundant   role   for   CX3CR1/CX3CL1   axis   in   promoting   the   passage   of  
either  developing  (BM-­‐‑derived)  or  trafficking  (blood-­‐‑derived)  KLRG1+  NK  cells  from  BM  
parenchyma  towards  the  sinusoidal  compartment.  Considering  the  lack  of  effect  of  AMD-­‐‑
3100  administration  on  KLRG1+  NK  cell  BM  positioning  (Figure  13g,h),  it  can  be  assumed  
that   CXCR4   is   not   involved   in   this   process.   This   model   of   CX3CL1-­‐‑dependent  
endothelium-­‐‑directed   NK   cell   migration   is   in   agreement   with   a   previous   publication,  
showing  that  NK  cells,  in  addition  to  T  cells  and  monocytes,  were  captured  and  activated  
by  CX3CL1  expressed  on  endothelial  cells  under  physiologic  flow  conditions341.  Moreover,  
the   results   shown   in   Figure   22   point   out   that   CX3CR1   does   not   play   a   role   in  NK   cell  
migration   towards  extramedullary  organs   in  homeostatic  conditions.  On   the  other  hand,  
CX3CR1   is  abundantly  expressed  on  a   significant   fraction  of  peripheral  NK  cells,  but   its  
function  in  periphery  remains  to  be  clarified.  
Notwithstanding   the   evidences   obtained   so   far,   the   poly(I:C)-­‐‑induced   acute   hepatitis  
model  uncovered  a  link  between  CX3CR1  on  NK  cells  and  their  trafficking  outside  BM,  in  
particular   to  spleen  and  liver,   in  an   inflamed  context   (Figure  25).  Some  years  ago,  Wang  
and   colleagues   described   an   increase   in   hepatic   CX3CL1   production   after   Poly(I:C)  
injection,  and  correlated  it  with  the  robust  NK  cell  migration  to  the  liver.  Accordingly,  we  
found  an   impairment   in  KLRG1+  NK  cell  migration   to   the   liver   18  hours  after  Poly(I:C)  
injection,  suggesting  that  CX3CR1,  which  is  abundantly  expressed  by  KLRG1+  splenic  NK  
cell   fraction,   could  actively  promote   their   recruitment   to   the   inflamed   liver.   In   the   same  
Discussion	  
118	  
report  it  was  hypothesized  that  NK  cells  migrated  from  the  spleen  (but  not  from  BM,  LNs  
or  thymus)  to  the  liver,  as  splenectomized  mice  did  not  display  enhanced  hepatic  NK  cell  
recruitment330.  This  is   in  agreement  with  the  significant  numeric  reduction  of  splenic  NK  
cells  and  with  the  3-­‐‑fold  increase  of  liver  NK  cells  observed  in  WT  (and  CX3CR1-­‐‑deficient)  
mice   after   6   and   18   hours   in   our   experimental   conditions   (Figure   25a).  Nevertheless,   in  
contrast  with  what  was  reported  in  that  paper,  we  also  detected  a  significant  reduction  of  
BM  NK  cells  after  Poly(I:C)   injection,  pointing  out  that  BM  NK  cells  might  replace  those  
migrated  from  the  spleen  to  the  liver.    
Besides,   the   more   pronounced   NK   cell   egress   from   the   BM   in   CX3CR1GFP/GFP   mice   is  
complex   to   decipher.   Given   the   results   obtained   from   the   in   vitro   degranulation   assay,  
CX3CR1-­‐‑lacking  NK   cells   are  more   efficiently   activated,   and   this   finding   is   in   line  with  
their  readier  response  displayed  in  case  of  Poly(I:C)-­‐‑induced  activation.  In  fact,  the  effect  
of   CX3CR1-­‐‑deficiency   in   maintaining   NK   cells   within   BM   parenchyma,   during   steady  
state  conditions,  could  possibly  be  overcome  by  other  powerful   (chemotactic)   stimuli,   to  
which   CX3CR1-­‐‑deficient   NK   cells   might   even   be   more   sensitive   than  WT   cells.   In   this  
regard,  another  group  reported  the  involvement  of  CXCR3  ligands  (CXCL9  and  CXCL10)  
as  well   as  CCL5,   in  NK   cell  migration   from   the   red   pulp   to   the  white   pulp   area   in   the  
spleen,   after   Poly(I:C)   administration333:   this   migration   took   place   early   in   the  
inflammation,  and  peaked  after  16  hours,  while   the   initial  conditions  were  restored  after  
about   48   hours.   Thus,   it   is   tempting   to   speculate   that   the   the   increased   splenic  NK   cell  
recruitment   observed   at   6   and   18   hours  might   be   related   to   a   differential   expression   of  
CXCR3  and/or  CCR5  between  CX3CR1+/GFP  and  CX3CR1GFP/GFP  NK  cells  in  an  inflammatory  
context.  
Although   in  our  study  we  did  not   investigate  NK  cell  number  within   the   lung,  CX3CL1  
production  in  the  airways  has  been  described  during  different  inflammatory  conditions340,  
342,   and  moreover   pulmonary  NK   cells   are   known   to   contribute   via   IFNγ  production   to  
immune   cell   recruitment   after   Poly(I:C)   treatment343,   indicating   the   lung   as   part   of   an  
alternative  route  in  the  Poly(I:C)-­‐‑induced  NK  cell  mobilization.  
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In  CX3CR1-­‐‑sufficient   animals,   IFNγ  production   and  YAC-­‐‑1-­‐‑induced  degranulation   after  
cytokine   exposure   highlighted   significant   differences   between   KLRG1+/CX3CR1-­‐‑   and  
KLRG1+/CX3CR1+   NK   cell   subpopulation   (Figure   14),   implying   that   the   CX3CR1-­‐‑
expressing  subset  might  be   less   functional,  or,   rather,  more  difficultly  activated  by  those  
stimuli.   When   the   same   features   were   tested   in   CX3CR1-­‐‑deficient   animals,   we   did   not  
detect   any   changes   in  KLRG1+/GFP±  populations,   neither   in  degranulation   assay  nor   in  
IFNγ   production   experiments,   as   in   both   cases   KLRG1+/GFP+   NK   cells   were   less  
functional  than  their  KLRG1+/GFP-­‐‑  counterpart,  in  heterozygous  as  in  homozygous  mice  
(Figure   24a,b).   Nevertheless,   the   positivity   for   the   degranulation   marker   CD107a   was  
increased   on   total   NK   cell   population   in   CX3CR1-­‐‑deficient   mice,   and   was   NK   cell  
dependent   (Figure  24c),   but   surprisingly   it  was  mainly  due   to   the  KLRG1-­‐‑   contribution,  
and   even   more   strikingly,   to   the   GFP-­‐‑   fraction   of   that   population.   Since   it   has   been  
previously   demonstrated   that   CX3CL1/CX3CR1   axis   does   not   directly   affect   NK   cell  
cytotoxicity  towards  YAC-­‐‑1  cells  in  vitro344,  it  is  possible  that  this  effect  could  be  related  to  
putative  maturative   alterations   linked   to  CX3CR1  deficiency,  which  would   then   interest  
the  whole  NK  cell  population,  both  GFP-­‐‑  and  GFP+.  
One  of  the  most  relevant  features  of  the  chemokine  system  is  its  apparent  redundancy,  or  
better  its  resiliency,  caused  by  the  overlapping  roles  played  by  more  than  one  chemokine  
or   chemokine   receptor124.   This   results   in   the   absence   of   significant   alterations   when   a  
component   of   this   system   is   lost,   for   example   in   KO  mice.   There   are   some   exceptions,  
namely  CXCR4  and  CXCR7158,  345,  346,  which  are   involved   in  organogenesis  of   the  nervous  
and  cardiovascular  systems,  and  incidentally  are  the  most  conserved  chemokine  receptors  
in  vertebrates,  highlighting  their  unicity  within  the  chemokine  universe.    
In  contrast,  several  receptors  were  reported  to  be  unrelated  with  NK  cell  development,  for  
example   CCR1-­‐‑,   CCR2-­‐‑,   CXCR3-­‐‑   and   CXCR6-­‐‑deficient   mice   displayed   normal   NK   cell  
number   and   frequency   in   peripheral   organs,   even   though   the   assessment   of   NK   cell  
maturation   was   not   the   primary   aim   of   those   papers347,   348,   349,   350.   CCR5   role   has   been  
objectect  of  debate,  as  some  authors  first  reported  the  absence  of  evident  changes349,  while  
some  years  later  it  was  described  to  influence  NK  cell  development351.  Its  absence  caused  a  
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drop  of  NK  cell  number  in  BM,  spleen  and  liver,  as  well  as  the  developmental  shift  of  NK  
cell   subsets   towards  an   immature  phenotype.  Moreover,   later   studies  demonstrated   that  
CXCR6-­‐‑deficient  mice  display   an   altered  NK   cell   repertoire,   although   exclusively   in   the  
liver111.  
Though   it   cannot   be   considered   a   chemokine,   S1P   has   been   demonstrated   to   be  
fundamental   for   NK   cell   trafficking   and   maturation116.   S1P5   is   the   only   S1P   receptor  
expressed  on  murine  NK  cells,  and  S1P5-­‐‑/-­‐‑  NK  cells  are  reduced  in  liver,  spleen,  blood  and  
lung,  while  their  number  rises  in  BM  and  LNs.  Furthermore,  these  alterations  are  mostly  
due  to  the  CD11bhigh/CD27-­‐‑  subpopulation,  which  mainly  expresses  S1P5  in  WT  mice.  
Although   the   phenotype   observed   in  CX3CR1GFP/GFP  mice   is   not   really   overturned  when  
compared   to   CX3CR1+/GFP   mice,   the   significant   increase   of   KLRG1+   NK   cell   subset  
frequency   in   BM   (Figure   17b),   due   to   the   GFP-­‐‑expressing   fraction   (which   would   be  
CX3CR1+   in   WT   or   heterozygous   mice),   is   reminiscent   of   what   described   in   Walzer’s  
work116.  
The  increase  of  GFP+,  but  not  of  KLRG1+,  NK  cell  population  observed  in  BM  reverberates  
in  all  the  analysed  organs,  hinting  at  a  role  for  CX3CR1  in  NK  cell  development,  besides  
the  effect  in  trafficking  evidenced  with  adoptive  transfer  experiments.  It  is  likely  that  the  
two   phenomena   are   related,   or   even   that   there   is   just   one   biologic   effect   modulating  
different   aspects   of   NK   cell   biology,   in   this   case   BM   trafficking   properties   and   cell  
development.    
Interestingly,   another   similarity   with   the   phenotype   observed   in   S1P5-­‐‑KO   mice   is   the  
intrinsic  effect  of  the  receptor  deficiency  on  the  NK  cell  population,  demonstrated  through  
mixed   BM   chimeras   (Figure   20b,c).   Nevertheless,   given   the   technical   difficulty   in  
determining  S1P5  proteic  expression  level  (as  of  now  it  can  be  detected  just  as  mRNA),  it  is  
currently   unknown  whether   CX3CR1   and   S1P5   are   co-­‐‑expressed   on  NK   cells,   and   thus  
cooperate   in  promoting  NK  cell   exit   from  BM,  or   instead  are  expressed  by  different   cell  
subpopulations.  
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The  data  deriving  from  this  serie  of  experiments  were  published  in  two  separate  papers,  
dealing  with   the   characterization   of   the   KLRG1+/CX3CR1+  NK   cell   population   and   the  
definition  of  the  role  of  CX3CR1  in  BM  NK  cells,  respectively323,  352.  
  
The   second   part   of   this   thesis   work   was   focused   on   NK   cell   trafficking   during   the  
progression  of  Multiple  Myeloma,  a   tumor   that  grows   in  and  affects  mainly   the  BM.  To  
this   aim   we   made   use   of   a   well-­‐‑known   murine   model   of   MM,   the   5TMM,   which  
reproduces  most  of  the  features  of  the  human  pathology301,  353.  
The  5TGM1  cell   line  we  used  in  our  in  vivo  model  was  susceptible  to  NK  cell  killing,  as  
also   assessed   in   in   vitro   assays   (Figure   27),   confirming   the   results   obtained   by   other  
groups   with   human   NK   cells   against   U266   human  myeloma   cell   line281   and   with   5T33  
murine  myelomatous  cells287.    
  
Subsequently,  we   examined   the   in   vivo  model   of  MM   in   kinetics.   The   obtained   results,  
both   in   terms   of   BM   colonization   (Figure   28a)   and   of   macroscopic   symptoms   such   as  
paraplegia  (not  shown),  were  in  line  with  the  previous  reports  on  5TMM354.  Besides,  organ  
cellularity  was  analysed  in  relation  to  MM  growth,  not  evidencing  any  alterations  either  in  
BM  or  spleen  up  to   the  3rd  week  of   tumor  growth,  while  after  4  weeks  we  observed  on  
one  hand  a  strong  reduction  of  BM  cell  number  and  on  the  other  a  marked  splenomegaly  
(not  shown).  Thus,  similarly  to  the  human  disease,  it  is  possible  to  define  an  asymptomatic  
phase  of   tumor  progression  (third  week),   in  which  hematopoiesis   is  not  affected,  and  an  
aggressive  phase  (fourth  week),  where  the  detrimental  effects  caused  by  MM  progression  
are  evident.    
  
The  increased  tumor  growth  highlighted  after  NK  cell  depletion  demostrates  an  important  
role  for  these  lymphocytes  in  the  immune  response  against  MM  (Figure  28b).  Indeed,  the  
spleen  was  more   robustly  affected   than  BM  by  NK  cell   absence,  perhaps  because  of   the  
different   composition   of   NK   cell   subsets   residing   in   those   organs,   as   splenic   NK   cells  
include   an   higher   frequency   of   the   functionally   competent,   likely   licensed   and   primed,  
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CD11bhigh   NK   cell   subset,   whereas   BM   NK   cells   are   substantially   represented   by   the  
heterogeneous  CD11blow  NK  cell  subset.  
The  MM  growth  curve  over  time  shows  an  exponential  acceleration  between  the  3rd  and  
the  4th  week,  while  before  its  proliferation  seemed  to  be  controlled.  Interestingly,  NK  cell  
number   within   the   BM   starts   to   decrease   just   at   the   3rd   week,   suggesting   a   possible  
contribution  in  MM  restraint  after  the  estabilishment  of  the  disease.  Indeed,  by  depleting  
NK   cells   before   the   5TGM1   cell   injection   we   were   able   to   evaluate   their   role   in   BM  
colonization  of  tumor  cells  and  subsequent  progression.  However,  additional  experiments  
with  different  NK  cell  depletion  protocols  would  be  necessary  to  determine  whether  these  
cells  might  be  needed  at  specific  time  points  of  tumor  progression.  
Another  intriguing  aspect  is  that  analysing  CD3+  T  lymphocyte  or  CD3+/NK1.1+  NKT  cell  
number  in  the  BM,  we  did  not  find  any  alterations  at  the  3rd  week  of  tumor  growth  (not  
shown),   uncovering   a   selective   effect   on   NK   cells,   at   least   regarding   their   change   in  
cellularity.    
  
The   assessment   of   cell   activation   state   in   vivo   through   CD107a   expression   analysis  
denoted  the  impairment  of  BM  NK  cell  function,  in  contrast  to  what  was  observed  in  the  
spleen   (Figure   29).   The   advantageous   ratio   (for  NK   cells)   between  NK   and   tumor   cells  
reported   in   the   spleen,   but   not   in   the   BM,   is   a   possible   explanation   for   the   differential  
activation   propensity   in   the   two   organs   (Figure   31).   Furthermore,   MM   cells   produce   a  
great   amount   of   immunosuppressive   molecules   that   inhibit   NK   cell   function,   such   as  
TGFβ  and  IL-­‐‑10355,  356,  357,  or  PD-­‐‑L1358,  which  might  overcome  the  NK  cell  activating  signals  
deriving  from  MM  presence  in  the  BM.  In  addition,  the  recruitment  of  tolerant  cell  types  
such  as  MDSCs  or  regulatory  T  cells  might  contribute   to  NK  cell   functional   impairment.  
Alternatively,   the   prolonged   state   of   activation   induced   by   tumor   cells   could   gradually  
affect   NK   cell   efficiency   (NK   cell   exhaustion359),   particularly   at   a   time   in   which   the  
generation   of   new   and   fresh   NK   cells   is   slowed   down   by   tumor   growth   in   BM   (as   it  
occurred  at  the  fourth  week).  
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It  should  also  be  taken  in  consideration  that  the  effect  of  NK  cells  against  the  tumor  can  be  
exerted   through   mechanisms   different   from   cytotoxicity   (i.e.   cytokine   or   chemokine  
production,  TRAIL/FAS  pathways),  which  were  not  analysed   in   this   context.   It   could  be  
possible,  then,  that  BM  NK  cells  are  not  really  functionally  impaired  after  3  weeks,  but  just  
display  an  anti-­‐‑tumoral  activity  other  than  cell  degranulation.  
  
Conversely,   the   spleen   NK   cell/MM   cell   ratio   reaches   0.87   at   the   4th   week,   which,  
apparently,  seems  to  be  still  sufficient  for  the  NK  cells  to  be  activated  and  degranulate  in  
vivo.  
In  other   tumor  contexts,   in  particular   in  solid   tumors,  such  as  metastatic  melanoma,  NK  
cells   have   been   involved   in   the   control   of  metastasis360,  361:   as   a   result,   it   is   possible   that  
splenic  NK  cells  might   react  more   efficiently   against   “metastatic”   5TGM1  cells   than  BM  
NK  cells  did,  even  if  this  would  not  explain  the  increase  of  CD107a+  cells  observed  after  2  
weeks  in  BM.  
The  shift   in  NK  cell   subset   frequency,  more   specifically   the   increase  of  KLRG1+   fraction  
observed  in   the  BM  at   the  3rd  week  (Figure  32b)  recalls  what  was  observed  in  CX3CR1-­‐‑
deficient  mice,  in  the  first  part  of  this  work.  Nevertheless,  in  this  case  this  increase  was  the  
consequence  of   an  actual  numeric   reduction  of   the  KLRG1-­‐‑  NK  cell   subset   (Figure  32a).  
Because  there  was  no  difference  in  survival  among  NK  cell  subsets  (Figure  34a),  we  tested  
the  hypothesis  of  an  altered   trafficking   for   the  analysed  NK  cell   subsets,   in  MM-­‐‑bearing  
mice,  finding  a  reduced  NK  cell  retention  in  BM  of  MM-­‐‑bearing  mice,  specifically  due  to  
the   KLRG1-­‐‑   fraction   (Figure   34b).   Moreover,   no   difference   in   the   conversion   rate   of  
KLRG1-­‐‑  NK  cells  to  KLRG1+  cells  was  observed  between  healthy  and  tumor-­‐‑bearing  mice  
(Figure   34c).   Together,   these   two   evidences   remark   that   the  modulation   of   the   homing  
properties   of   NK   cell   subsets   is   mainly,   if   not   totally,   responsible   for   the   phenotype  
observed  in  tumor-­‐‑bearing  mice.  
Importantly,   no   differences   were   observed   at   the   3rd   week   in   the   spleen,   neither   for  
endogenous   NK   cell   subset   composition,   nor   for   their   retention   potential.   This   might  
reflect  the  primary  role  of  BM  in  MM  growth  inasmuch  as,  differently  from  the  spleen,  it  
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provides   unique   signals   (adhesion   molecules,   cytokines,   growth   factors,   feeder   cells,  
extracellular   matrix   components   and   so   on).   Indeed,   the   BM   microenvironment   of  
C57BL/KaLwRij   mice   seems   to   present   decisive   differences   compared   to   other   mouse  
strains,   such  as   the   commonly  used  C57BL/6,   in  which   the  5TGM1  MM  model  does  not  
grow.  For  example,  Fowler  and  colleagues  demonstrated  that  RAG2-­‐‑/-­‐‑  mice  (deficient  in  T  
and   B   cells),   but   not   athymic   nude  mice   (deficient   in   T   cells),   were   5TGM1-­‐‑permissive  
strains,   suggesting   that  B  cells   (absent   in  RAG2-­‐‑/-­‐‑),  and  NK  cells   (more  active   in  athymic  
mice)  might  condition  MM  progression  in  this  mouse  strain362.  
  
The   analysis   of   NK   cell   chemokine   receptor   repertoire   revealed   a   significant   CXCR3  
downregulation   (Figure   35b),   apperently   in   contrast  with   the   increase   of   CXCR3   ligand  
concentration   in   the   BM   extracellular   fluids   (Figure   35d),   although   that   may   condition  
other  CXCR3+  cell  types  (e.g.  activated  CD8+  T  lymphocytes).  
  
As   described   in   paragraph   1.2.3.,   there   are   multiple   levels   of   regulation   of   chemokine  
receptor  activity:  for  example,  the  observed  CXCR3  downmodulation  on  NK  cells  could  be  
due   to   the   altered   NK   cell   development,   to   ligand-­‐‑induced   desensitization   (especially  
given  the  BM  increase  of  CXCL9  and  CXCL10),  or  simply  to  the  impaired  CXCR3+  NK  cell  
recruitment  to  BM  in  MM-­‐‑bearing  mice.  
  
Having  excluded  the  first  of  these  hypotheses  with  an  adoptive  transfer  approach  (Figure  
36),   the   augmented   homing   to   BM   of   CXCR3-­‐‑deficient   NK   cells,   (mainly   ascribable   to  
KLRG1-­‐‑  subpopulation)  (Figure  37a,b),  confirmed  the  importance  of  CXCR3  in  leading  NK  
cells  outside  BM,  and  contextually  ruled  out  the  possibility  that  CXCR3  downmodulation  
could  be  due  to  ligand-­‐‑induced  receptor  desensitization.  
Taken   together,   the   data   obtained   from   the   competitive   adoptive   transfer   experiments  
demonstrate  that  CXCR3  drives  KLRG1-­‐‑  NK  cells  outside  the  BM  to  other  compartments,  
such  as  the  liver.  This  finding  opposes  what  recently  reported  by  another  group:  indeed,  
CXCR3  was  demonstrated  to  be  important  for  NK  cell  intratumor  infiltration,  in  a  mouse  
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lymphoma   model363.   Besides,   considering   the   importance   of   BM   microenvironment   in  
MM,  this  discrepancy  is   likely  related  to   the  different   tumor  model  used  by  the  authors.  
Interestingly,   the  advantage   in   trafficking   to   the   liver  displayed  by  CXCR3-­‐‑deficient  NK  
cells   compared   to  WT  NK  cells   is   significantly  weakened   in  presence  of   the   tumor.  This  
could   be   related   to   the   enhancement   of   CXCR3   ligand   production   from   several   organs  
(including   liver   and   spleen),   and   the   consequent   increase   in   their   blood   concentration.  
Thus,  CXCR3-­‐‑sufficient  NK  cells  might  be  more  attracted  to  the  peripheral  circulation  than  
what  was   observed   in   normal   conditions;   nevertheless,  WT  NK   cell   preference   in   liver-­‐‑
directed  homing  is  maintained  also  in  tumor-­‐‑bearing  mice.  
  
Besides,  it  is  already  been  described  how  CXCR3  is  important  for  NK  cell  migration  to  the  
inflamed   liver364,   365,   366,   367,   and   furthermore   the   higher   sensitivity   of   BM,   compared   to  
splenic,  CXCR3+  NK  cells  to  CXCL9  and  CXCL10  has  been  reported347,  probably  because  
of  their  higher  CXCR3  expression  level.  Interestingly,  the  same  authors  described  that  after  
IFNγ  systemic  activation,  splenic  CXCR3+  NK  cells  are  highly  sensitive  to  CXCL9,  and  are  
quickly  mobilized  to  peripheral  circulation.  
  
At  any   rate,  with   the  experimental  methods  applied  here   it   is   complex   to  determine   the  
directionality   of   the   CXCL9/CXCL10   gradient   across   the   BM/blood   interface,   since   we  
detected   an   increase   of   CXCL9,   but   not   CXCL10,   in   sera   of   tumor-­‐‑bearing   mice,   as  
compared  to  healthy  controls.  Indeed,  the  individual  contribution  of  each  CXCR3  ligand  to  
cell  migration  varies  depending  on  the  context368.  
  
We  have  shown  in  Figure  26  that  the  majority  of  CXCR3+  and  CXCR4+  NK  cells  are  also  
KLRG1-­‐‑.   Therefore   we   hypothesize   that   the   other   axis   involved   in   KLRG1-­‐‑   NK   cell  
impaired  BM  retention   is  CXCR4,  especially  because   its   ligand  CXCL12  was  found  to  be  
significantly  downregulated  in  BM  extracellular  fluid  of  tumor-­‐‑bearing  mice  (Figure  35d).  
Given   the   importance   of   CXCL12   within   BM   microenvironment,   this   alteration   might  
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likely  have  considerable  biological  consequences  on   tumor  progression  and   immune  cell  
recruitment  in  the  inflamed  environment.  
Interestingly,  we  did  not  detect   changes   in  CXCL12  mRNA  (not   shown),   indicating   that  
post-­‐‑translational   mechanisms,   such   as   shedding   by   MMPs   or   citrullination   and  
ubiquitination,  could  be  involved  in  this  reduction.  Intriguingly,  there  are  several  papers  
showing  the  importance  of  the  metalloproteinase-­‐‑9  (MMP-­‐‑9)  in  MM  progression  and  BM  
colonization369   of   C57BL/KaLwRij   mice,   and   CXCL12   has   been   demonstrated   to   be  
processed  by  this  enzyme  (and  by  many  others)222.  
Similarly   to   our   results,   CXCL12   downmodulation   in   MM-­‐‑bearing   mice   was   recently  
described,   together  with   upregulation   of   CXCL9   and   CXCL10370,   by   van   der   Voort   and  
colleagues,   although   in   another   experimental  model.   Differently   from   our   observations,  
the  authors  reported  the  reduction  of  CXCL12  at  the  mRNA  level:  this  difference  with  our  
data   could   be   due   to   the   employed  model.   In   fact,   the   paper   dealt  with   allogeneic   BM  
transplantation  and  multiple  myeloma,  and  tumor  cells  were  transplanted  along  with  BM  
cells  into  previously  irradiated,  and  thus  immunocompromised,  mice.    
Hence,  it  is  plausible  that  the  kinetics  of  tumor  growth  in  the  two  experimental  settings  are  
not   perfectly   matched,   and   thus   CXCL12   expression   could   be   controlled   by   different  
factors.  
Importantly,  the  reduction  of  CXCR4  ligand  in  BM  should  not  be  functionally  relevant  for  
KLRG1+  subset,  but  mainly  for  KLRG1-­‐‑  cells,  since,  as  shown  in  Figure  13g,h,  KLRG1+  NK  
cell  BM  retention  is  mostly  independent  by  CXCR4  effect.  
Indeed,   as   BM   retention   of   KLRG1+   NK   cells   is   not   altered   in   MM-­‐‑bearing   mice,   the  
absence   of   differences   in   CX3CL1   levels   in   BM   extracellular   fluids   is   not   surprising,  
although  we  cannot  exclude  changes  in  S1P/S1P5  axis.  
  
Overall,   the   data   presented   in   the   second   part   of   this   thesis   uncover   a   critical   role   of  
CXCR3   and,   most   likely,   CXCR4   axes   in   NK   cell   retention   at   the   tumor   site,   at   an  
intermediate  phase  of  MM  growth.  As  KLRG1  expression  on  mature  NK  cells  has  not  been  
formally  associated  to  reduced  functionality,  it  might  be  incautious  to  mark  the  exclusion  
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of  KLRG1-­‐‑  NK  cells   from  the  BM  as  a   tumor  strategy  of   immune  evasion,  since  KLRG1-­‐‑  
fraction  may  still  play  an   important  role   in  peripheral   tissues.  Nevertheless,   the  reduced  
number   of   total   NK   cells   in   the   BM   found   in   MM-­‐‑bearing   mice   is   unambiguously   a  
negative  sign  for  the  host  immune  response.    
Further   efforts,   with   different   experimental   approaches,   are   currently   being   made   to  
elucidate  the  biological  relevance  of  CXCL12  reduction.    
Moreover,   the  interference  with  CXCR3  axis  can  be  hypothesysed  in  the  future,  with  the  
aim   of   increasing   BM-­‐‑directed   NK   cell   migration,   to   counter   MM   growth   before   its  
exponential  proliferative  phase,  in  NK  cell-­‐‑based  transfer  therapies.  
  
Collectively,  the  data  presented  herein  contribute  to  the  understanding  of  the  signals  that  
govern  NK  cell  trafficking  in  BM  during  normal  and  pathological  conditions,  highlighting  
an   important   role   for   specific   chemokines-­‐‑chemokine   receptor   axes   in   the   NK   cell  
population  and  within  different  NK  cell  subsets.    
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